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CHAPTER I
INTRODUCTION
Parkinson’s disease (PD) affects the lives of millions of people worldwide. It is
the second most common chronic, neurodegenerative disease— second only to
Alzheimer’s dementia (Bertram & Tanzi, 2005; Nutt & Wooten, 2005). Parkinson’s is a
progressively debilitating disease that has an impact on the quality of life (QOL) of
patients with this condition and their families (Jahanshahi & Marsden, 2000).
Efforts to address the impact of PD encompass not only basic research, but also
applied research. As a chronic, progressive condition with no currently known cure,
treatment is aimed at slowing the progression of the disease, managing symptoms, and
lessening their impact on functional limitations. This investigation was designed to
address questions about methods for educating patients about self-managing their
disease. Specifically, it was designed to evaluate a collaborative care method that
involves patient education and implementation of treatment regimens that have been
established by the patients themselves with guidance and support from health care
professionals. This is consistent with the observation by Marjama-Lyons and Shomon
(2003) that “ultimately, living well with Parkinson’s requires knowledge of how
Parkinson’s affects both mind and body” (p. xix).
Chapter I introduces the components and hypotheses of this intervention study. It
also summarizes the magnitude of the problem of PD, as well as its scope in terms of
impact on QOL. Treatment adherence issues in PD are described as well. The research
1
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design and specific aims of the study, research questions and hypotheses are also
introduced, as well as key constructs and their operational definitions.
The purpose of the study was to address the question of how to positively
influence patient self-efficacy by comparing a new model of PD patient education and
health care delivery to a traditional model of information transmission. The plan was to
compare the effects of a PD collaborative care model of patient education to a traditional
PD education model on patients’ perceptions of their QOL and efficacy for managing
their disease.
A pre-post design was used that involved asking participants with PD to
complete measures of QOL and self-efficacy prior to training, immediately
postintervention, and again 4 weeks later. The results were expected to have implications
for health care professionals and health systems that provide care to PD patients,
pharmaceutical companies, health insurance companies, policymakers, and PD patients
and their families.

Magnitude of the Problem of Parkinson’s Disease
Epidemiological studies of Parkinson’s disease (PD) are scarce, but an estimated
4 million people worldwide are believed to experience this progressively disabling,
neurodegenerative disease (Blake-Krebs & Herman, 2001; Huse, Schulman, et al., 2005;
Marjama-Lyons, 2003). In the United States, approximately 1 to 1.5 million people have
been diagnosed with PD (Bushnell & Martin, 1999; Maijama-Lyons, 2003) and about
60,000 new cases are diagnosed annually (Blake-Krebs & Herman, 2001). The average
age of onset of PD is 55, but 15% of cases are diagnosed in individuals under the age of
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50, and 10% are in individuals under the age of 40 (Blake-Krebs & Herman, 2001). The
incidence of PD increases significantly with age (Huse et al., 2005), with its prevalence
estimated to be as high as 1 in 100 persons over 60 years of age (Lang & Lozano, 1998;
Maijama-Lyons & Shomon, 2003).
The latest morbidity and mortality trends data from 2003 from the Centers for
Disease Control and Prevention (CDCP, 2006) have shown a significant increase in
deaths attributable to PD. Parkinson’s disease now ranks as the 14th leading cause of
death in the United States (CDCP, 2006). Given the aging population and its increasing
longevity, the prevalence of PD and other chronic diseases is expected to rise (Global
Parkinson’s Disease Survey Steering Committee [GPDSSC], 2002). Research studies
have shown that 45% of the U. S. general population and

88

% of individuals aged 65

years and older have at least one chronic disease (Wolff, Starfield, & Anderson, 2002).
Demographic trend projections estimate that by 2020, 157 million Americans (nearly
50% of the population) will have at least one chronic disease (Anderson, 2003; Wolff et
al., 2002). Individuals with multiple chronic conditions, especially the frail elderly, are
likely to experience a more rapid decline in functional health status and an increased
likelihood of disability (Manton & Gu, 2001; Singer & Manton, 1998; Wolff et al.,
2002).
People with chronic conditions accounted for more than 78% of the health care
expenditures in 2000 (Anderson, 2003). Based on their analysis of health insurance
claims data from January 1999 to December 2002, Huse et al. (2005) estimated that the
annual direct health care costs per PD patient for care in the U. S. was $10,439 (in 2002
dollars) and $25,326 in indirect costs, such as uncompensated caregiving and
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productivity loss. The cumulative effect is approximately $34 billion (in 2004 dollars) in
annual health care expenditures for PD care (Noyes, Liu, Li, Holloway, & Dick, 2006).
As the prevalence of PD increases, society can expect to see a substantial rise in the cost
of PD care that will likely have a profound economic impact on health care systems
(Blake-Krebs & Herman, 2001; Huse et al., 2005; Marjama-Lyons & Shomon, 2003).
Thus, clinicians may be required to care for and support PD patients who are living
longer with the disease. Although a cure is a legitimate long-range goal, an appropriate
interim goal is to seek the most effective means for helping patients to maintain their
quality o f life (Welsh, 2004).
Scope o f the Problem of QOL and Adherence Issues

The research that has been done in this area has shown that Parkinson’s disease
has a substantial impact on patients’ health-related quality of life (HRQOL) (Karlsen,
Larsen, Tandberg, & Maeland, 1999; Karlsen, Tandberg, Arsland, & Larsen, 2000;
Martinez-Martin, 1998). Cardinal features of Parkinson’s disease are tremor,
bradykinesia (slowness o f movement), rigidity, and postural instability—with
bradykinesia and tremor being the most commonly occurring symptoms (Lang &
Lozano, 1998). These symptoms can make it difficult forPD patients to perform routine
activities of daily living (ADLs), such as dressing, bathing, and grooming; getting out of
bed or arising from a seated position; and walking or climbing stairs. Besides the motor
impairment, many nonmotor symptoms also are associated with PD. These include
dysfunction of the autonomic nervous system and cognitive changes, which have been
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shown to have had a multifaceted impact on the QOL of these patients (GPDSSC, 2002;
Welsh, 2004).
The symptoms that PD patients may experience and that influence their QOL are
related in complex ways to their adherence (or nonadherence) to treatment regimens.
Adherence can be a double-edged sword, with positive and negative consequences on
symptom management and QOL. For example, some of the symptoms that affect QOL
for patients with PD and their families include: impaired mobility, balance, and nutrition;
emotional and sleep disturbances; fatigue, depression, cognitive changes, altered social
roles, altered libido, sexual dysfunction, blurred vision, and other autonomic nervous
system-related symptoms. Medication regimens are a mainstay in the treatment of such
PD symptoms. Although drug regimens heavily focus on the control of PD-motor
symptoms (Grosset & Grosset, 2005; Leopold, Polansky, & Hurka, 2004),
pharmacological interventions are expensive, may have limited effects, and can also
create side effects that have a negative impact on QOL (Welsh, 2004). Patients who take
sufficient medication (dopamine) to control tremor, bradykinesia, and rigidity symptoms
may over time develop involuntary motor movements (dyskinesia), which create an
additional problem. When side effects become a source of social embarrassment or a
person becomes dosage tolerant or other complications occur, patients may be
influenced to become nonadherent to the prescribed treatment regimen in effort to
achieve better symptom control.
Therefore, a major impediment to pharmacological management of PD is
nonadherence to prescribed drug regimens (Leopold et al., 2004). Extant research on
drug adherence to prescribed regimens and HRQOL in PD patients is limited (Leopold et
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al., 2004; Welsh, 2004), but preliminary results suggest that adherence or nonadherence
to prescribed medication regimens can significantly influence how well patients are able
to control and manage their PD symptoms which, in turn, can directly affect their QOL.
Although pharmacological treatments have been the hallmark o f PD therapy,
there are several other beneficial treatment modalities available to aid in the management
and control of PD symptoms that may improve the QOL and help to prevent injuries in
this population (Chen, Zhang, Schwarzschild, Heman, & Ascherio, 2005). Underutilized
interventions include exercises, environmental design, and social support systems, all of
which may be effective in improving QOL for these patients.
Significance of the Research

To maximize effective treatment of Parkinson’s disease patients, clinicians from
multiple disciplines need a better understanding of the factors that contribute to
adherence that may impact the QOL in this population. The current research constitutes
an attempt to help bridge this knowledge gap.
Extant research is limited regarding the role of self-efficacy and patient education
for disease self-management in Parkinson’s disease, and ultimately, the influence of such
factors on self-reported HRQOL in PD (GPDSSC, 2002; Welsh, 2004). Further, this
knowledge deficit has hindered the development and implementation of both conceptual
models o f health care delivery and clinical guidelines for the care management of patients
with PD (GPDSSC, 2002; Welsh, 2004). Limited research has been reported regarding
PD patients’ adherence to prescribed treatment regimens: self-report of perceived ability
o f PD patients to self-manage their disease, the impact of patient-centered educational
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7
approaches on PD patients’ self-reported adherence to treatment protocols, and patientreported perceptions o f impact on PD QOL indicators.
Insight gained from the results of this study may help to influence the
implementation o f patient education methods that will meet the needs of PD patients
more appropriately, thereby enabling them to improve their self-management of PD and
PD HRQOL. Further, information collected from this research study will provide
background data for stakeholders, such as health care institutions, health care
policymakers, and insurance and pharmaceutical companies that are responsible for
developing and delivering health care services and products to treat PD and to enhance
the care of Parkinson’s patients and their families.
Research Design and Specific Aims

This research involved a small randomized clinical trial with pre-post assessment
of desired outcomes of patient self-efficacy and QOL to investigate the effectiveness of
an emerging paradigm in patient education and chronic disease self-management in
comparison to the traditional patient education and disease management approach. The
experimental patient education approach investigated was called the PD collaborative
care (PDCC) model for purposes of this investigation. The conceptual model for this
approach has been stimulated by the Chronic Disease Self-Management Program
(CDSMP) developed by Stanford University researchers (Lorig, Stewart, et al., 1996),
based on its purpose being to promote the PD patient’s disease self-management skills,
problem-solving capabilities, and knowledge. The PDCC model (also called the
collaborative care model) enfolded components of the CDSMP (Lorig et al., 1996).
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For contrast, some patients were randomly assigned to a comparison group that
received a traditional standard of care model, which was referred to as the PD
Informational Training (PDIT) model. The intent in selecting these two designators
(PDCC and PDIT) was to have two terms that would not signal to the participants in the
study which group was considered experimental and which was control (i.e., comparison
group).
Both groups received information from interdisciplinary health care professionals
regarding pertinent aspects o f disease management specific to PD and were given
information about technical skills specific to this disease. The experimental PDCC group
participated in additional collaborative goal setting activities related to specific aspects of
general recommendations they could select for immediate implementation. That is, in the
PDCC model, peer mentors assisted these participants to create patient-identified, short
term “action plans,” which they worked on between sessions and updated at subsequent
sessions.
The specific aims of this random control pre-/posttest intervention study (with
one-month follow-up) were:
1. To compare the effectiveness of two health care delivery and patient education
models (PDCC and PDIT) in enhancing PD patients’ perceived self-efficacy in
PD disease self-management, and
2. To compare the effectiveness of the two health care delivery and patient
education models (PDCC and PDIT) in enhancing PD patients’ self-reported
perceived PD-HRQOL.
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Research Questions, Hypotheses, and Definitions
The following research questions and hypotheses were generated to
operationalize the intended aims of this study.
Research Questions and Hypotheses

1. Is there a difference between pre- and posttest scores (Time 1 - Time 2) on the
Self-Efficacy fo r Managing Chronic Disease 6-Item Scale between Parkinson’s
disease patients who participate in the PDCC or PDIT intervention?
Hypotheses:
Hoi: Pre-post scores on the Self-Efficacy fo r M anaging Chronic Disease 6-Item
Scale (Stanford University) will not differ between the two groups.
Hai: Pre-post scores on the Self-Efficacy fo r M anaging Chronic Disease 6-Item
Scale (Stanford University) will differ between the PDCC (experimental) group
and the PDIT (control) group.
2. Is there a difference between pre- and posttest scores (Time 1 - Time 2) on the
PDQ-39 Parkinson’s Disease Quality o f Life Scale between Parkinson’s disease
patients who participate in the PDCC or PDIT intervention?
Hypotheses
H„2: Pre-post scores on the PDQ-39 Parkinson’s Disease Quality o f Life Scale
will not differ between the two groups.
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10
Ha2: Pre-post scores on the PDQ-39 Parkinson’s Disease Quality o f Life Scale
will differ between the PDCC (experimental) group and the PDIT (control)
group.
3. Is there a difference between change scores from posttest (Time 2) to the 4-week
follow-up (Time 3) on either of the dependent measures {Self-Efficacy fo r
M anaging Chronic Disease 6-Item Scale or PDQ-39 Parkinson’s Disease
Quality o f Life Scale) between the PDCC and PDIT groups?
Hypotheses
Ho3: Time 2 - Time 3 change scores on the Self-Efficacy fo r M anaging Chronic
Disease 6-Item Scale will not differ between the two groups.
Ha3 : Time 2 - Time 3 change scores on the Self-Efficacy fo r M anaging Chronic
Disease 6-Item Scale will differ between the two groups.
Ho4: Time 2 - Time 3 change scores on PDQ-39 Parkinson’s Disease Quality o f
Life Scale will not differ between the two groups.
Ha4: Time 2 - Time 3 change scores on PDQ-39 Parkinson’s Disease Quality o f
Life Scale will differ between the two groups.
4. Is there a difference between change scores from baseline (Time 1) to the 4-week
follow-up (Time 3) on either of the dependent measures {Self-Efficacy fo r
M anaging Chronic Disease 6-Item Scale or PDQ-39 Parkinson’s Disease
Quality o f Life Scale) between the PDCC and PDIT groups?
Hypotheses
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H 0 5 : Time 1 - Time 3 change scores on the Self-Efficacy fo r M anaging Chronic
Disease 6-Item Scale will not differ between the two groups.
Ha5: Time 1 - Time 3 change scores on the Self-Efficacy fo r M anaging Chronic
Disease 6-Item Scale will differ between the two groups.
Ho6 : Time 1 - Time 3 change scores on the PDQ-39 Parkinson’s Disease Quality
o f Life Scale will not differ between the two groups.
Ha6: Time 1 - Time 3 change scores on PDQ-39 Parkinson’s Disease Quality o f
Life Scale will differ between the two groups.
Constructs and Operational Definitions Relevant to Research Questions
The key constructs (concepts) embedded within these research questions have
been operationally defined as they relate to this study. These definitions are outlined in
the sections below.
Chronic Care Model: This is a health care delivery model created by the
Improving Chronic Illness Care National Program (Glasgow, Funnell, et al., 2002;
Glasgow, Davis, Funnell, & Beck, 2003), which recommends evidence-based
interventions within six areas known to improve processes of care and patient outcomes:
delivery system design, self-management support, organization of the health system,
decision support, information systems, and linkages to the community (Cretin, Shortell,
& Keeler, 2004). The Chronic Care Model, along with Stanford University’s Chronic
Disease Self-Management Program (Lorig et al., 1996), provided the conceptual
frameworks for the PDCC model used to present a patient education and disease self
management program to PD patients who participated in this study.
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Patient-Professional Partnership Paradigm: This is a new chronic disease self
management paradigm in which the expertise of the patient is regarded as important as
the expertise of the health care professionals in making mutually-established health care
goals and decisions for patient disease self-management (Bodenheimer, Lorig, Holman,
& Grumbach, 2002; Tattersall, 2002). For the purpose of this study, PD patients who
were enrolled in the treatment (experimental) group received a structured PD disease
self-management, interdisciplinary patient education intervention over a 3-week period.
Collaborative Patient Education Model: This is another term sometimes used in
the literature (Bodenheimer et al., 2002; Lorig, 2003a, 2003b) to refer to a collaborative
care model (CCM), in which patients act as equal participants in helping to formulate
what type o f information and skill-learning (technical and problem solving) that they
require to manage their PD and its related sequelae to improve their QOL. For the
purpose of this study, PD patients who were enrolled in the experimental PDCC group
used their expertise and interacted with an interdisciplinary team of health care
professionals to identify patient learning needs relevant to PD disease self-management,
including but not limited to disease information, technical skills, and problem-solving
skills.
Disease Self-Management Education: The disease self-management educational
approach is related conceptually to the emerging paradigm of patient-centered care,
which is context-based and emphasizes the teaching of problem-solving skills, such as
patient empowerment and disease information, thereby complementing a traditional
patient education (see next term). The goal of self-management education is to increase
the patient’s perceived self-efficacy, thereby improving patient’s clinical outcomes
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(Bodenheimer et al., 2002). In the current study, PD patients who were enrolled in the
experimental group received this interventional educational approach as part of the
PDCC model, whereas patients in the control group received the traditional patient
education approach, but without the additional self-management components.
Traditional Patient Education Model: In the traditional patient education
approach to disease treatment (called PDIT in this study—the control group), the health
care professional team members are viewed as the experts, and the patients are the
designated learners whose expertise is not actively engaged as part of the educational
interaction and who offer very little to the educational process (Bodenheimer et al.,
2002). The traditional patient educational model emphasizes the sharing of information
and teaching of technical skills relevant to disease management as identified by the health
care team, whereas the patient is the passive recipient of this education. Problem-solving
skills, such as patient empowerment, are not taught in the traditional patient education
model. The goal of the traditional patient education model is to increase patient
adherence to the behavior changes that have been taught, thereby improving patients’
clinical outcomes (Bodenheimer et al., 2002). In the current study, PD patients who
were enrolled in the control group received this type of interventional educational
approach. It was friendly and informational but lacked the peer-supported collaborative
action planning components.
Self-Efficacy: This is a concept derived from social cognitive theory that relates
to the human motivation and confidence that one has the ability to produce the desired
changes by one’s actions (Bandura, 2004). As it is difficult to measure self-efficacy
directly, for the purpose of this study it was measured as the self-reported perceived self
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efficacy that PD patients had in their ability to self-manage their PD and other comorbid
illnesses, if they existed. The self-reported perceived self-efficacy for PD disease self
management by patients enrolled in this study was measured serially by using the SelfEfficacy fo r Managing Chronic Disease 6-Item Scale (Lorig et al., 1996) developed by
the Chronic Disease Self-Management Program researchers at Stanford University.
Parkinson’s Disease: A progressive, neurodegenerative disease with hallmark
features o f tremor, bradykinesia (slowness of movement), rigidity, and postural
instability; other symptoms include autonomic nervous system dysfunction, mood and
cognitive changes, hallucinations, psychoses, masked facies, sleep disorder, sexual
dysfunction, dysphonia, and micrographia (Nutt & Wooten, 2005). Incidence increases
with age, affects all races and ethnicities, and has a slightly greater prevalence in males
than females.
Parkinson’s Disease Patient: For purposes of this study, the PD patient was
either male or female; > 3 0 years of age, but not greater than 80 years old; with middle
stage (Modified Hoehn & Yahr stages 2 and 3) PD, who did not have a known diagnosis
of Dementia with Lewy Bodies (DLB) or other dementiae.
Parkinson’s Disease Self-Management Skills: Skills in PD self-management
generally encompass the degree to which a person can demonstrate knowledge and
application o f disease information, technical skills, and problem-solving skills relevant to
the disease. Self-management skills comprise areas related to a variety o f professional
domains, including skills for managing one’s medications (as recommended by physicians
and supported by pharmacists); physical exercise (as recommended by physical
therapists), functional activities and home modification/environmental design (as
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recommended by occupational therapists); speech intelligibility and social communication
functions (as recommended by speech-language pathologists); and identification and
access of appropriate social support systems (as recommended by social workers). In this
study, pertinent information that met the standard of care for PD patients was offered by
specialists in each o f these key content areas to patients in both groups, but the delivery
method o f patient education, instructional materials, and skills development differed
between the two groups. Patients in both groups were given information about the
relevant technical skills for PD disease self-management. The difference was that the
experimental PDCC group was engaged in peer-supported active learning of problem
solving skills to enhance their self-efficacy in PD disease self-management. The control
group PDIT members received the information and technical skills, but did not receive
the additional peer-supported collaborative planning and problem-solving skills practice.
Self-Reported Perceived Parkinson’s Disease Self-Management Skills: For
purposes of this study, this was the PD patients’ self-reported assessment of their selfefficacy of PD disease self-management skills as noted above and measured on the SelfEfficacy fo r Managing Chronic Disease 6-Item Scale developed by the Stanford
University Chronic Disease Self-Management Program.
Prescribed Treatment Regimen: For purposes of this study, pharmacological and
nonpharmacological interventions prescribed by the PD interdisciplinary health care team
for treatment o f PD and other comorbid conditions for patients enrolled in this research
project.
Quality o f Life: The adequacy of one’s physical and psychosocial functioning as
based on key QOL indicators valued by the individual. For purposes of this study, this
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was measured by the self-reported perceived PD QOL as expressed by both patient .
groups on serial measures o f the PDQ-39 over a 7-week period. The PDQ-39 measures
several parameters of each o f the QOL indicators identified by PD patients, i.e.: mobility,
activities o f daily living, emotional well being, stigma, social support, cognition,
communication, and bodily discomfort (Peto, Jenkinson, & Fitzpatrick, 1998). The
PDQ-39 measure was self-administered to both groups at baseline, after completion of
the intervention, and at one month after completing the intervention.
Chapter Summary
In summary, Chapter I has provided an introduction and overview of this
research project including its significance, aims, research questions, and hypotheses. Key
concepts and operational definitions related to the research questions and outcome
measures have also been discussed. Results of this study may provide information that
health care institutions and clinicians can use to enhance the care they provide to PD
patients and their families, can serve as the impetus for realignment of reimbursement
systems to support evidence-based practices, and can stimulate development of health
policies that support healthcare innovation and safe, effective, patient-centered quality
care.
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CHAPTER II
LITERATURE REVIEW
The efforts o f research scientists to unveil the mysteries of PD have led to
valuable insights into its myriad complexities, disease models, and symptoms. These
research endeavors have resulted in a new understanding of the organization of the
brain’s neural circuitry, especially within the basal ganglia (deep brain structures)
(Olanow, 2004), and its associated effects on the body. Research also has illuminated
how symptoms of PD impact the quality of life for patients (Global Parkinson’s Disease
Survey Steering Committee [GPDSSC], 2002). Further, this knowledge has helped
scientists to reaffirm the use of standard treatments (for example, levodopa) as well as
developing new treatments (Olanow, 2004), such as pharmaceuticals, neural tissue
implants, physical rehabilitation modalities (DeGoede, Keus, Kwakkel, & Wagenaar,
2001; Ferry, Johnson, & Wallis, 2002; Ramig et al., 2001; Schenkman, 2002), and such
medical devices as Deep Brain Stimulators. Such treatments are specifically targeted to
abate the onset of PD, treat its constellation of symptoms, or delay disease progression
(Quality Standards Subcommittee of the American Academy of Neurology [QSSAAN],
2006a, 2006b, 2006c, 2006d; Rascol, Goetz, Koller, Poewe, & Sampaio, 2002).
Health care professionals caring for patients with PD have translated this research
into the clinical setting in an effort to improve both the quality of care and lives of PD
patients and their families. Given the chronic nature of PD, these clinicians are also
seeking to develop and implement new models of health care delivery that will better
17
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address the needs of PD patients and their families (McRae, Sherry, & Roper, 1999).
Health care delivery models, such as the Patient-Professional Partnership Collaborative
Care Model (PPPCCM), engage Parkinson’s patients as active partners in the care
process (Bodenheimer et al., 2002). Through self-management patient education, the
PPPCCM and other similar models, collaboratively empower patients to be efficacious in
the daily management of their PD and to manage any comorbidities (Bandura, 2004;
Barr et al., 2003; Clark, 2003; Epping-Jordan, Pruitt, Bengoa, & Wagner, 2004; Fries,
Lorig, & Holman, 2003; Holman & Lorig, 2000, 2004; Lorig, 2001, 2002, 2003 a,
2003b; Marks, Allegrante, & Lorig, 2005a, 2005b).
The purpose of this chapter is to present a scholarly review o f the literature
relevant to the: (a) overview o f PD: including its epidemiology, symptomatology,
treatment options and their ramifications, and the financial impact of PD; (b) PD patient
health-related quality of life issues: including PD HRQOL indicators, impact of PD
treatment options on the physical and social functioning of Parkinson’s patients, impact
of patients’ adherence or nonadherence to treatment options and the role of patient
education in promoting patient adherence; (c) PD and health care patient education and
delivery paradigms: including the traditional care-patient education model and the new
collaborative care model, PPPCCM; and, lastly, (d) the impact of PD and chronic disease
self-management, patient education programs on self-reported patient outcomes and
systems outcomes.
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Parkinson’s Disease
Overview o f Parkinson’s Disease
Description o f PD and Its Symptomatology
The first description of the “shaking palsy” was written by James Parkinson in
1817 as an observational case review of 6 patients who had motor symptoms of tremor,
bradykinesia (slowness o f movement), and rigidity (Slaughter, Slaughter, Nichols,
Holmes, & Martens, 2001). Since then, a fourth cardinal symptom, postural instability
with gait disturbance, has been added to the classic triad of symptoms that typify the PD
syndrome. Nonmotor symptoms of PD affect three domains: (a) autonomic dysfunction
(impaired functioning of the autonomic nervous system), such as visual disturbances,
bowel and bladder dysfunction, and erectile dysfunction; (b) neuropsychological
dysfunction, such as depression, emotional lability, hallucinations, sleep disturbances,
psychoses, cognitive impairment, and dementia; and (c) sensory dysfunction, including
pain (Olanow, 2004; QSSAAN, 2006a, 2006b, 2006c, 2006d). Effective control of the
major and minor symptoms of PD impacts the health-related QOL (HRQOL)
experienced by Parkinson’s patients and their families.
The presentation of PD motor and nonmotor symptoms is due to the loss and
imbalance of neurochemical transmitter substances in the brain, particularly dopamine,
but also norepinephrine, acetylcholine, serotonin, and glutamate which are thought to
play a role in the manifestation of PD symptoms (Bergman & Deuschl, 2002; Olanow,
2004; Schrag, Ben-Shlomo, & Quinn, 2002). Pathologically, a loss of melanized
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dopaminergic neurons is seen in the deep structures of the brain, specifically the
substantia nigra pars compacta (SNc), which is accompanied with abnormal protein
inclusions, called Lewy bodies (Olanow, 2004). It is estimated that 70-80% of
dopaminergic cell loss has already occurred by the time the clinical diagnosis of PD is
made (DeGoede et al., 2001; QSSAAN, 2006c). Basic neuroscience research has shown
that neurodegeneration may also affect other deep brain structures resulting in loss of
norepinephrine from the locus ceroelus, serotonin from the cerebral cortex, brainstem,
spinal cord, dorsal raphe nucleus, and peripheral autonomic nervous system, and
cholinergic neurons from the nucleus basalis of Meynert (Bergman & Deuschl, 2002;
Olanow, 2004). It is thought that the neurochemical imbalances caused by the
neurodegeneration seen in PD disrupts the neural circuitry of the basal ganglia (deep
brain structures) resulting in the motor (including the involuntary movements called
dyskinesia) and nonmotor symptoms of PD (Bergman & Deuschl, 2002; Betarbet,
Sherer, DiMonte, & Greenamyre, 2002; Olanow, 2004; Schrag & Quinn, 2000). The
basal ganglia are part of the neural circuitry that arises from the cortex of the brain,
passes through the striatum, pallidum, and thalamus, and then project back to the
cerebral frontal cortex (Bergman & Deuschl, 2002).
Epidemiology o f PD

Epidemiological studies of PD are relatively scarce; however, approximately 1.5
million Americans have been diagnosed as having PD, and PD is estimated to affect
about 4 million people worldwide (Bertram & Tanzi, 2005; Bushnell & Martin, 1999;
Lang & Lozano, 1998). As previously noted, about 60,000 new cases of PD are
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diagnosed annually in the United States (Blake-Krebs & Herman, 2001). The incidence
rate is expected to increase significantly as the population continues to age (Nutt &
Wooten, 2005; Olanow, 2004; Welsh, 2004). The likelihood of developing PD increases
with age; its prevalence is estimated to be as high as 1 in 100 persons over 60 years o f
age (Lang & Lozano, 1998; Nutt & Wooten, 2005). Payami, Larsen, Bernard, and
N utt’s (1994) study (as cited in Nutt & Wooten, 2005) noted that genetics play a role in
approximately 10-15% ofPD cases with 10 autosomal dominant and recessive genes
being linked to PD. Bertram and Tanzi (2005) noted, however, that Mendelian
inheritance appears to be associated with an early or even juvenile onset of PD. The role
genetics plays in the onset of PD in persons greater than 50 years of age remains
debatable. All racial and ethnic groups are affected, with a slightly higher preponderance
among Caucasians (Lang & Lozano, 1998; VanDenEeden et al., 2003). Males have a
slightly greater preponderance for developing PD than do women (Bertram & Tanzi,
2005).
Some studies have indicated that a rural environment (Lang & Lozano, 1998)
and geographical distribution of pesticide usage (Bertarbet et al., 2002; Gorell, Johnson,
Rybicki, Peterson, & Richardson, 1998) are associated with an increased risk for
developing PD. Further, many other factors have been implicated as plausible etiological
agents of PD, including exposure to radiation, viruses, oxidative stress, and drug abuse
(Bergman & Deuschl, 2002; Betarbet et al., 2002; Lang & Lozano, 1998). Marras and
Tanner (2004) noted (as cited in Nutt and Wooten, 2005), however, that there have been
no clear environmental determinants of PD identified. Yet, Vaughan and Hardie (2002)
contended that the “absence of any specific and sensitive diagnostic test or bioassay for
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PD has always meant that epidemiological studies underestimate PD in any given
population exposed to environmental triggers” (p. 47). Regardless of its etiology, PD is a
slowly, progressively debilitating disease that exacts a heavy toll on PD patients,
spouses, and families. The latest morbidity and mortality data (2003) from the Centers
for Disease Control and Prevention (CDCP) has shown a significant increase in deaths
attributable to PD. Parkinson’s disease now ranks as the 14th leading cause o f death in
the United States (CDCP, 2006).
Financial Burden o f PD

As previously noted, PD exacts a significant economic burden on PD patients,
their families, and society. Noyes et al. (2006) compared the utilization of health
services, health care expenditures, and economic burden o f self-reported PD among
35,217 Medicare beneficiaries with and without PD, using data obtained from the 19922000 Medicare Current Beneficiaries Survey. Noyes et al. found that total annual health
expenditures o f PD patients were over two times greater than in their non-PD
counterparts. PD patients also paid more out-of-pocket costs for prescription
medications than non-PD beneficiaries and for long-term insurance (Noyes et al., 2006).
Further, an increased use of all health care services by community-dwelling PD versus
non-PD beneficiaries was noted, but this difference was not evident among
institutionalized PD versus non-PD beneficiaries (Noyes et al., 2006). PD patients used
3.0 times more home health services and had 1.3 times more outpatient visits, 1.7 times
more hospice events, 2.8 more short-term care stays, and 1.8 times more long-term care
stays, than did their non-PD counterparts (Noyes et al., 2006).
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Adjusted annual expenditures for PD patients in the 1990s exceeded $20,000
yearly in direct medical costs (Noyes et al., 2006). Medicare PD-beneficiaries’ total
annual health care costs were 70% higher than non-PD beneficiaries even after adjusting
for socioeconomic status, ADLs, and comorbidities, i.e., $18,528 versus $10, 818 (p =
<0.001), respectively (Noyes et al., 2006). Noyes et al. found that PD patients had
higher levels of costly comorbidities, including depression, dementia, falls, diabetes, and
cardiovascular disease, whereas cerebrovascular disease and cancer were determinants of
higher medical costs among non-PD beneficiaries.
Guttman, Slaughter, Theriault, DeBoer, and Naylor (2003) conducted a 6-year
inception cohort study o f N = 45, 912 patients in Ontario, Canada (n = 15,304 with PD;
n = 30,608 without PD) which revealed findings similar to those of Noyes and colleagues
(2006) with regard to increased utilization of health care services and increased health
care expenditures. Among members of this inception cohort, PD patients had 1.45 times
more acute care hospitalizations with 1.19 times longer length of stay (LOS); they also
incurred 1.4 times more cost for physician services and 3.0 times more drug costs than
did their non-PD control group members (Guttman et al., 2003).
Few studies exist that analyze the cost of illness ofPD and only one published
cost effectiveness study addressed the value of PD interventions (Siderowf, Holloway, &
Stem 2000). Hoerger, Bala, Rowland, et al.’s (1998) study assessed the effectiveness of
the use of pramipexole (a dopamine agonist) in comparison to baseline levodopa therapy
in early and late-stage PD based on changes in the patients’ scores on the Unified
Parkinson’s Disease Rating Scale (UPDRS). Siderowf et al. (2000) reported that results
from this study revealed that pramipexole was both more effective and more costly than
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baseline levodopa therapy for early and late-stage PD patients. Based on change in
UPDRS scores, the cost-effectiveness ratio per QALY (quality-adjusted life years) for
treatment o f early PD with pramipexole versus baseline levodopa was $9,139 (in 1998
dollars) and $12,714 per QALY for treatment of late-stage PD with pramipexole versus
levodopa (Siderowf et al., 2000). QALY is life expectancy adjusted based on the
patient’s subjective preference for the value of a given health state in which one’s
remaining life expectancy is spent (Siderowf et al., 2000). Siderowf et al. noted that an
incremental cost-effectiveness ratio of less than $20,000 per QALY is strong evidence in
support of interventions that are both more costly and more effective than standard care.
The economic burden of PD and rising national health care expenditures,
mandate the need for conducting more cost-effectiveness analysis (CEA) and costbenefit analysis (CB A) studies to determine the value of existing resource-intensive and
emerging PD therapies, including surgical, pharmacological, and nonpharmacological
interventions.
PD Symptoms and Related Patient Health Issues
Motor Symptoms

Tremor. The asymmetrical occurrence of a resting tremor (rhythmic shaking of a
body part) that disappears with voluntary movement is the most common symptom of
PD. It usually affects the arm, leg, or chin (Nutt & Wooten, 2005; Vaughan & Hardie,
2002). Postural instability generally occurs later in PD and is not particularly helpful in
diagnosing early PD; however, it aids in differentiating incipient PD from other forms of
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parkinsonism, such as multiple system atrophy (MSA), progressive supranuclear palsy
(PSP), or drug-induced parkinsonism (QSSAAN, 2006a). Nutt and Wooten (2005) have
noted four common presentations of PD, including (a) tremor, (b) a weak and clumsy
limb, (c) a stiff and aching limb, and (d) a gait disorder.
The resting tremor of PD, which may be present in early PD, is often confused
with the symmetrical tremor seen in patients with essential tremor. Essential tremor
usually affects the hands and may be accompanied by voice and head tremor, whereas
PD tremor may involve the cranial musculature, but usually does not cause head tremor
(Nutt & Wooten, 2005; Vaughan & Hardie, 2002). Resting tremor can be further
distinguished from essential tremor based on the patient’s handwriting. Micrographia
(small, irregular handwriting) is typically seen in PD patients, but the handwriting of
patients with essential tremor is usually large and tremulous (Nutt & Wooten, 2005).
Bradykinesia. About 75% of PD patients initially experience asymmetrical
bradykinesia (Nutt & Wooten, 2005) resulting in impaired mobility and balance.
Bradykinesia may present itself in a variety of ways. PD patients may complain of having
a weak and uncoordinated limb. Clinical examination of the patient’s rapid, alternating
movements, such as finger tapping or toe tapping, however, reveals slowness of
dexterity, decreased amplitude of movement, and irregular, rhythmic movement; yet
muscle strength is normal (Nutt & Wooten, 2005). Bradykinesia usually results in fine
motor and repetitive movements being impaired more than gross motor movements,
which may interfere with the patient’s ability to perform activities of daily living (ADLs)
such as dressing, fastening buttons, and brushing one’s teeth (Nutt & Wooten, 2005;
Wade, Gage, Owen, Trend, Grossmith, & Kaye, 2003). The presence of any of the
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following symptoms are suggestive of bradykinesia: difficulty with fine motor tasks,
difficulty initiating movement, dysphagia, hypophonia, micrographia, change in gait or
walking, masked facies, and freeze attacks (the “off’ phenomenon due to wearing off of
antiparkinson’s medications, such as dopamine) (Maijama-Lyons & Shomon, 2003).
Rigidity. Rigidity resulting from increased muscle tone or stiffness limits mobility
and affects the balance of PD patients. Initially, rigidity symptoms may occur on one side
of the body and affect only one limb. Early symptoms of rigidity may include complaints
of vague stiffness and aching in a limb which may be difficult to differentiate from
musculoskeletal conditions, such as bursitis or arthritis (Marjama-Lyons & Shomon,
2003; Nutt & Wooten, 2005). The rigidity gradually worsens and the patient may exhibit
signs of dragging a foot, slowing of gait, and decreasing arm swing on the affected side,
which may mimic a mild hemiparesis (unilateral paralysis) (Nutt & Wooten, 2005).
Research studies have shown that gait disturbances resulting in reduced velocity, reduced
stride and step length, increased duration of double-limb support phase of stance,
decreased arm swing, and increased trunk flexion are common in PD patients
(Krystowiak et al., 2003). Patients may experience difficulty in ambulation, climbing
stairs, rising from a sitting position, and difficulty rolling over in bed (Ashburn, Stack,
Pickering, & Ward, 2001; DeGoede et al., 2001; Schenkman, 2002). Some PD patients
also experience visual disturbances, most notably spatial contrast sensitivity and blurring,
which complicates their ability to walk safely and predisposes them to falls (Uc, Rizzo,
Anderson, Qian, Rodnitzky, & Dawson, 2005).
Shuffling gait, falls, and freezing are not commonly seen in early PD, however,
and should prompt the astute clinician to consider other diagnoses such as one of the
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other parkinsonism disorders, such as MSA or PSP (Nutt & Wooten, 2005; Olanow,
2004; Vaughan & Hardie, 2002). MSA or PSP should be suspected if the patient’s
parkinsonian symptoms are symmetrical, tremor is absent, and there is rapid disease
progression (QSSAAN, 2006a). Wenning, Ebersbach, Verny, et al.’s (1999) case control
study o f 77 PD patients (as cited in QSSAAN, 2006a) revealed that falling within one
year of diagnosis was the strongest predictor of other forms of parkinsonism. The
QSSAAN’s (2006a) recent evidence-based review practice parameter pertaining to the
diagnosis and prognosis o f new onset Parkinson’s disease concluded that the following
are useful signs in identifying forms of parkinsonism other than PD in patients: (a) falls at
presentation or early in disease course, (b) poor response to levodopa, (c) rapid
progression to Hoehn and Yahr stage 3, (d) symmetry of motor signs, (e) lack of tremor,
and (f) early dysautonomia. Tests useful in distinguishing PD from other forms of
parkinsonism are: (a) levodopa and apomorphine challenge tests, (b) olfaction testing,
and (c) magnetic resonance imaging (MRI) scans. The QSSAAN also concluded that
growth hormone stimulation with clonidine, electrooculography, and SPECT imaging
scans were not useful test in differentiating PD from other forms of parkinsonism.
Postural instability and gait difficulty. Jankovic and Kapadia’s (2001)
retrospective cohort study o f 297 PD patients (as cited in QSSAAN, 2006a) used the
UPDRS to measure the rate o f disease progression among patients categorized as having
either tremor-dominant or postural instability-gait difficulty (PIGD) PD. They found that
older age (> 57 years) at onset of PD and PIGD-dominant PD patients experienced a
more rapid rate of disease progression than did patients with middle-age onset and
tremor-dominant PD (QSSAAN, 2006a). Roos, Jongen, and van der Velde’s (1996)
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single-blind, retrospective cohort study of PD patients (as cited in QSSAAN, 2006a)
revealed the importance of the first presenting symptom of PD in predicting rate of
disease progression, with tremor patients progressing more slowly to Hoehn and Yahr
stage 3 than rigidity/hypokinetic patients. The evidence-based review of seven qualifying
studies (out o f 59) conducted by the QSSAAN (2006a) revealed more rapid rate of
disease progression and greater intellectual, motor, and occupational impairment among
PIGD-dominant PD patients than among tremor-dominant PD patients.
Speech and communications disorders in PD. Hypophonia and other voice
changes occur in 80-90% of PD patients; 45-50% have articulation changes (Miller,
Noble, Jones, & Burn, 2006). Based on diagnostic speech testing, the underlying
mechanisms involved in producing the speech changes evidenced in PD patients are due
to reduction in vocal muscle movement strength, endurance, peak velocity, and
amplitude (Miller et al., 2006). Miller et al. conducted a qualitative study to investigate
the impact o f communication changes in 37 PD patients (n = 23 men; n = 14 women)
and noted four impact themes: (a) interaction with others, (b) problems with
conversations, (c) feelings about intelligibility, and (d) voice. PD patients’ perceptions
regarding their voices conveyed concern about the decreased strength of voice;
deterioration in its quality, rate, and clarity; and difficulty with initiating speech
movements. Patients had expressed concern regarding the physiological and mental
burden and limitations that PD had imposed on their ability to communicate with others,
how they were perceived by others, and how they were able to cope with these changes.
Patients also were cognizant of their distractibility and difficulty with word-finding and
thought processing while engaging in conversation, which influenced their decision to
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participate or not in conversation. As a consequence of their speech and communication
difficulties, PD participants reported that they experienced loss of self-esteem, loss of
dignity, humiliation, and altered socialization processes ranging from apprehension,
disengagement, to complete withdrawal. In the study by Miller et al. (2006), PD patients
reported managing their speech difficulties by using coping strategies that were contextbased, dynamic, and dependent on their cognitive appraisal of the importance of the
situation. Coping strategies used included: (a) monitoring their strength and fatigue
levels before engaging in conversation; (b) using alternative forms of communicating,
including writing notes, sending e-mails, or gesturing; and (c) gauging the reactions of
others. Miller et al. (2006) reported that written communication is further affected in PD
due to tremor resulting in the typical micrographic handwriting seen in PD.
The Lee Silverman Voice Training (LSVT) method has been shown to be
efficacious for improving vocal function in PD patients (Ramig et al., 2001). Ramig et al.
conducted a randomized trial involving 33 PD patients who were randomized either to
receive the LSVT treatment or respiratory therapy (RET) (high respiratory effort only).
The researchers reported that the LSVT group maintained improved vocal loudness and
inflection in voice fundamental frequency when sound level pressure (SLP) and semitone
standard deviation (STSD) were measured at 2-year follow-up.
Nonmotor Symptoms o f PD
Depression. Depression is a major nonmotor symptom of PD (Global
Parkinson’s Disease Steering Committee [GPDSC], 2002; Leentjens, 2004; QSSAAN,
2006b). With the availability of better therapeutics to treat the motor symptoms of PD,
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nonmotor symptoms such as depression, psychosis, cognitive impairment, and dementia
may be responsible for significant disability in PD patients (QSSAAN, 2006b). The
pathological mechanisms for many of the nonmotor symptoms in PD remain poorly
understood (QSSAAN, 2006b). The prevalence of depression inPD and its impact on
QOL for PD patients and their families is significant (GPDSSC, 2002). Based on their
meta-analysis o f 45 PD depression studies (total N = 5,911 PD patients; of whom 1,835
were depressed), Slaughter et al. (2001) calculated the prevalence of depression in PD to
be 31%. Prevalence of minor depression in PD was noted to be 36.6% (n = 155) in three
studies of PD patients (N= 423) (Slaughter et al., 2001). Dysthymia was diagnosed in
22.5% (n = 48) o f 213 PD patients evaluated in four studies (Slaughter et al., 2001). As
Slaughter and colleagues noted in the meta-analysis, the consensus opinion across
researchers is that depression is one of the most common neuropsychiatric disorders in
PD.
Santamaria, Tolosa, and Valles (1986) noted that depression may actually be a
prodromal symptom in a subgroup of PD patients who have onset of PD at a younger
age, decreased disease severity, and a stronger family history of depression. Cummings
(1992) noted that the most reliable indicators of depression in PD are dysphoria,
pessimism, irritability, sadness, and suicidal ideation, but the incidence of suicidal
behavior in PD patients does not differ from that seen in the general population.
Starkstein, Mayberg, Leiguarda, et al. (1992) also noted that duration of PD and prior
history of depression preceding onset of PD was significantly correlated with major
depression. They further noted that greater risk of depression was associated with a
unilateral left hemispheric versus right hemispheric presentation of PD. Converging
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evidence reviewed by the QSSAAN (2006b) suggests that the behavioral symptoms in
PD may be pathophysiologically different from behavioral symptoms observed in the
general population. The meta-analysis of PD depression studies by Slaughter et al.
(2001) indicated that “PD personality” features may be due to the insidious
neurochemical abnormalities, such as depleted serotonin levels associated with PD, and
the resulting cognitive and behavioral changes may be manifestations of progressive
neurochemical deficits. Rogers, Lees, Smith, et al. (1987) noted that progressive frontal
lobe dysfunction may be present in PD patients with major depression due to decreased
dopaminergic neuronal input or secondary pathological changes to the frontal cortex.
Slaughter et al. (2001) conjectured that lack of improvement in depression despite
physical improvement in PD may be due to the severity of the underlying neurochemical
abnormalities versus depressive reaction to the physical limitations imposed by PD.
The Global Parkinson’s Disease Survey Steering Committee’s (GPDSSC) (2002)
multi-center international (six countries) survey of patients (N= 1,020) with PD,
caregivers, and clinicians (N= 203) to assess the HRQOL of people with PD revealed
that Hoehn and Yahr stage o f disease severity and medication use explained only 17.3%
of the variability in the HRQOL of PD patients. Further, the GPDSSC (2002) reported
that multiple regression data analysis results indicated that depression was the most
significant predictor PD-HRQOL (adjusted R1= 0.597) and explained 59.7% of the
variability in HRQOL. The Global Parkinson’s Disease Survey (GPDS) study was a
cross-sectional, randomized selection clinical trial conducted in the United Kingdom,
Italy, Spain, the United States, Canada, and Japan (GPDSSC, 2002). PD participants in
the GPDS study were screened for depression with the Beck Depression Inventory
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(BDI) measurement instrument (GPDSSC, 2002). Despite the fact that depression is
considered to be highly prevalent in PD patients, it is underreported and should be
screened for routinely at PD patients’ office visits (GPDSSC, 2002; Slaughter et al.,
2001). In the GPDS study (2002), only 1% of the PD patients (N= 1,020) reported
depression as being a problem for them, but BDI screening results revealed that 50% of
these patients were considered depressed. Although the QSSAAN (2006b) has recently
endorsed the use of the BDI, Hamilton Depression Rating Scale, and the MontgomeryAsberg Depression Rating Scales to screen for depression in PD patients, it also
concluded that clinically relevant, PD-specific screening and diagnostic tools need to be
developed to better assess for depression, psychosis, and cognitive decline in PD patients
(Weintraub, Oehlberg, Katz, & Stern, 2006). The GPDSSC (2002) also concluded that
better screening for and treatment of depression in PD patients was essential to
improving the QOL for PD patients and their families.
Four classes of antidepressant medications have been used in treating depression
in PD patients, including tricylic antidepressants (TCAs), serotonin reuptake inhibitors
(SSRIs), norepinephrine reuptake inhibitors, and combined reuptake inhibitors
(Slaughter et al., 2001). Slaughter and colleagues (2001) noted that efficacy is lacking
for many o f these medications. Only TCAs have been studied in randomized, placebocontrolled, double-blind clinical trials. The potential ameliorative anticholinergic effects
o f TCAs on other PD symptoms still make them a drug of choice for treating depression
in PD by some neurologists (Slaughter et al., 2001); however, many clinicians prescribe
SSRIs instead to treat depleted serotonin levels, due to their improved safety and better
side effects profile versus that of TCAs. Side effects commonly seen with use o f TCAs
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include, but are not limited to, orthostatic hypotension due to alpha-adrenergic blockade
(which increases risk of falls and injuries), delirium, and memory impairment. In contrast,
SSRIs may increase the likelihood of hepatotoxicity and interfere with hepatic
metabolism of other drugs, but they do not have the cardiac conduction and alphaadrenergic blockade effects seen in TCAs (Slaughter et al., 2001).
Nonpharmacological treatments of depression of PD have shown that
psychotherapy can be o f particular benefit in the younger PD population, which also
have been shown to improve the motor symptoms of PD (QSSAAN, 2006b; Slaughter et
al., 2001; Wint, Okun, & Fernandez, 2004). Electroconvulsive Therapy (ECT) has been
shown to be of short-term benefit in treating depression in PD and its use is
recommended only for emergencies in treating suicidal PD patients due to its risk of
inducing delirium (Slaughter et al., 2001; Wint et al., 2004).
Psychosis, hallucinations, and delusions in PD. The prevalence of drug-induced
psychosis in PD patients, particularly in advanced PD, has been reported to be as high as
22% (Rascol, Goetz, et al., 2002; Rascol, Payoux, Ory, Ferriera, Brefel-Courbon, &
Montrastruc, 2003). Whether or not they are drug-induced, psychoses, hallucinations,
and delusions contribute significantly to the disability in PD and present another
treatment challenge for the clinician (Holroyd, Currie, & Wooten, 2001; QSSAAN,
2006b; Thanvi, Munshi, Vijaykumar, & Lo, 2003; Wint et al., 2004). Cummings (1991)
reported that the prevalence of hallucinations and delusions in PD ranges from 6-40%.
Naimark, Jackson, Rockwell, et al. (1996) have noted that psychosis, hallucinations,
delusions (as well as dementia) are major risk factors for nursing home placement.
Effective agents for treatment of psychosis include clozapine and quetiapine. Clozapine
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also appears to improve the motor symptoms seen in PD, but this has not been noted
with quetiapine (QSSAAN, 2006b). However, quetiapine has a better safety profile than
clozapine, which needs to be closely monitored for the life-threatening side effect of
agranulocytosis (QSSAAN, 2006b).
The most common types of hallucinations that occur in PD are visual (30%),
auditory (10%), and tactile (8%) (Wint et al., 2004). Biousse, Skibell, Watts, Loupe,
Drews-Botsch, and Newman (2004) studied the ocular symptoms in 61 patients (n —30
PD patients; 31 non-PD patients) to assess the ophthalmologic features of PD. They
found that 25% o f the PD patients had visual hallucinations that were attributable to
decreased visual acuity, cognitive impairment, medications such as dopamine or
anticholinergics, or a combination of these factors. Visual hallucinations in early,
untreated PD implies that they may be a direct result from underlying PD pathology
rather than side effects of PD medications. This is an ominous prognostic finding in early
PD and may indicate the potential evolution of this process into dementia with Lewy
bodies (DLB). At 2-year follow-up, Biousse et al. (2004) reported that none of their PD
patients who had hallucinations had progressed to developing dementia. Blepharospasm
and eyelid apraxia, which often occur in PD, were noted only in a few PD participants;
however, decreased tear-film breakup time (TFBUT) leading to increased incidence of
dry eye did occur in two thirds of PD patients. Their research points to the need for
clinicians to be aware of the potential effect that prescribed medications may have on the
vision of PD patients. Other significant findings included: decreased blink rate likely due
to hypokinesia related to decreased dopamine activity, and complaint of ocular irritation
(Biousse et al., 2004).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

35
Uc et al. (2005) studied visual dysfunction in 237 (n = 76 PD patients; n = 161
non-PD patients) community-dwelling adults. They used a battery of visual and
neuropsychological cognitive testing to assess participants’ visual acuity (VA), contrast
sensitivity (CS), visual speed of processing and attention, spatial and motion perception,
visual and verbal memory, visuoconstructional abilities, executive functions, depression,
and motor function (Uc et al., 2005). PD patients were also assessed using Hoehn and
Yahr Scale for stage of PD and the UPDRS Motor Scale. Salient research findings
reported by Uc et al. (2005) indicated that PD participants performed significantly worse
than controls on (a) near and far visual acuity, and contrast sensitivity; (b) tests of speed
of processing, attention, and usual field of vision; (c) tests of visual cognition and
construction and memory; (d) tests of executive functions; and (e) visual motion
perception testing. Further, Hoehn and Yahr stage correlated with impairment in visual
attention, memory, and constructional abilities, whereas the UPDRS motor scores did
not correlate with any o f the vision or cognitive tests (Uc et al., 2005). A disturbing
finding among PD participants that the researchers noted, yet consistent with other
research, was the presence o f mild, widespread cognitive deficits across multiple
domains (Uc et al., 2005). This finding does not prognosticate well for those with early
PD since it indicates increased risk of developing dementia in later stages of PD (Rascol,
Goetz, et al., 2002; Uc et al., 2005; Vaughan & Hardie, 2002; Wint et al., 2004).
Dementia in PD. Prevalence of dementia is estimated to occur in one third of PD
patients, particularly in late stage PD (Rascol, Goetz, et al., 2002). The Mini-Mental
State Examination (MMSE) and the Cambridge Cognitive Examination (CAMCog) may
be considered for use in screening PD patients for possible cognitive impairment or
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dementia (Hobson & Meara, 1999; QSSAAN, 2006b), but the MMSE is recommended
as being the more easily administered tool. MacPhee and Steward (2001) identified the
following risk factors for developing dementia in PD: older age at onset of PD, severity
o f initial motor deficit, longer duration of illness, and psychotic reactions to levodopa.
Lewy body dementia, the second most common type of neurodegenerative dementia, is
seen in both PD and Alzheimer’s disease (Bertram & Tanzi, 2005). Dementia, like the
presence of hallucinations and psychosis, is a major risk factor for nursing home
placement (Wint et al., 2004). The evidence-based review conducted by the QSSAAN
(2006b) has determined that rivastigmine is effective in improving cognitive functioning
in patients with PD dementia or DLB, but it may exacerbate PD tremor; alternatively,
PD dementia may be treated with donepezil (Aricept).
Dysautonomia. PD’s impairment of autonomic nervous system functioning may
be manifested by symptoms such as orthostatic hypotension; neurogenic bladder,
including urgency, frequency, and incontinence; constipation; drooling; and sexual
dysfunction, including erectile dysfunction (Rascol, Goetz, et al., 2002). Minimal
research exists regarding PD’s role in dysautonomia. One study was conducted to
evaluate treatment of erectile dysfunction in PD. Hussain, Brady, Swinn, Mathias, and
Fowler (2001) conducted a randomized trial of 24 men (n = 12 PD patients; 6 MSA
patients) with erectile dysfunction (ED) to evaluate the treatment effectiveness of
sildenafil (Viagra) 50 milligrams on ED and its impact on orthostatic hypotension.
Sildenafil was efficacious in treating ED in the PD patients and caused only a minimal
change (5mm to 9 mmHg) in blood pressure, whereas it improved the ED in MSA
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patients, but caused a severe drop (approximately 50%) in blood pressure that resulted in
closure o f this arm o f the study (Hussain et al., 2001).
Medical Treatments fo r Motor Symptoms o f PD
Pharmacotherapeutics are a mainstay in the treatment and control of Parkinson’s
disease-related symptoms. For initial PD therapy, effective agents include dopamine
agonists such ropinirole or pramipexole, carbidopa plus levodopa, anticholinergics,
amantadine, and certain monoamine oxidase B (MAO-B) inhibitors (Huse, CastelliHaley, Orsini, Lenhart, & Abdalla, 2006; Nutt & Wooten, 2005). Although drug therapy
is the major treatment modality for PD, it may have its own attendant consequences and
side effects that can also impact the HRQOL for PD patients causing symptoms such as
dyskinesiae, hedonistic dopamine dysregulation syndrome (Giovannoni, O’Sullivan,
Turner, Manson, & Lees, 2000; Marras et al., 2004), freezing orthostatic hypotension,
hallucinations, psychoses, (Nutt & Wooten, 2005; Wint et al., 2004), and visual
disturbances (Uc et al., 2005). Such consequences are generally seen in patients that
consume increased and more frequent doses of dopamine to control their PD symptoms
or are on combination therapy.
Levodopa was introduced more than 30 years ago for the treatment of PD (Lang
& Lozano, 1998). Levodopa’s success in treating the motor symptoms of PD resulted in
less interest in using surgical treatments for PD (Olanow, 2004). Despite its success in
treating PD symptoms, theoretical concerns have been raised regarding the possibility
that levodopa increases the rate of progression of PD because of toxic free radical
generation (QSSAAN, 2006c; Wasielewski & Koller, 1998). Murer, Raisman-Vozari,
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and Gershanik’s (1999) research indicated that there is no clinical evidence to support
that such toxicity occurs. Thus, levodopa remains the most effective treatment for PD
even today, but it is not without its attendant complications and consequences.
Levodopa-induced dyskinesias (LID), involuntary jerking movements, often
become very problematic for PD patients. Most PD patients require increasingly higher
doses over the course o f their disease to control their PD symptoms which can lead to
the development o f LID. These motor complications usually are seen in patients who
have been treated with levodopa for more than 5 years (Nutt & Wooten, 2005; Olanow,
2004). As patients become refractory to increasing doses and frequencies of levodopa
administration, other medications are added to their medical treatment regimen.
A new class o f drugs called catechol-O-methyltransferase inhibitors (COMT), for
example tasmar and comtan, may be used to supplement the levodopa and help decrease
the PD patient’s “off” time. “Off” states potentially occur when PD medications wear off
and are no longer available to control the symptoms. During an “off” state, patients can
literally “freeze” in position and are unable to move until more medication is given and
reaches an adequate blood level to control patient’s symptoms. The difficulty with
COMT inhibitors is that they can increase the levodopa dyskinesias, whereas amantadine
may lessen them (Marjama-Lyons & Shomon, 2003).
Anticholinergic drugs such as cogentin and artane do help to control the PD
tremor, excessive drooling, and muscle rigidity, but they are not very effective in
lessening the bradykinesia. Like the COMT inhibitors, anticholinergic drugs also create
troublesome side effects manifested as hallucinations, urinary retention, constipation, dry
mouth, blurred vision, and orthostatic hypotension (Marjama-Lyons & Shomon, 2003).
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Orthostatic hypotension further increases the incidence of falls in the PD patient
population.
The MAO inhibitor selegiline was once thought to help slow the progression of
PD, but more recent research studies have not supported this claim, and it now has a
limited role in treatment of PD (Weiner, Shulman, & Lang, 2001). Several
neuroprotective agents such as Vitamin E, Coenzyme Q10, and bromocriptine have been
studied in clinical trials, but no conclusive evidence exists to support their efficacy
(Rascol, Goetz, et al., 2002; Nutt & Wooten, 2005; QSSAAN, 2006c).
Surgical Treatments fo r PD

Renewed interest in surgical treatment of PD symptoms has occurred due to
limitations o f drug therapy, improved surgical techniques and instrumentation, use of
microelectrode monitoring to more precisely define surgical targets, and better
understanding of neuroanatomy and neurophysiology (Gray et al., 2002; McRae, Cherin,
et al., 2003; Olanow, 2004; Poliak et al., 2002). Ablative lesioning of the globus pallidus
interna (GPi) has yielded beneficial results from pallidotomy as evidenced by a marked
reduction in contralateral dyskinesia (Olanow, 2004). Attendant side effects may occur
from pallidotomy, however, including hemorrhage and damage to surrounding structures
(Olanow, 2004). Dysarthria, dysphagia, and cognitive impairment can occur in bilateral
pallidotomy (Olanow, 2004).
Ablative procedures have largely been replaced by deep brain stimulation (DBS)
procedures, which involve implanting a permanent electrode in the selected brain target
and connecting it to an external radioffequency stimulating device at 100-180 Hz (Lang
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& Widner, 2002; Olanow, 2004). Poliak et al. (2002) reviewed 117 primary research
studies that focused on three types of DBS procedures as a treatment for PD and its
associated symptomatology. The ventral medial nucleus of the thalamus (Vim), globus
pallidus internus (GPi), and the subthalamic nucleus (STN) were the three main DBS
surgical sites specifically identified to treat the cardinal symptoms of tremor, rigidity, and
bradykinesia. The researchers noted that there was little comparative data between these
procedures to date. Their review article was an attempt to bridge that gap. They
attempted to make the case that given appropriate patient selection, DBS is an
efficacious treatment for PD that contributes to improved patient functional status and
quality o f life outcomes.
Poliak et al. (2002) compared and contrasted the benefits and risks of Vim, GPi,
and STN DBS procedures to each other as well as to pharmacological management of
PD symptoms. Vim DBS’ effectiveness is limited to controlling tremor symptoms only
and has fallen into disfavor as a viable treatment for PD. Bilateral STN DBS seems to be
more effective than GPi DBS in controlling PD symptoms, but a large longitudinal
randomized clinical trials need to be conducted to garner further support for this as the
treatment of choice for PD patients (Krack et al., 1998; Lang, 2000; Obeso et al., 2001;
Poliak et al., 2002).
While noting that DBS procedures carry adverse effects resulting in patient
morbidity and mortality, Poliak et al. (2002) concluded that most researchers agreed that
the benefit-risk ratio for DBS as an effective treatment for PD patients is favorable. Their
systematic review o f 117 research studies resulted in support of three findings:
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1. The benefit-to-risk ratio of DBS to treat movement disorders, particularly
PD, was favorable.
2. STN DBS is the most efficacious DBS procedure in treating the cardinal
symptoms of PD.
3. Young-onset PD patients with levodopa-induced motor dyskinesias, who still
respond well to levodopa and who exhibit no cognitive, behavioral, or mood
impairment, benefit the most from STN DBS (Pollack et al., 2002).
Moro, Scerrati, Romito, Roselli, Tonali, and Albanese (1999) conducted a
descriptive, nonrandomized, investigational research study in which they recruited 7
patients (n = 6 females; n = 1 male) who had severe PD. Their research attempted to
determine whether or not the use of chronic stereotactic neurostimulation to inactivate
the STN would result in effective treatment of off-state related signs of motor
fluctuations, i.e., tremor, rigidity, and bradykinesia. They did determine that chronic,
bilateral high-frequency stimulation of the STN was an effective treatment modality to
inactivate hyperactive STNS, thereby reducing parkinsonian signs and off-drug related
phenomena in their sample o f 7 patients. Given the small numbers of participants in many
o f these research trials, there is a need for further research trials to determine the efficacy
of DBS, the best surgical location for controlling PD symptoms, and the most
appropriate patient selection for DBS implantation (Lang, 2000; Sheriff & Chenoweth,
2003; Siderowf, Jaggi, et al., 2006).
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Quality of Life in Parkinson’s Disease
The Global Parkinson’s Disease Survey Steering Committee (2002) has noted
that current PD disease-management guidelines are limited due to lack of knowledge of
the factors that influence the HRQOL in PD. Quality of life (QOL) is a multidimensional
concept, which means different things to people depending on their perspective at any
given point in time. Health is another domain that contributes to QOL (Cheng, Siderowf,
Swartruber, Eisa, Lee, & Vickrey, 2004; Marinus, Ramaker, vanHilten, & Stiggelbout,
2002). For people living with chronic diseases such as PD, QOL may change daily and
even frequently within the course of a day, as they struggle to adapt to and manage the
challenges which the disease thrusts upon them (Baker & Graham, 2004; Cote,
Sprinzeles, Elliott, & Kutscher, 2000; Damiano, Snyder, Strausser, & Willian, 1999;
Harrison, Preston, & Blunt, 2000; Hobson, Holden, & Meara, 1999). In a general sense,
QOL refers to a person’s sense of well-being, autonomy, and purpose in life, which
encompasses the person’s physical, mental, and social functioning (Fleming, Cook,
Nelson, & Lai, 2005; Jahanshahi & Marsden, 2000; Siderowf, Ravina, & Glick, 2002;
Welsh, 2004).
Health-related quality of life (HRQOL) comprises the total effect that illness and
wellness has on a person’s biopsychosocial well-being and the effect that illness has on
his or her actual and desired life (Jahanshahi & Marsden, 2000; Shindler, Brown,
Welburn, & Parkes, 1987; Walsh & Bennett, 2001). Health-related QOL has become a
central issue in health care delivery because of its impact on measuring the effectiveness
o f patient-centered clinical interventions with respect to patient and system outcomes, as
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well as determining resource allocation and policies (Damiano et al., 2000; Gage,
Hendricks, Zhang, & Kazis, 2003; Guyatt, Feeney, & Patrick, 1993; Hays et al., 1994).
Measuring Quality o f Life in PD
Peto, Jenkinson, and Fitzpatrick (1998) endeavored to assess the impact of PD
on QOL by developing an instrument, the Parkinson’s Disease Questionnaire-39 (PDQ39), that would measure disease-specific quality of life indicators for Parkinson’s disease.
They surveyed PD patients (N —359) from eight branches of the PD Society in the
United Kingdom on 65 items pertaining to aspects of PD. A factor analysis was
performed on the data, which led to elimination of redundant items and resulted in a 39item questionnaire comprised o f eight factors denoting quality of life indicators (mobility,
activities o f daily living, emotional well-being, stigma, social support, cognitions,
communication, and bodily discomfort) (Peto et al., 1998). Repeat testing has shown
that the PDQ-39 is sensitive to change (p < 0.01) as well as having good reliability,
validity, and reproducibility.
Determinants o f Quality o f Life in PD

Schrag, Jahanshahi, and Quinn (2000) used the self-administered PDQ-39,
ED-5D, and SF-36 to assess the QOL of 124 probable PD patients from 15 general
practices in the United Kingdom. Participants also completed the Beck Depression
Inventory (BDI). Clinicians assessed participants’ status on the Hoehn and Yahr disease
severity scale, motor portion o f the UPDRS, and the MMSE. Response rate for
completed questionnaires was 78%. Research findings revealed that depression was the
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strongest indicator o f QOL in PD patients. Schrag and colleagues (2000) noted that
other key contributors to QOL of life were disability, postural instability, and cognitive
impairment. Significant correlations with QOL included disease severity (r = 0.6,
p < 0.001), UPDRS motor score (r = 0.41, /? < 0.001), and UPDRS motor score o f axial
features (r = 0.57, p < 0.001), but duration of disease (r = 0.18,/? = 0.19) and age (r =
0.14,/? = 0.25) were not significantly correlated with QOL.
The cross-sectional, randomized Global Parkinson’s Disease Survey study (2002)
conducted in six countries withPD patients (N= 1, 020), caregivers (N = 687), and
clinicians (N= 203) to identify the determinants of HRQOL in PD yielded similar results
to those noted by Schrag and colleagues (2000). The aim of the GPDS was to identify
key management issues that have the greatest effect on HRQOL in PD and utilize that
information to develop universal interdisciplinary guidelines for the effective
management o f PD. Several medication regimens were assessed for their impact on
QOL, but only one was shown to be a significant predictor of QOL in PD—levodopa.
Using stepwise multiple regression analysis, disease severity as measured by Hoehn and
Yahr stage and levodopa treatment explained 17.3% of the variance in HRQOL in Step
one regression. Step two regression analyses identified three other significant
determinants o f HRQOL in PD—depression (adjusted R2 = 0.582, p = <0.001)
(GPDSSC, 2002), satisfaction with explanation of condition at diagnosis, and current
feelings of optimism. PD patients, however, underreported their depression (1%), which
conflicted with the 50% rate detected by BDI results.
Satisfaction with the explanation o f condition at diagnosis and current feelings of
optimism were also significant (p < .05) contributors to HRQOL in PD (GPDSSC,
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2002). The significance o f the explanation o f one’s condition at time of diagnosis
acknowledges the important role that accurate information giving and patient education
plays in contributing to the QOL of PD patients and their families (GPDSSC, 2002).
Further, it supports the need for quality patient educational materials and psychological
interventions to better meet the needs of PD patients when giving them their diagnosis
(GPDSSC, 2002; Nutt & Wooten, 2005).
Adherence and Nonadherence to Treatment Regimen and QOL
Patient adherence not only to prescribed drug treatments, but also adherence to
treatment schedules is essential to achieve effective symptom control, enhance QOL, and
improve outcomes forPD patients (Grosset, Bone, & Grosset, 2005; Peterson, Takiya,
& Finley, 2003). Dunbar-Jacob et al. (2000) noted that approximately 50% of patients
with chronic diseases have medication adherence problems that limit their obtaining the
optimal benefit from their prescribed treatment regimens (Cameron, 1996; MacStravic,
2005; Schaffer & Yoon, 2001; Vermeire, Hearnshaw, VanRoyen, & Denekens, 2001).
Leopold et al. (2004) reported that although drug adherence to prescribed treatment
regimens has been well studied in several other chronic diseases such as asthma,
hypertension, and diabetes, it has not been studied in PD patients prior to their research
(Sherbourne, Hays, Ordway, DiMatteo, & Kravitz, 1992). To date, there is limited
extant research regarding drug adherence to prescribed treatment regimens in PD
patients, which further supports the importance of the current study. Nonadherence to
prescribed drug and other treatment regimens can result in poor symptom control that
could result in serious consequences to PD patients, such as increased frequency of
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“on-off’ states, falls, injuries, etc. Research that may provide insight to perceived
barriers and facilitators o f PD patients’ adherence to prescribed treatment regimens may
lead to improvement in patient safety and quality of care, patient outcomes, and systems
outcomes.
Parkinson’s Disease and Health Care Delivery Models
Confronting the life-changing diagnosis of Parkinson’s disease and its complex
biopsychosocial ramifications is, undoubtedly, one of the most daunting tasks for PD
patients and their families. As Clark (2003) noted, clinicians have a central role in
establishing the partnership between patients and clinicians that is essential to effective
chronic disease management. PD patients have complex health-related and social issues
that impact their QOL as well as their ability to self-manage the PD. Clinicians across
disciplines need to expand their conceptual approach to PD care and other chronic
diseases to more effectively and holistically address the multiple issues facing patients
and their families (Clark, 2003; Koch, Jenkin, & Kralik, 2004; Kralik, Koch, Price, &
Howard, 2004; Lorig, Stewart, et al., 1996; Sanson-Fisher, Campbell, Redman, &
Hennrikus, 1989; Welsh, 2004; Yarcheski, Mahon, Yarcheski, & Cannella, 2004).
Welsh (2004) reported on a QOL conceptual model for delivering health care to
PD patients that she and her colleagues have developed. Further, Welsh and her
colleagues have advocated adopting their QOL conceptual model for delivering health
care to PD patients and discarding the traditional medical model with its limited scope.
The Parkinson’s disease QOL model espoused by Welsh and colleagues addresses 12 PD
QOL domains, including physical function, mental health/emotional well-being, self-
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image, social functioning, health-related distress, cognitive function, communication,
sleep and rest, eating, role function, energy/fatigue, and sexual function (Welsh, 2004).
Holman and Lorig (2004) contended that there must be a “complementary
sharing o f knowledge and authority in the health care process between patient and health
care professionals” (p. 239) in order to achieve effective and efficient chronic disease
management. This philosophical approach has been the underpinning of the patient
education, collaborative Chronic Disease Self-Management Program that was developed
at Stanford University by Lorig and Holman (see Model 1 in Appendix A) (Lorig, 2003 a,
2003b; Lorig, Homan, et al., 2006; Lorig et al., 1996). Lorig et al.’s (1996) Chronic
Disease Self-Management Program integrated within a PD quality of life context
provides the conceptual framework for the PDCC patient education model developed for
implementation in this research study (represented as Model 2 in Appendix A).
Traditional Health Care

The traditional health care delivery model, which is often referred to as the
medical model, places constraints on the role of the patient as the recipient of health care
and patient education (see Model 3 in Appendix A). The traditional health care model
focuses on disease markers for establishing diagnoses and assessing outcomes of care
(Welsh, 2004), yet many complex diseases such as PD may be better managed if a more
holistic, QOL approach is used to address the multidimensional aspects of the illness.
In the traditional patient education approach, health care professionals define the
patients’ problem(s) and identify the learning needs that they think patients may have for
effective management of their disease. Patients are not active participants in the
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education process, but rather the passive recipients of knowledge being conveyed by
health care professionals (Lorig et al., 1996).
Collaborative Patient-Professional Health Care
Bodenheimer et al. (2002) have noted that emerging chronic disease paradigms
focus on the patient-professional partnership that includes collaborative care and disease
self-management education (see Model 2, Appendix A). PD patients, like patients with
other chronic diseases, have to learn how to live with and self-manage their symptoms
and disease-related issues on a daily basis. Central to the ability of self-managing their
disease is having the confidence that they have the knowledge, skills, and ability, i.e.,
self-efficacy, to carry out the required behaviors and tasks to achieve the desired goals
(Bodenheimer et al., 2002). The concept of self-efficacy is derived from social-cognitive
theory (Bandura, 1977, 1986, 2004; Bandura, Reese, & Adams, 1982; Lorig et al.,
1996).
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METHODS
The purpose of this project was to investigate the effectiveness of an emerging
paradigm in patient education and disease self-management in a population of patients
diagnosed with middle-stage Parkinson’s disease in comparison to the traditional patient
education and disease management approach. This paradigm is illustrated with Model 1
(see Appendix A), which conceptually depicts the interaction between disease self
management education and patient’s self-efficacy for PD self-management. Resulting
from their interactions with health care professionals, patients established and wrote
action plans based on problems, goals, and short-term objectives identified by the
patients that might impact PD-QOL. The investigator used the concepts shown in Model
1 (see Appendix A) to develop a collaborative, interdisciplinary care approach,
Collaborative Care and Patient Education for PD Self-Management Model (see Model 2,
Appendix A), to teach PD self-care management strategies to Parkinson’s patients.
Secondly, the study was designed to compare the effectiveness of the new model
of health care delivery and patient education with the traditional model (see Model 3,
Appendix A) in enhancing PD patients’ self-reported perceived PD-HRQOL one month
after completion of the treatment intervention. Based on their conceptual consistency to
the variables being studied and their psychometric properties, the Self-Efficacy fo r
Managing Chronic Disease 6-Item Scale and the PDQ-39 Parkinson’s Disease Quality
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o f Life Questionnaire were the data collection instruments selected to measure these
outcomes.
Design and Setting
A single-center, randomly assigned intervention study was conducted with
Parkinson’s disease patients to compare the two paradigms of patient education for
disease management and their impact on patient self-reported self-efficacy and PD QOL
outcomes—the Parkinson’s Disease Collaborative Care (PDCC) and Parkinson’s
Disease Informational Training (PDIT) models. The PDCC and PDIT participants were
recruited from patients who attended the outpatient Hauenstein Parkinson’s Center
(HPC) in Grand Rapids, Michigan. Formal Human Subjects Institutional Review Board
(HSIRB) applications for approval to conduct research on human subjects were
submitted to the institutional review boards at Western Michigan University and St.
Mary’s Health Care in Grand Rapids, Michigan, with which the HPC is affiliated. The
investigator was granted formal approval to conduct the study by Western Michigan
University’s HSIRB in July 2007 and by the HSIRB at St. Mary’s Health Care in August
2007 (see Appendix B). Having received HSIRB approval from both institutions, the
process for recruiting study participants was initiated. Subsequent expedited HSIRB
approval was received for additional patient education materials and for the revised
postintervention follow-up letter to study participants (see Appendix B).
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Participants
Sample
The current patient population at the Hauenstein Parkinson’s Center (HPC) was
estimated to be approximately 300 patients. The entire patient population at the HPC
was screened by the nurse clinical manager for possible enrollment based on the inclusion
and exclusion criteria for the study (Table 1). She deemed that a total of 202 PD patients
were potentially eligible for the study. Given the nurse clinical manager’s workload
demands, she obtained permission (in compliance with the Health Insurance Portability
and Accountability Act [HIPAA] regulations) for the investigator to help with mailing
letters about the study to potential participants (see Appendix C).
For this study’s sample population, the investigator had planned to enroll up to 48
participants (N= 48) and then randomly assign them to two equal groups (24 per group),
that is, either the treatment group (PDCC) or the control group (PDIT). For a Phase II
clinical trial, such as this pilot study, a maximum enrollment of 20 patients per intervention
group is recommended (Friedman, Furberg, & DeMets, 1998; Hulley et al., 2001). Thus,
allowing for 10% rate of attrition, a maximum enrollment of 48 patients was desirable.
Recruitment
The nurse clinical manager of the HPC provided the investigator with the list of
the 202 potential participants over a period of several weeks. Over a period of 9 weeks,
the investigator mailed a letter o f invitation (see Appendix C) to all potential
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Table 1
Study Inclusion and Exclusion Criteria
Item

Inclusion

Exclusion

Modified Hoehn & Yahr
Parkinson’s Disease
Stage

Equal to Modified Hoehn &
Yahr Stages 2 through 3

Less than Modified Hoehn &
Yahr Stage 2 or greater than 3

Age

>30 years of age, but have
not had their 80th birthday

Less than 30 years or greater
than or equal to 80 y. o.

Language

Speak, read, & write English

Unable to speak, read, or write
English

Hearing

Hearing or aided-hearing
sufficient to support normal
conversation and direction
following

Deafness or hearing loss (aided
or not) insufficient to support
normal conversation and
direction following

Mini-Mental State
Exam (MMSE)

Score of 23 or greater

Score of 22 or less

Dementia

No established diagnosis of
dementia or other cognitive
impairments

Known diagnosis of Dementia
with Lewy Bodies (DLB) or
other dementiae

Education

9thgrade or higher

Less than 9th grade

Telephone Access

Has access to telephone in
home (either land line or
cellular phone)

Does not have access to
telephone in home (either land
line or cellular phone)

Transportation

Has access to reliable
transportation to and from
clinic site to attend the 3
educational sessions

Does not have access to reliable
transportation to and from clinic
site to attend the 3 educational
sessions

Informed Consent

Signed

Not signed

HIPAA Consent

Signed form

Not signed
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participants informing them about the study and inviting them to participate in it. A study
brochure (see Appendix C), which explained the study in greater detail, was enclosed
with the letter. Patients were asked if they were interested in participating in the study
and, if so, were requested to complete the enclosed response form (see Appendix C). On
the patient response form, potential participants were asked to answer two demographic
questions that pertained to the patient’s date of birth and the number o f years since
diagnosed as having Parkinson’s disease. They were also asked if they had access to
reliable transportation and telephone. If participants were willing to have the investigator
contact them, they were asked to include their telephone number on the response form.
A stamped, self-addressed envelope was included for patients to submit their
responses to the investigator. Returned response forms were mailed directly to the
investigator at the Graduate Center of Western Michigan University in Grand Rapids,
Michigan. Thirty-one percent (62/202) of the potential participants mailed their response
forms to the investigator. The investigator screened all returned patient response forms
and called the HPC patients who had indicated an interest in the study (N= 62). The
investigator did not contact participants who indicated that they were not interested in
the study (N= 140) by their lack o f response. The investigator also attended PD patient
support group meetings to disseminate information about the study in effort to stimulate
recruitment o f study participants.
The investigator or a trained research associate arranged to meet with the
potential participants in their home or at the Parkinson’s Association of West Michigan,
to explain the study and do the pretesting related to the study’s eligibility criteria.
Research associates were hired to assist with the recruitment and enrollment of study
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participants. Two o f the three research associates were experienced clinical research
associates and one was an upper division undergraduate college student. Prior to
recruiting study participants, all three took and passed a research integrity course offered
either by Citiprogram.org or the National Institutes of Health and obtained certification.
Subsequently, the investigator trained all three research associates how to administer and
score the Mini-Mental State Exam. The investigator also reviewed the study and HIP AA
consents, informed consent process, and demographic information sheet with the
research associates.
Each research associate completed two prospective participant home visits with
the investigator. During the first joint home visit, each research associate observed how
the investigator conducted the informed consent process and administered the required
screening tests to determine the client’s eligibility, and if client wanted to be enrolled in
the study. At the second joint home visit, roles were reversed so that the investigator
observed and supervised the research associate’s conduct of the informed consent
process and administration of the screening tests to the potential study participant. At
this point, each research associate had met the researcher’s expectations and then was
permitted to independently screen and enroll potential study participants. Because letters
were sent out to potential participants over a period of several weeks (rather than as a
mass mailing as had been originally planned), only one research associate and the
investigator were needed to recruit and enroll all eligible participants over a period of
approximately 12 weeks.
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Informed Consent and HIPAA
At the patient’s clinic or home visit, the investigator or research associate
conducted the informed consent process for the study with the patient. During the
informed consent process, potential participants had the following explained to them:
(a) the purpose and indications of the study; (b) study procedures; (c) risks, benefits, and
alternatives o f study; (d) assurances of anonymity and confidentiality; (e) authorized
entities that would have access to their information; (f) that participation in the study was
voluntary and they should not feel coerced to participate; (g) that they had the freedom
to withdraw from the study at any time without incurring any risk of penalty or prejudice
or suffering diminution of care; (h) how to contact the investigators and chair o f the
Human Subjects Institutional Review Board (HSIRB) at Western Michigan University
and at St. Mary’s Health Care if they had any concerns; and (i) when study results would
become available to them (see Appendix D).
Both HSERBs concurred with the investigator that the study posed minimal
potential risks to the participants and that potential benefits might be significant.
Identified potential risks to participants included: (a) fatigue, (b) emotional distress due
to confronting health concerns, (c) participating in a group process, and (d) concerns
regarding confidentiality of personal data. The recruiters informed potential participants
about the measures that were to be implemented to assure confidentiality and protection
o f any o f their personal data that were collected during the study. Further, participants
were informed that it was impossible to assure them of complete anonymity due to
participation in a group process in either the treatment or control group. To minimize
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other identified risks, a break period was scheduled during each interventional session to
assure that participants had time to relax, interact with others in their group, and take
nourishment. Several of the participants in both groups, however, preferred to have
access to refreshments throughout the session rather than just during a formal break
time.
Recruiters also informed participants of any potential benefits that they may
experience by being in the study which included (a) increased knowledge of and selfconfidence (self-efficacy) regarding management of PD care and other health issues,
(b) increased problem-solving skills to deal with health-related and social support issues,
(c) opportunities for increased social interaction, (d) increased QOL, and (e) an
opportunity to participate in research that may benefit other PD patients and families. To
provide participants with further assurances of confidentiality of collected data, collected
data would be stored in a locked file in the investigator’s office in Grand Rapids,
Michigan. To further protect participants’ personal health information, participants were
given a study-specific identification number assigned by the investigator. The participant
numbering system (ranging from 1 to 41) was determined by the investigator and did not
use any personal identifiers unique to individual participants, such as social security or
medical record numbers. A master list and code book for all study participants was
developed and used by the investigator. This was destroyed by the investigator once all
data had been analyzed. Only the principal investigator, co-principal investigator, and
biostatistician had access to the data. Participants were informed that, after data analysis
was completed, the data would be stored and secured in locked cabinets housed in the
doctoral program data storage unit at Western Michigan University. Dr. Nickola W.
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Nelson, director o f the doctoral program in Interdisciplinary Health Studies at Western
Michigan University, will be responsible for the secured data and maintaining
confidentiality until such time that it is deemed that the data can legally be destroyed.
The Health Insurance Portability and Accountability Act (HIPAA) and its role in
the protection o f research participants also was explained to study participants. The
HIPAA consent for the study was then reviewed and discussed with the participant (see
Appendix D). Copies of the participant’s signed research study consent and H3PAA
consent were placed in the participant’s medical record at the Hauenstein Parkinson
Center. Copies o f both consents also were given to the participant to retain for their
personal record.
After the patient had signed the informed consent for the study and the HIPAA
consent, the investigator or research associate then proceeded to determine the
participant’s eligibility status based on inclusion and exclusion criteria which included
administering screening tests (Table 1) (see Appendix E) and obtaining demographic
information (see Appendix F). Participants who were deemed ineligible for the study
were not enrolled, but their interest in the study was acknowledged and they were
informed as to when study results would become available.
All 62 respondents were screened (see Appendix G), but only 41 were enrolled in
the study. O f the 21 respondents who were not enrolled, 13 declined to participate due
to disinterest or the possibility of inclement weather, two had a possible diagnosis of
dementia, three were older than the upper age limit for eligibility, one had early-stage PD
rather than required criterion of middle-stage PD, and the spouses of two potential
participants informed the investigator that the person had died. After all participants
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were enrolled, Excel’s random number operators program was used to assign
participants randomly to condition. This procedure was used to decrease systematic bias
in group assignment and to increase the likelihood of equivalent groups. Indeed, this
procedure resulted in groups that were approximately of equal size in that the
experimental group (PDCC) had 21 participants, and the control group (PDIT) had 20.
As will be seen subsequently, the groups were similar in other ways as well. The
investigator developed a code book (using an Excel spreadsheet) for registering
participants. This codebook also served as a tracking system denoting each participant’s
randomly assigned group. The system also recorded later: participants’ study
identification number, gender, age, birth date, Modified Hoehn and Yahr stage of PD,
MMSE score, years of education, monitored their attendance at intervention sessions,
date and reason(s) for attrition, and completion of PDQ-39 and Self-Efficacy measures
at baseline, completion o f intervention, and at 1-month follow-up.
Measurement Instruments
Screening Instruments
After initially screening interested patients for research eligibility, the investigator
or research associate administered screening measures (Table 1) to potentially eligible
participants to assess their cognitive status (Mini-Mental Status Exam [MMSE]) (see
Appendix E) and stage of Parkinson’s disease using the Modified Hoehn andYahr (MH
& Y) scale (see Appendix E).
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Mini-Mental State Examination (MMSE)
The MMSE is a clinical assessment tool that includes 11 items and has a
maximum score of 30 points. It can be used to assess a participant’s cognitive status
based on their orientation to time and place, registration (repeating three objects), recall
ability, naming objects, calculation or attention (Serial 7s or spelling “world”
backwards), short-term memory, following verbal and written commands, and
constructional ability (drawing an object) (McDowell, 2006). The MMSE can be used to
assess change in the cognitive status of an individual, but it cannot be used to diagnose
dementia (McDowell, 2006).
Several research studies (Butler, Ashford, & Snowdon, 1996; Launer, Dinkgreve,
Jonker, Hooijer, & Lindeboom, 1993) have shown that the respondent’s age and
educational level impact the validity of the MMSE and recommend that lower cut-off
scores, i.e., 17/18, instead of the 23/24 cut-off score used with respondents who have
less than a ninth-grade education level (McDowell, 2006). The MMSE has been shown
to have good sensitivity and specificity, but its reliability has been shown to decrease as
the time lapse between repeat testing increases (Table 2; McDowell, 2006).
Folstein et al. (2001) have noted that the MMSE is a very useful measurement
tool for assessing cognitive function in PD patients as the disease progresses (middle and
late stages), but it is not an adequate screening tool to use in early stage PD. Severity of
depression also has been shown to correlate with MMSE scores (Mayeux, Stem, Rosen,
& Leventhal, 1981). Tandberg, Larsen, Aarsland, and Cummings (1996) also reported
that PD patients who were depressed scored lower on the MMSE. Further, some PD
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patients develop subcortical dementia, and these patients are likely to experience
impaired calculation ability early in their disease process (Folstein, Folstein, & Fanjiang,
2001). Churchyard and Lees (1997) have noted that severity of dementia in PD patients
(N= 38; 27 with PD and 11 controls) was positively correlated with MMSE scores and
increased density of Lewy bodies in the anterior cingulate gyrus and Lewy neurites in the
amygdala. Lower MMSE scores were noted in PD patients as stage of dementia
worsened (Churchyard & Lees, 1997). When administering the MMSE to PD patients,
Folstein et al. (2001) recommend that the Serial 7s task be used to check for calculation
and attention rather than spelling the word “world” backwards. Thus, the investigator
and research associate used the Serial 7s task on the MMSE to assess calculation and
attention for all 41 participants enrolled in this study. Potential participants had to
achieve a score of 23 or greater on the MMSE to meet the inclusion eligibility criterion
for this parameter.
Hoehn and Yahr Scale
The Hoehn and Yahr Scale (see Appendix E) is a widely used instrument for
staging the severity of Parkinson’s disease symptomatology. The original Hoehn and
Yahr Scale described five stages of progressive PD severity based on presenting
symptoms (Hoehn & Yahr, 1967). The scale was criticized as lacking sensitivity to less
than major changes in the patient’s condition (Diamond & Markham, 1983). Thus, to
increase its sensitivity to the gradual deterioration of the PD patient’s condition, the scale
was further divided into eight stages, ranging from 0 to 5, with half-point gradations
between stages 1 and 2 and stages 2 and 3. The Modified Hoehn and Yahr Scale is used
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widely for evaluating disease severity in PD and is considered to be the gold standard for
staging severity o f PD symptomatology. Further, it has been added to the Unified
Parkinson’s Disease Rating Scale (UPDRS), which has become the gold standard for
measuring PD disability.
Measurements o f Dependent Variables
If their Modified Hoehn and Yahr Stage of PD (equal to stages 2 through 3) and
MMSE score (> 23 out o f 30) qualified them for participation, individuals were enrolled
in the study. At that point, two validated questionnaires were completed by the
participants (later repeated at two additional points across the study) to assess their selfreported perceived self-efficacy (Stanford Chronic Disease Self-Management Program’s
Self-Efficacy fo r Managing Chronic Disease 6-Item Scale) (see Appendix E) and selfreported perceived Parkinson’s disease HRQOL (Parkinson’sDisease Questionnaire
[PDQ-39] version 1.1) (see Appendix E). The features o f these tools are outlined in
Table 2.

Self-Efficacy fo r Managing Chronic Disease 6-Item Scale
The Self-Efficacy fo r Managing Chronic Disease 6-Item Scale is one of several
scales that are included in the Chronic Disease Self-Measurement Program Study
Measures developed by researchers at Stanford University. As noted by Lorig et al.
(1996), self-efficacy involves having self-confidence in one’s ability and the motivation to
produce the desired changes by one’s actions (Bandura, 2004). Enhanced self-efficacy is
the primary target o f the interventions in the Chronic Disease Self-Management Program
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Table 2
Measurement Instruments
Instrument & Purpose
Modified Hoehn & Yahr
Scale for Staging of
Parkinson’s Disease
Purpose: for staging severity
ofPD
(screening test)

*Mini-Mental State
Examination
(screening test)

Scoring Method

Number of
Items

Administration
Method

Completion
Time

Scale ranges
from 0 to 5
(with
increasing
severity)

Clinician
assessment or
abstracted from
patient’s
medical record

Brief
(< 5 min.)

Based on clinical
assessment of patient
(Use for screening
inclusion criterion of
Stages 2 through 3)

Considered to be the gold standard for
staging of Parkinson’s disease.
Specific psychometric properties not
reported.

11 items for a
total of 30
points

Clinician or
trained
interviewer
(nurse)

5-15 minutes
to complete

Questions are summed;
cutoff score of 23/24 or
less indicative of
dementia

**Sensitivity = 81-93%
Specificity = 75-100%
Test-retest Reliability = not less than
0.89
Interrater reliability = not less than
0.82
Concurrent Validity = 0.66 to 0.83
(Wechsler adult intelligence test;
Lawson’s dementia rating scale)

39 items
(eight
subscales)

Self
administered or
interviewer
administered

10-15
minutes or
less to
complete

Lower scores indicate
better self-reported
perceived health status.

Good internal consistency
(range of 0.69 to 0.94 for all eight
subscales)

Scored on a scale of 0100; All eight subscales
can be
summed to create a PD
Summary Index Score
(PDSI) or reported in a
profile format.

Test-retest reliability (range of 0.68 to
0.94 for all eight subscales) and good
face & construct validity (Jenkinson,
Fitzpatrick, Peto, et al., 1998).

Purpose: for assessing
cognitive status/cognitive loss
in elderly patients

PDQ-39 Quality of Life
(PD-QOL)

(This is a dependent
variable.)

Psychometric Properties

Note: PDQ-39SI has a Cronbach’s
alpha of 0.84-0.89
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Table 2—Continued
Instrument & Purpose

Number of
Items

Administration
Method

Completion
Time

***Chronic Disease SelfMeasurement Program Study
Measures (self-management
behaviors, self-efficacy,
exercise scale, health distress,
mental health stress, fatigue,
pain, health outcomes, and
communication with
physician/interdisciplinary
team members) (Lorig,
Stewart, et al.)

Consists of
multiple short
scales (only
the SelfEfficacy for
Managing
Chronic
Disease was
used in this
study)

Self
administered or
intervieweradministered

15-40
minutes to
complete
depending
on degree of
assistance
needed

6 items

Self or
intervieweradministered

• Self-Efficacy for
Managing Chronic
Disease 6-Item Scale

5 minutes or
less

Scoring Method

Psychometric Properties

See separate scales

See separate scales

Number circled is the
score for each item

Internal consistency reliability = 0.91

(This is a dependent
variable.)

*MMSE has recently been copyrighted by the American Psychological Association; permission and payment are required to use it.
**Sensitivity and specificity of the MMSE is significantly affected by level of one’s education (McDowell, 2006). Available at: http://www.parinc.com
*** Stanford Scales and related psychometric information obtained from Stanford School of Medicine Patient Education website at:
http://patienteducation.stanford.edu/materials/
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(CDSMP). Lorig et al. (1996) noted that the three tenets of Bandura’s (1986) SelfEfficacy Theory that underpin the theoretical framework for the CDSMP are:
1. Strength of belief in one’s capability to do a specific task or achieve a certain
result is a good predictor of motivation and behavior.
2. One’s self-efficacy belief can be enhanced through performance mastery,
modeling, reinterpretation of symptoms, and social persuasion.
3. Enhanced self-efficacy leads to improved behavior, motivation, linking
patterns, and emotional well-being, (pp. 5-6)
These three tenets also were used by Lorig et al. (1996) to identify key elements
descriptive of how well persons were managing their chronic disease(s). Lorig et al.
sorted these key elements into three categories: behaviors, beliefs about self-efficacy, and
outcomes. The three categories were later divided into the following subcategories:
(a) behaviors (self-management); (b) beliefs about self-efficacy (to perform specific
behaviors, manage disease generally, and achieve outcomes); and (c) outcomes (health
status and health care utilization). Then, Lorig and her colleagues constructed a series of
short scales to measure the outcomes of self-management behaviors and self-efficacy of
participants in the CDSMP.
Lorig et al. (1996) reported that the Chronic Disease Self-Measurement
Program Study Measures were either modified from existing measures that had been
shown to have good reliability, validity, and responsiveness to change or developed de
novo. The researchers noted that the earlier versions of their self-efficacy scales, which
had been designed to use a 1 to 5 Likert scale, had sensitivity problems detecting change
(Lorig et al., 1996). Hoping to circumvent the potential problem of lack of scale
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sensitivity, they modified the format of their self-efficacy scales to a 1 to 10 scale with
labeled end points, which appears to have improved the scales’ sensitivity to change
(Lorig et al., 1996).
The Self-Efficacy fo r Managing Chronic Disease 6-Item Scale was the short
scale selected from the CDSMP to measure the self-efficacy outcome in this study. Lorig
et al. (1996) reported that testing of the self-efficacy measures in the CDSMP revealed
that most o f them had means slightly above the midpoint (± 1 to 2 points) of the 10-point
scale. Floor and ceiling effects of the self-efficacy scales were not evident. Further,
reliability of all the self-efficacy scales appeared to be good, with test-retest reliability
coefficients ranging from .82 to .89 and internal consistency coefficients ranging from
.77 to .92. The researchers reported an internal consistency coefficient for the SelfEfficacy fo r Managing Chronic Disease 6-Item Scale of .91.
Parkinson’s Disease Questionnaire (PDQ-39)
The PDQ-39 (see Appendix E) is a Parkinson’s disease-specific QOL
questionnaire that was developed by researchers in the United Kingdom (Health Services
Research Unit at Oxford University) on the basis of interviews with Parkinson’s patients
who identified key QOL indicators that were important to the patients (Fitzpatrick, Peto,
Jenkinson, Greenhall, & Hyman, 1997; Peto, Jenkinson, & Fitzpatrick, 2000, 2001). The
items on the PDQ-39 measure eight dimensions identified by PD patients as being
important to their health and quality o f life: (a) mobility, (b) activities of daily living
(ADLs), (c) emotional well-being, (d) stigma, (e) social support, (f) cognition, (g)
communication, and (h) bodily discomfort (Peto et al., 2001).
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The PDQ-39 is a measure of PD-QOL widely used in several countries, and its
psychometric properties have been evaluated cross-culturally (Jenkinson, Fitzpatrick,
Norquist, Findley, & Hughes, 2003). Jenkinson et al. (2003) reported that results of
cross-cultural evaluation o f the PDQ-39 have shown it to be a valid and reliable measure
o f PD-QOL across all eight o f its dimensions (subscales), with the exception of the social
support subscale (range o f r = 0.13 [Japan] to 0.68 [United States]). Cross-cultural
evaluation of floor and ceiling effects of the PDQ-39 yielded limited evidence of such
effects (extent to which respondents score at the bottom or top of a scale) of this
measure except on the social support dimension (Jenkinson et al., 2003). Jenkinson et al.
reported that over 50% o f respondents in the United States, Japan, Canada, and Spain
scored at the floor (i.e., scored zero) on the social support subscale.
The PDQ-39 also has been shown to be a valid and reliable instrument that is
responsive to change and able to detect minimally important differences on serial
measures (Jenkinson & McGee, 1998; Jenkinson, Peto, Fitzpatrick, Greenhall, & Hyman
1995; Peto et al., 1998, 2001; Peto, Jenkinson, Fitzpatrick, & Greenhall, 1995).
Minimally important differences reflect the smallest change in scores on repeated
measures that are subjectively meaningful to patients (Peto et al., 2001).
The scoring methodology of the PDQ-39 is presented in Appendix E. PDQ-39
scores can be reported in either a profile format, thereby delineating the scores on each
o f the eight dimensions or as a summary index score (i.e., global score) which also has
been determined to be an internally reliable and valid measure of PD-QOL (Jenkinson,
Fitzpatrick, Peto, Greenhall, & Hyman, 1997a, 1997b). PDQ-39 profile scores on the
eight dimensions have value in determining the merit of various treatment regimens
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targeting the functioning and well-being of PD patients, whereas the summary index
score has value for determining the overall impact on QOL of such treatment regimens
(Jenkinson et al., 1997a).
Procedure
Parkinson’s Disease Collaborative Care (Experimental Educational Method)
The components of the PDCC intervention are illustrated in Model 2 (see
Appendix A). The PDCC intervention was developed as the experimental patient
education method for teaching middle-stage Parkinson’s patients who were enrolled in
this study. It was taught by an interdisciplinary team of health care professionals who had
expertise in caring for PD patients and by Parkinson’s patients who were trained as peer
mentors/leaders to work in collaboration with the participants. The health care
professional(s) and four Parkinson’s patients who were trained by the investigator to be
patient peer-mentors(s) also acted as cofacilitators at each of the training sessions for the
Parkinson’s patients enrolled in this study.
The investigator based the PDCC experimental educational approach on two
related approaches that have been discussed in the literature on patient self-management
education for chronic disease. First, the PDCC treatment was modeled after the Chronic
Disease Self-Management Program (CDSMP) developed at Stanford University (Lorig
et al., 1996). The Parkinson’s Disease-CDSMP was designed to help Parkinson’s
patients gain requisite knowledge and skills, and enhance self-efficacy to self-manage
their PD and, if present, other comorbid chronic diseases such as heart disease, diabetes,
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arthritis, and lung diseases. Prior to initiating the intervention, the investigator had
completed training offered by the Area Agency on Aging in Grand Rapids, Michigan, to
become certified as a facilitator for Stanford University’s Chronic Disease SelfManagement Program (CDSMP).
Secondly, the conceptual framework for the CDSMP was used in conjunction
with the National Parkinson Foundation’s (NPF) Allied Health Team Training (ATTP) in
Parkinson’s disease care model. In June 2006, the investigator participated in a 5-day
workshop that was offered by the National Parkinson’s Foundation at the Oregon Health
Sciences University for training interdisciplinary allied health professional teams in the
care o f PD patients. The NPF’s allied health team training linked the interdisciplinary
health professionals’ perspectives to the care interventions required at each stage (i.e.,
early, middle, and late) of PD.
After completing the NPF Allied Health Team Training workshop, the
investigator ordered the NPF’s Rainbow Series of PD patient education booklets. These
informative patient education booklets contained essential material for PD patients and
their families to learn about PD, including general overview of PD and related
conditions, PD medications, nutrition, physical fitness, mental health, speech and
swallowing disorders in PD, and available social support resources. The PD Rainbow
Series booklets were included in toolkits given to each participant at each educational
session in the study. Participant toolkits contained information specific to the educational
content that was offered at each particular session of the intervention.
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Parkinson’s Disease Information Transfer (Comparison Educational Method)
The components of the PDIT intervention are illustrated in Model 3 (see
Appendix A). The PDIT (control) group received patient education about PD and other
comorbid illnesses from the same team of interdisciplinary health care professionals who
provided information to the PDCC group, but they used the traditional approach to
patient education for the PDIT (control) group (Table 3). The traditional patient
education approach emphasized the expert role of the health professional who shared
information with and taught technical skills to the patient based on patient problems
identified by the health care professionals rather than by the patient, but patients were
not taught explicitly how to develop the necessary problem-solving skills to self-manage
their disease. Nor was the expertise that the patient brought to this situation recognized
as an integral component of the patient-education interaction; whereas it was recognized
as an essential component in the patient-professional collaborative care model. Thus, the
patient in the traditional care, patient education model was a passive learner and was
acted upon rather than being an active partner engaged in the patient education process,
as in the collaborative care model (CCM) used with the PDCC group.
Training and Scheduling Procedures
Recruitment o f Interdisciplinary Health Team Professionals
Meetings also were held with the administrative representatives from RehabPros
Physical Rehabilitation and the Hauenstein Parkinson Center to determine their
willingness to provide the expert allied health professionals needed to deliver the PD
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Table 3
Schema fo r Intervention Sessions
Session &
Content Area

Collaborative Care Model (CCM)

Informational Care Model (ICM)

Session 1

Led bv Nurse Facilitator & 4 Patient
Peers
Welcome Remarks (5 min) &
Pretest (15 min)

Led bv Nurse Facilitator
Welcome Remarks (5 min.) &
Pretest (15 min.)

Parkinson’s
Disease
Overview

Introduction & Overview of Parkinson’s
Disease (Facilitator) (25 min.)

Introduction & Overview of
Parkinson’s Disease (Facilitator) (25
min.)
Q & A (10 min.)

Break (20 min.)
&
PD
Medications

Parkinson’s Drugs
(Pharmacist) (25 min)
Review PD Toolkits and develop Action
Plans (participants divide into 4 groups of
4-6 participants each for individualized
mentoring with peer & floating
facilitator) and Evaluation (30 minutes)

Session 2

Led bv Nurse Facilitator & 4 Patient
Peers
Physical Functioning/ Mobility/Exercise
Physical Therapist (35 min.)

Physical
Functioning

Break (20 min.)
Environmental Design
Occupational Therapist (35 min.)
Develop Action Plan (Participants
divided into 4 groups of 4-6 participants
each for individual mentoring with peer
& floating facilitator) and Evaluation (30
minutes)

Session 3

Led bv Nurse Facilitator & 4 Patient
Peers Communication & Social
Functioning
Speech-Language Therapist (35 min.)

Social
Functioning

Break (20 min.)

Distribute PD Toolkits & handout
materials (Session I-Parts I & II)
(10 min.)
Break (20 min.)
Parkinson’s Drugs
(Pharmacist) (25 min.)
Q & A and Evaluation (10 min.)
Led bv Nurse Facilitator
Physical Functioning/
Mobility/Exercise
Physical Therapist (35 min.)
Review of Toolkit materials (10
min.)
Break (30 min.)
Environmental Design
Occupational Therapist (35 min.)
Review of Toolkit materials and
Evaluation (10 min.)

Led bv Nurse Facilitator
Communication & Social
Functioning
Speech-Language Therapist (35
mm.)
Review of Toolkit materials (10
min.)

Social Worker (35 min.)
Break (30 min.)

Fo11ow-Ud
Mailing
(4 weeks after
completion of
education
sessions)

Develop Action Plan (Participants
divided into 4 groups of 4-6 participants
each for individualized mentoring with
peer & floating facilitator) (30 min.)

Social Worker (35 min.)
Review of Toolkit materials (10
min.)

Posttest and Evaluation (15 min.)

Posttest and Evaluation (15 min.)

Mail participants a packet containing:
Letter requesting them to complete PDQ39 & Self-Efficacy Questionnaires within
1 week and return to investigator in the
enclosed self-addressed, postage-paid
envelope.

Mail participants a packet
containing:
Letter requesting them to complete
PDQ-39 & Self-Efficacy
Questionnaires within 1 week and
return to investigator in the enclosed
self-addressed, postage-paid
envelope.
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educational content to the PDCC and PDIT groups. RehabPros endorsed the study and
agreed to solicit for volunteers within its organization who were willing to assist in
delivering the PD educational intervention to both groups. As an in-kind budgetary
contribution, RehabPros provided the support of a physical therapist, occupational
therapist, and speech therapist. The Hauenstein Parkinson’s Center provided the in-kind
contribution of their pharmacist and social worker who had both volunteered to assist
with the intervention. St. Mary’s Health Care also agreed to provide the meeting rooms
where the education sessions were held. The investigator contacted the facilities manager
at St. Mary’s Health Care approximately 3 months prior to implementation of the
intervention and room reservations were made for 4 consecutive weeks. Room
reservations were made for 4 weeks to allow for a make-up session due to the possibility
o f inclement weather. However, no make-up session was required.
Once the allied health professionals were recruited, the investigator conducted a
separate early planning session with each one to discuss the nature of the study, the
differences between the two patient education methods, expectations of their role; and to
provide them with related materials, such as journal article, schema for intervention
sessions, and NPF educational materials related to their content area. The same
professionals were involved in both educational approaches; therefore, it was important
for them to have explicit instruction in the elements that were similar and different across
the two models. To minimize bias and increase interrater reliability, the investigator
created handouts that provided separate descriptions of standard operating procedures
regarding the distinctions between the two educational programs. The professional
presenters were given these materials to help guide their activities during their session
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with each group. The materials were derived from the primary journal article
(Bodenheimer et al., 2002) that depicted the distinctions between the two patient
education methods, along with materials from the CDSMP training program in which the
investigator had participated. Lastly, the investigator asked professionals to provide any
additional materials or handouts that they wanted to give participants at the sessions so
these could be submitted for expedited HSIRB approval prior to launching the
intervention. All additional handouts developed by the presenters were submitted for
expedited HSIRB approval which was obtained in early January 2007.
Approximately 4 weeks prior to the inception of the intervention, the investigator
contacted all of the allied health professionals again via e-mail to (a) review the
expectations for their particular sessions, (b) provide them with the journal article (which
also had been given to them earlier) that detailed the differences between the two patient
educational approaches, (c) provide them with additional handouts created by the
investigator for use with the PDCC group which had been given expedited approval by
the HSIRB, (d) provide schedule and room assignments for intervention sessions, and (e)
ascertain if they had any questions or concerns about their role with the two groups or
expectations of the investigator.
Patient Peer Mentors
One week prior to the inception of the intervention, a training session was held
by the investigator with the selected PD patient peer mentors at the Parkinson’s
Association of West Michigan. One of the peer mentor trainees was unable to attend this
session, so the investigator conducted a separate training session for that particular peer
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mentor. According to Bodenheimer et al. (2002), the role of patient peer mentors has
been an important element in the success of the patient-professional collaborative health
care delivery model. Patients recommended for the peer mentor role should be
individuals who have demonstrated strengths in self-management of their disease and
who have social skills that suggest they would be good at working with others
(Bodenheimer et al., 2002).
PD patient peer mentors selected to participate in the study had been identified
for recruitment based on the recommendation of the medical director and nurse clinical
manager of the HPC or from the pool of ineligible PD patients identified by the
investigator (see Appendix H). Two of the age-ineligible PD patients were experienced,
retired college or primary school teachers who were in middle-stage PD with a history of
good management o f their PD symptoms. Both were very interested in being a patient
peer mentor and willing to participate in the study. After either the medical director or
the nurse clinical manager had discussed this volunteer opportunity with the other PD
patients, their name and contact information were given to the investigator if the patient
had expressed an interest and willingness to possibly participate as a peer mentor in the
study. A very active businessman and a retired gentleman were selected to also be PD
patient peer mentors. Four (3 men, 1 female) peer mentors were recruited and trained.
The age o f the peer mentors ranged from mid-50s to 83. All peer mentors were given a
$40 gift card to help defray their transportation expenses related to attending and
performing their volunteer roles at the educational sessions.
Materials provided to the PD patient peer mentors were similar to those given to
the health care presenters and emphasized their interactive role in mentoring patients in
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the PDCC group. The investigator informed and discussed the role expectations of peer
mentors with the volunteers. Further, the investigator discussed the distinctions between
the two patient education approaches with the patient peer mentors. They were also
given the journal article (Bodenheimer et al., 2002) that delineated the two patient
education methods and discussed the important support that the patient peer mentor role
made in contributing to the success of the collaborative care model. Patient peer mentors
received training and materials to assist them in working with the PDCC participants and
helping them to develop the requisite knowledge and problem-solving skills to aid them
in developing their patient-identified action plans.
PD Education Intervention Groups
Both experimental and control group training programs comprised three 2-hour
weekly training sessions conducted one afternoon per week, over a period of 3
consecutive weeks (Table 3). Care was taken to communicate with the participants in
such a way that they were not aware whether they had been randomized into the
“experimental” (hence, potentially better, worse, or no difference) or “control” (i.e.,
traditional) condition. Participants were instructed that they would be informed as to
which group they had been randomized to once the study had been completed and results
were analyzed. Participants had been informed, in advance of starting the intervention,
that Sessions 1 and 3 would run an additional 15 minutes longer to allow time for them
to complete the PDQ-39 and Self-Efficacy, and session evaluation measures.
Participants were asked to complete the PDQ-39 and Self-Efficacy measures at the
beginning o f Session 1 and at the end of Session 3. Recognizing the potential for fatigue

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

75
and the importance o f the socialization process for study participants, a 20-minute (Table
3) period for group socialization and relaxation was included in each 2-hour weekly
training session. As previously noted, some participants, however, preferred to have
access to refreshments and restroom facilities at random versus just at the designated
break period.
At each session, participants received a free toolkit which comprised materials
specific to the educational content of the session and included (a) NPF patient education
books; (b) handouts prepared by the presenters; (c) reference materials related to PD
websites, PD research resources, and community resources; (d) NPF PD identification
card; (e) a 5" x 7 " notepad; and (f) an ink pen. Participants in the PDCC group received
additional educational materials that were to be used to assist them in developing the
knowledge and problem-solving skills that they needed to self-manage their PD and any
comorbid illnesses. At each session, participants in the PDCC group conducted the
additional step o f developing short-term action plans based on the problems that they
had identified that they wanted to work on during the coming week. For each of the
patient-identified problems, the patient partnered with patient peer mentors and members
of the interdisciplinary health care team to establish personal goals and objectives for
which the patient had the confidence, (i.e., sense of self-efficacy) of reasonable
attainment during the coming week. Peer mentors and participants also contacted each
other in between sessions to offer support and discuss problems. Patients reviewed these
action plans at the following session with their health care professional and peer-leader
mentors to evaluate how well the participant had been able to achieve or not achieve the
mutually established goals and objectives they had written in their action plans at the
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prior week’s session. The participants identified the facilitators and/or impediments to
adherence to the action plans that they had developed. Then the participants and mentors
engaged in active problem-solving skill building strategies to facilitate adherence to their
action plan, to reduce or remove any impediments, and to establish new goals and
objectives for the following weeks. Some of the PDCC participants and their peer
mentors elected to maintain contact with each other after the intervention sessions
ended.
One month after completion of the program, participants in both groups were
sent a letter (see Appendix I) from the investigator asking them to complete the PDQ-39
and Self-Efficacy questionnaires. Participants were asked to complete and return these
questionnaires to the investigator within

1

week after receiving them by using the

enclosed addressed, postage-paid envelope.
To summarize, participants were requested to complete study questionnaires at
baseline, upon completion o f the 3-week program, and at 1 month later. Participants
were also requested to complete a brief evaluation questionnaire at the end of each
session to evaluate each intervention session (see Appendix J). One week and 2 weeks (if
necessary) after final questionnaires had been mailed to participants, a follow-up letter
(see Appendix K) was sent to participants who had not returned their questionnaires
informing them that their surveys had not been received and providing replacement
surveys in case the earlier set had been misplaced.
To reduce the possibility of leakage of information between the two groups,
participants, peer leaders, facilitators, and interdisciplinary health care team members
participating in the intervention sessions were asked not to discuss their participation in
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or any other aspects o f the research study with anyone outside their group. Participants
were informed that upon completion of the intervention and all posttests, they were at
liberty to discuss the study with whomever they wished.
PDIT Education Group
The traditional care patient education program comprised 2-hour weekly training
sessions for 3 weeks which covered the same content areas as in the collaborative care
PDCC group. Like the PDCC participants, the PDIT participants had been informed, in
advance of starting the intervention, that Sessions 1 and 3 would run an additional 15
minutes longer to allow time for them to complete the PDQ-39 and Self-Efficacy, and
session evaluation measures. PDIT participants were asked to complete the PDQ-39 and
Self-Efficacy measures at the beginning of Session 1 and at the end of Session 3.
A 30-minute period for group socialization was included in each 2-hour training
session. Like PDCC participants, at each session PDIT participants received a free
toolkit which comprised materials specific to the educational content of the session and
included (a) NPF patient education books; (b) handouts prepared by the presenters; (c)
reference materials related to PD websites, PD research resources, and community
resources; (d) NPF PD identification card; (e) a 5" x 7" notepad; and (f) an ink pen.
PDIT group members were also taught the technical skills that would be helpful to them
to self-manage their PD and any comorbid illnesses, but they did not receive the extra
instruction in problem-solving skills to resolve their health care issues. PDIT group
members neither were asked to develop goals, objectives, or action plans to address their
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health care problems, nor did they receive the patient peer and health care professional
mentoring that was offered to PDCC members.
One month after completion of the program, participants were sent a letter (see
Appendix I) from the investigator asking them to complete the PDQ-39 and SelfEfficacy questionnaires one more time as a follow-up measure. On this occasion,
participants were asked to complete and return these questionnaires to the investigator
within

1

week after receiving them by using the enclosed addressed, postage-paid

envelope. PDIT group participants were requested to complete study questionnaires at
baseline, upon completion of the 3-week program, and 1 month later. Participants also
were requested to complete a brief evaluation questionnaire (see Appendix J) at the end
of each session to evaluate each intervention session. Two weeks and 4 weeks (if
necessary) after final questionnaires had been mailed to participants, a follow-up letter
(see Appendix K) was sent to participants who had not returned their questionnaires
informing them that their questionnaires had not been received and providing
replacement questionnaires in case the earlier set had been misplaced.
Analysis
The respondents’ data were entered into an SPSS version 15 database for
analysis. Excel spreadsheet programs were also used and data imported into SPSS.
Descriptive statistics such as percentages, frequencies, means, and standard deviations,
were used to describe the sample population, e.g., demographic data, and responses to
questionnaires. These distributional characteristics, along with tests of skewness and
kurtosis, were used to determine whether the sample met the assumptions for conducting

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

79
parametric analyses o f data. If the distributional requirements for using parametric
analyses were met, t tests were used to analyze single-time between-groups data. When
parametric distributional assumptions were not met, the nonparametric Mann-Whitney U
test was used. Between-groups repeated measures analyses were performed using
repeated measures o f analysis of variance (ANOVA). Data quality assurance and
cleaning procedures were used to ensure that all data entry was accurate prior to
analysis.
The four hypotheses proposed in this study were assessed by using inferential
statistics to analyze data obtained to assess the association between independent
variables, i.e., patient education method/group and elapsed time (see Appendix M) and
the dependent (outcome) variables (see Appendix M), i.e., self-reported perceived selfefficacy in PD self-management, self-reported perceived PD-HRQOL, and change
scores. The first research question and hypotheses addressed the relationship between
the independent variable, PD educational method/group, and the outcome variable, selfefficacy (dependent variable). The Mann-Whitney U test was used to assess the
difference in means between groups on the independent variable, PD educational
method, and self-efficacy (dependent variable). ANOVA repeated measures were also
used to assess for statistically significant differences in means between groups on the
independent variable, PD educational method in terms of self-efficacy (dependent
variable) measured over time.
The second research question and its related hypotheses addressed the
relationship between groups on the independent variable, PD educational method/group,
and the outcome variable, PD-QOL (dependent variable). The Mann-Whitney U test was
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used to assess the difference in means between the two groups on the outcome
(dependent) variable, PD-QOL. ANOVA repeated measures tests were also used to
assess for statistically significant differences between the two PD educational groups
(independent variable) as measured by the PD-QOL (dependent variable) over time.
ANOVA repeated measures tests were also used to answer the third and fourth research
questions to assess for any change in scores on both dependent measures (self-efficacy
and PD-QOL) postintervention, or from baseline to the point of follow-up testing.
Effect sizes were also calculated to determine the magnitude of any observed
effect o f the PD education intervention between the two groups over time. Streiner and
Norman (2003) defined effect size as “the difference between the two means expressed
in standard deviation (SD) units (mean difference/SD at baseline)” (p. 117). Cohen
(1988) proposed the following conventions for assessing the magnitude of observed
effect sizes:

0 .2

represents a small effect (i.e., a difference between the means equal to

one fifth o f the SD), 0.5 is a medium effect, and 0.8 is a large effect.
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CHAPTER IV
RESULTS
Original data obtained from middle-stage PD participants (N= 41) on the SelfEfficacy fo r Managing Chronic Disease 6-Item Scale and the PDQ-39 Parkinson’s
Disease Quality o f Life Scale were used to examine the effects o f two patient education
models (independent variable, two levels: PDCC and PDIT) on the outcome (dependent)
variables: (a) self-reported perceived self-efficacy for PD disease self-management, and
(b) self-reported perceived PD-HRQOL. The sample for this study was obtained from a
fixed population of middle-stage PD patients who received their care at the Hauenstein
Parkinson Clinic (HPC) and who met the eligibility criteria for enrollment (Table 1). The
specific aims of this single-blind randomized control study were to: (a) compare the
effectiveness of two health care delivery and patient education models (PDCC and
PDIT) in enhancing PD patients’ perceived self-efficacy in PD disease self-management,
and (b) compare the effectiveness of the two health care delivery and patient education
models (PDCC and PDIT) in enhancing PD patients’ self-reported perceived quality of
life (PD-HRQOL). The baseline measures were re-administered immediately
postintervention and at 4 weeks postintervention.
This chapter presents the results of the data analyses of the outcome measures. It
is divided into two sections: (a) descriptive analysis of demographic characteristics o f the
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sample, and (2 ) inferential statistical analysis of the research questions addressed by this
study and their associated hypotheses.
Research Questions and Hypotheses
The following research questions and null hypotheses were addressed in this
study:
1. Is there a difference in pre-post test scores (Time 1 - Time 2) on the SelfEfficacy fo r Managing Chronic Disease 6-Item Scale between Parkinson’s
disease patients who participate in the PDCC or PDIT intervention?
Hypothesis:
Hoi: Pre-post scores on the Self-Efficacy fo r Managing Chronic Disease 6Item Scale (Stanford University) will not differ between the two groups.
2. Is there a difference in pre-post test scores (Time 1 - Time 2) on the PDQ-39
Parkinson’s Disease Quality o f Life Scale between Parkinson’s disease
patients who participate in the PDCC or PDIT intervention?
Hypothesis:
H 0 2 : Pre-post scores on the PDQ-39 Parkinson’s Disease Quality o f Life
Scale will not differ between the two groups.
3. Is there a difference between change scores from posttest (Time 2) to the
4-week follow-up (Time 3) on either of the dependent measures {SelfEfficacy fo r Managing Chronic Disease 6-Item Scale or PDQ-39
Parkinson’s Disease Quality o f Life Scale) between the PDCC and PDIT
groups?
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Hypotheses:
H 0 3 : Time 2 - Time 3 change scores on the Self-Efficacy fo r Managing
Chronic Disease 6-Item Scale will not differ between the two groups.
H 0 4 : Time 2 - Time 3 change scores on PDQ-39 Parkinson’s Disease
Quality o f Life Scale will not differ between the two groups.
4. Is there a difference between change scores from baseline (Time 1) to the
4-week follow-up (Time 3) on either of the dependent measures {SelfEfficacy fo r Managing Chronic Disease 6-Item Scale or PDQ-39
Parkinson’s Disease Quality o f Life Scale) between the PDCC and PDIT
groups?
Hypotheses:
Hos: Time 1 - Time 3 change scores on the Self-Efficacy fo r Managing
Chronic Disease 6-Item Scale will not differ between the two groups.
H 0 6 : Time 1 - Time 3 change scores on the PDQ-39 Parkinson’s Disease
Quality o f Life Scale will not differ between the two groups.

Descriptive Analyses of Sample Characteristics
As previously noted in Chapter III, the records of all PD patients who received
their care at the HPC were screened by the nurse clinical manager for eligibility for
enrollment in the study based on criteria denoted in Table 1. Only 202 of the
approximately 300 PD patients at the HPC were deemed to be potentially eligible for the
study. Of the 202 potential participants who were mailed information about the study, 62
(30.6%) returned letters notifying the investigator that they were interested in possibly
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participating in the study. All 62 of these respondents were screened for eligibility either
by phone or home visit, but only 41 satisfied all eligibility inclusion criteria and were
enrolled in the study. This section reports the findings of the descriptive data analysis
conducted on the 41 participants.
The mean age of the 41 participants in the sample was 67.6 years (range 48 to 78
years) (Table 4). The sample comprised 58.5% (n = 24) males and 41.5% (n = 17)
females. The PDCC (experimental) group (N= 21) included 12 males (57.1%) and 9
(42.9%) females. The PDIT (control) group (N= 20) included 12 males (60%) and

8

(40%) females.
Two participants (1 male, 1 female) withdrew from the PDCC group prior to the
inception o f the study. The PDCC male participant withdrew because he considered his
diagnosis o f PD to be questionable and chose to undergo a trial withdrawal of all PD
medications and to obtain further medical evaluations o f his symptoms before engaging
in an educational seminar. The PDCC female participant had planned to relocate to
warmer climates for the winter, and, due to timing, elected to withdraw from the study.
Also prior to inception of the study, 1 male participant in the PDIT group chose to
withdraw due to multiple chronic health care problems, indicating that he no longer
wanted to participate in the study. Two participants (1 male, 1 female) in the PDIT
(control) group withdrew after participating in the first session due to health and
transportation issues. One male participant in the PDCC (experimental) group chose to
withdraw from the study after the first session because he did not want to participate in
the collaborative small group process nor share his personal health information with the
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group. Thus, the total number of participants who remained in the study was reduced to
35.

Table 4
Sample and Group Characteristics
Intervention Group
PDIT
(« = 2 0 )

PDCC
(n = 2 1 )

Mean Age (in years)

67.2

68

Gender
Male
Female

12

12

Marital Status
Single, never married
Married
Divorced
Widowed
Separated
Partnered - Not married

O II

Variable

67.6

8

9

24
17

0

2

2

16

18

34

2

0

2

1

0

1

0

1

1

1

0

1

Years o f Education (Mean [SD])

15.6(3.1)

14.1 (3.5)

Employment Status
Working
Retired

4
16

19

2

6

35

Years living with PD (Mean [SD])

7.6 (5.4)

6.5 (4.5)

-

Number o f Comorbid Illnesses
(Mean [SD])

5.1 (1.6)

5.0 (2.4)

_

28.9 (1.4)

28.8 ( 1 .2 )

MMSE Score (Mean [<SD])
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O f the original 41 enrolled participants, the majority (N= 35; 85.3%) o f these
community-dwelling participants were married (n = 34; 82.9%) or cohabited with a
partner (n = 1; 2.4%). Of the

6

remaining participants, 2 (4.9%) were single and had

never married, 1 (2.4%) was widowed, 2 (4.9%) were divorced, and 1 (2.4%) was
separated. With respect to race, 37 (90.2%) were Caucasian and 4 (9.8%) were
multiracial. Only 1 (2.4%) of the 41 participants indicated having any Spanish/Hispanic
origins.
The mean number of years o f education for the sample was 14.8 years (range 12
to 23 years). Mean score for the participants on the Mini-Mental State Examination
(maximum score o f 30 points) was 28.85 (range 26 to 30 points) with a standard
deviation (a) of 1.28. The 41 participants reported that they had attempted to learn more
about PD by accessing Internet resources (n = 12; 46.3%), attending a PD support group
(n = 17; 41.5%), attending PD education offerings ( n - 21; 51.2%), obtaining PD
education materials from their physicians (n - 27; 65.9%), or from other sources such as
newspaper articles, magazines, or friends (n = 5; 12.2%). Six participants (14.6%) were
engaged in either full-time or part-time employment; 35 (85.4%) were retired. Two
individuals (4.8%) had either self-elected to quit working or had their employment
terminated due to their PD. Another female participant (2.4%) reported that she was
terminated from her job due to her PD while she was enrolled in the study.
All 41 participants reported that they had some type of health care coverage.
However, 4 (9.8%) participants reported that they made decisions regarding medication
usage and choice of health care providers based on their ability to pay for these services.
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Seven participants (17.1%) indicated that they based their decision of whether or not to
participate in health care programs, such as patient education and exercise programs, on
their ability and willingness to pay incurred out-of-pocket costs not covered by their
insurance.
The mean number o f years living with PD was 7.0 years (range 0 to 18 years).
Six (14.6%) of the 41 participants had undergone Deep Brain Stimulator implantation
surgery for control o f their PD symptoms. Over 73% of the participants rated their
general health status as excellent (n = 1; 2.4%), very good (n = 16; 39.0%), or good (n =
13; 31.7%), whereas 26.9% rated their general health either as fair (n = 7; 17.1%) or
poor (n - 4; 9.8%).
All 41 of the participants reported taking at least one prescribed PD medication
to control their PD symptoms (range 1 to 5 medications) (Figure 1). Most commonly
prescribed PD medications included: levodopa (Sinemet [n = 29; 70.7%] and Sinemet
CR [n = 12; 29.3%]); dopamine agonists (Mirapex [n = 10; 24.4%] and Requip [n = 6 ;
14.6%]); COMT-inhibitor medication, either separately (Comtan [n = 2; 4.9%]) or in
combination with levodopa and carbidopa, i.e., Stalevo (n = 9; 22.0%). Eleven (26.8%)
o f the 41 participants were taking antidepressant medications, whereas

8

(19.5%) were

taking antianxiety medications. Three (7.3%) of the 41 participants who reported having
difficulty with executive functioning were taking Aricept; 1 (2.4%) of the 3 was also
taking Namenda to treat this symptom.
All of the participants had at least two or more comorbid illnesses with which to
contend (Figure 2). Thirty-five (85.4%) of 41 participants reported having up to
additional comorbid illnesses;

6

6

(14.6%) participants had >7 comorbidities coexisting
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Figure 1. Use o f Prescribed Parkinson’s Medications in Middle-Stage PD Patients.

with their PD. Overall, participants reported having a mean of 4.5 comorbid illnesses
(Figure 2). The most frequently occurring comorbid illnesses diagnosed in this sample
were: cardiovascular disease (n = 18; 43.9%); hypertension (n = 17; 41.5%),
dyslipidemia (n = 11; 26.8%); arthritis (n = 30; 73.2%); impaired vision (n = 39; 95.1%)
with presbyopia and cataracts being the most commonly reported problems; cancer (n =
26.8%); altered sense of smell (n = 26; 63.4%); altered sense of taste in = 6 ; 14.6%);
mood disorders reported as anxiety (n = 15; 36.6%) and depression (n = 19; 46.3%);
insomnia (n = 20; 48.8% ); and diabetes mellitus (n = 5; 12.2%).
Thus, several participants were taking multiple medications to control symptoms
associated with other comorbid illnesses as well as to manage their PD symptoms. Of
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Figure 2. Number of Comorbid Illnesses Present in a Sample of Community-Dwelling
Patients With Middle-Stage Parkinson’s Disease.

note, is the frequency o f nonmotor PD symptoms such as impaired vision, altered
sensory function of smell and taste, and insomnia and mood disorders reported by the
participants of this sample. Nonmotor symptoms of PD have more recently gained the
attention o f researchers and clinicians as negatively influencing the QOL of PD patients
Nine (21.9%) participants reported either that they used or needed to use hearing aids
Patients With Middle- Stage Parkinson’s Disease

Along with these distributional sample characteristics, tests o f skewness and
kurtosis were conducted to determine whether or not the sample could be described
using parametric measures. Baseline (Time 1) data were available for 38 of the
participants who remained in the study on the dependent measure, self-efficacy. The
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baseline results reported by group for all 38 participants on the self-efficacy measure
yielded a M = 7,00, SD - 1.60; skewness was -.833, and kurtosis was -.450 (Table 5).

Table 5
Self-Efficacy Summary Scores at Baseline (Time 1), Postintervention (Time 2), and
4 Weeks Postintervention (Time 3)

Time

N

Minimium

Maximum

Mean

Standard
Error

Standard
Deviation

1

38

3.17

9.17

7.01

.26

1.60

2

33

4.33

8.83

7.10

.21

1.18

3

34

3.00

9.00

6.94

.25

1.44

Baseline results forthePD IT group (n = 19) were M = 7.10, SD = 1.56;
skewness = -.799 and kurtosis = -.511. The baseline results for the PDCC group (n =
19) w ereM = 6.9, SD = 1.6; skewness was -.907, and kurtosis was -.303. Because
assumptions of normality were not met, the Mann-Whitney U test was used for between
group analyses within a single-time period (Time 1).
Baseline (Time 1) data were available for only 31 of the 38 participants who
remained in the sample on the dependent measure of PD-HRQOL because some failed to
complete all items Table 6 ). The baseline results for all 31 participants on th q PDQ-39
QOL measure yielded a M = 25.83, SD = 14.14; skewness = .700, and kurtosis = -.120
Baseline results for the PDIT group (n = 17) were M = 27.4, SD = 14.99; skewness =
.262 and kurtosis = -.978. The baseline results for the PDCC group (n = 14) were M =
23.95, SD - 13.35; skewness = 1.491 and kurtosis = 3.04.
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Table 6
PDQ-39SI Summary Scores at Baseline (Time 1), Postintervention (Time 2), and
4 Weeks Postintervention (Time 3)

N
Statistic

Standard
Deviation

Minimum

Maximum

Mean

Statistic

Statistic

Statistic

Std. Error

Statistic

Time 1

31

3.85

59.62

25.83

2.54

14.14

Time 2

26

4.49

60.26

30.91

2.87

14.66

Time 3

34

3.21

55.13

28.03

2.44

14.28

In summary, the sample was not normally distributed on either of the dependent
measures, i.e., self-efficacy for PD disease self-management or PD-HRQOL. The next
section will discuss the inferential statistical analysis conducted as related to the research
questions and null hypotheses.
Inferential Analyses of Research Questions
Group Equivalence at Baseline

Inferential statistical analyses of the sample were first conducted to ascertain if
the randomization process had produced assignment of roughly equivalent groups, i.e.,
groups with no systematic variability at Time 1 (baseline). For this purpose, MannWhitney U tests were used to analyze data collected from 21 participants (n = 9 PDCC
participants; n = 12 PDIT participants) on the PDQ-39 QOL questionnaire at Time 1
(baseline). Although the PDQ-39 was administered to 14 participants in the PDCC group
and 17 PDIT participants at baseline (N ~ 31), the PDQ-39 Summary Index (PDQ-39 SI)
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score which is used to calculate a respondent’s global QOL score, could be calculated
for only 21 o f the 31 participants due to missing data points on some of these PDQ-39s.
However, separate baseline summary scores could be calculated for each of the eight
subscales of the PDQ-39 for all participants who had completed the measure except for
any subscale that contained missing data points. As noted in Chapter HI, lower scores on
the PDQ-39 and its subscales indicate higher QOL, whereas higher scores indicate lower
QOL. The results o f the Mann-Whitney U test conducted on the baseline PDQ-39 QOL
scores available for both groups revealed that the PDCC and PDIT (z - -.75, p = .50)
groups were not significantly different.
Mann-Whitney U test analysis of baseline data on the Self-Efficacy 6-Item Scale
available for both groups also revealed that the PDCC and PDIT (z = -.28, p = .78)
groups were not significantly different on this measure either. This substantiated that the
randomization procedure resulted in assignment of equivalent groups of this sample,
even though the data were not normally distributed.
Research Question Analysis
Inferential statistical testing of the null hypotheses was conducted using
nonparametric statistical tests that included the following tests: Mann-Whitney U and the
Wilcoxon matched-pairs signed-rank. For comparisons between the two groups over
time, i.e., baseline to postintervention to 4 weeks postintervention, the parametric twoway factorial analysis of variance (ANOVA) repeated measures test was used. The
parametric repeated measures ANOVA is frequently used in such instances (i.e., even
when the distribution is not normal) because (a) there is no appropriate nonparametric
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analog to this ANOVA, (b) it is regarded as a very robust test even when its assumption
of normality (normal distribution) is violated, and (c) such violation should not
significantly affect the results o f the test (Beaumont, Lix, Yost, & Hahn, 2006; Myers &
Well, 1995; Norman & Streiner, 2000).
Research Question 1

Is there a difference in pre-post test scores (Time 1 - Time 2) on the SelfEfficacy fo r Managing Chronic Disease 6-Item Scale between Parkinson’s disease
patients who participate in the PDCC or PDIT intervention?
Hoi: Pre-post scores on the Self-Efficacy fo r Managing Chronic Disease 6-Item
Scale (Stanford University) will not differ between the two groups.
The outcome (dependent) variable, self-efficacy for Parkinson’s disease self
management, and the independent variable, patient education method, were calculated
for baseline to postintervention changes in test scores of participants (.N —33) on the
Self-Efficacy fo r Managing Chronic Disease 6-Item Scale. Statistical significance of
between group differences was determined using the Mann-Whitney U test. The pre-post
self-efficacy scores were calculated and no statistical significance was noted (U =
128.000,/? = .77).
A repeated measures ANOVA was conducted to evaluate the effects of group
and time (baseline to immediately postintervention) on the outcome (dependent) variable,
self-efficacy. As seen in Table 7, the results of the ANOVA repeated measures test was
not statistically significant either for group ip = .87) or time ip = .95).
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Table 7
Self-Efficacy: Baseline and Postintervention Group Comparisons

Time

Group

N

Mean

Standard
Deviation

1

PDIT

16

7.08

1.69

PDCC

17

7.08

1.49

PDIT

16

7.14

.99

PDCC

17

7.03

1.37

2

Total

p value
Group

Time

.87

.95

33

Thus, using either analysis approach, the results indicated that there was no
statistically significant difference between the PDCC and PDIT groups in pretest and
posttest scores on the Self-Efficacy fo r Managing Chronic Disease 6-Item Scale.
Therefore, the null hypothesis could not be rejected.
Research Question 2

Is there a difference in pre-post test scores (Time 1 - Time 2) on the PDQ-39
Parkinson’s Disease Quality o f Life Scale between Parkinson’s disease patients who
participate in the PDCC or PDIT intervention?
Ho2: Pre-post scores on the PDQ-39 Parkinson’s Disease Quality o f Life Scale
will not differ between the two groups.
The outcome (dependent) variable, PD-HRQOL, and the independent variables,
patient education method, were calculated for baseline to postintervention changes in
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test scores of participants (N= 21) on the PDQ-39 Parkinson’s Disease Quality o f Life
Scale. Statistical significance was determined using Mann-Whitney U test. Results of the
Mann-Whitney U test did not reveal any statistically significant effect of patient
education method and group on the outcome variable, PD-HRQOL (U = 53.50,/? = .97).
A repeated measures ANOVA also was conducted to evaluate for the effects of
group and time (baseline to immediately postintervention) on the outcome (dependent)
variable, PD-HRQOL. As seen in Table 8 , the results of the ANOVA repeated measures
test indicated that neither group (p —.40) nor time (p = .31) had a statistically significant
effect on the outcome (dependent) variable, PD-HRQOL .

Table

8

PDQ-39 Quality o f Life Summary Scores: Baseline and Postintervention Group
Comparisonsfo r Teaching Method/Group and Time

Variable

Group

N

Mean

Standard
Deviation

PDQ-39 SUM
Baseline (Time 1)

PDIT

12

29.9

16.2

PDCC

9

24.6

16.1

PDIT

12

31.9

13.4

PDCC

9

25.7

16.6

PDQ-39 SUM
Immediate
Postintervention
(Time 2)

p value
Group

Time

.40

.31

Thus, the results of this analysis indicate that there is no statistically significant difference
between the PDCC and PDIT groups in pretest and posttest scores on the PDQ-39
Parkinson’s Disease Quality o f Life Scale. Therefore, the null hypothesis could not be
rejected.
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Research Question 3

Is there a difference between change scores from posttest (Time 2) to the 4-week
follow-up (Time 3) on either of the dependent measures (<Self-Efficacy fo r Managing
Chronic Disease 6-Item Scale or PDQ-39 Parkinson’s Disease Quality o f Life Scale)
between the PDCC and PDIT groups?
Two null hypotheses associated with this research question are:
Ho3 : Time 2 - Time 3 change scores on the Self-Efficacy fo r Managing Chronic
Disease 6-Item Scale will not differ between the two groups.
HU: Time 2 - Time 3 change scores on PDQ-39 Parkinson’s Disease Quality o f
Life Scale will not differ between the two groups.
The nonparametric Mann-Whitney U test was used to evaluate the effect of the
independent variable, elapsed time (4 weeks), on the stability o f participants’ change
scores from immediately postintervention to 4 weeks postintervention, in self-efficacy of
PD disease self-management as measured by the Self-Efficacy fo r Managing Chronic
Disease 6-Item Scale. Although the mean ranks of change scores at postintervention
(Time 2) to 4-week postintervention (Time 3) were greater for the PDCC (n = 16; Mdn
= 18.9) group than the PDIT (n = 16; M dn = 14.0) group, this result was not statistically
significant (U = 89.0, p = .14). Wilcoxon matched-pairs signed-rank test analysis of selfefficacy change scores o f both groups for Time 1 (baseline) to Time 2 (postintervention)
(p = .84 PDIT; p = .76 PDCC) and Time 2 (postintervention) to 4-week postintervention
(Time 3) (p = .30 PDIT; p = .28 PDCC) revealed similar findings that were not
statistically significant. O f note, however, is that the change scores for Time 2 to Time 3
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for the PDCC group revealed an increase in their self-efficacy scores (from 7.0 to 7.4),
whereas the PDIT group experienced a decline in their mean self-efficacy scores (from
7.2 to 6.5), perhaps suggesting a trend in the expected direction.
Repeated measures ANOVA also was conducted to evaluate for the effects of
elapsed time on stability o f change scores between groups at postintervention (Time 2)
to 4-week follow-up postintervention (Time 3) intervention) on the outcome
(dependent) variable, self-efficacy (Table 9). Due to late responders at Time 3, the data
analysis for Time 3 was conducted twice. As seen in Table 9, the results o f the ANOVA
repeated measures test indicated that neither group (p = .34) nor time ip = .70) had a
statistically significant effect on change scores from Time 2 to Time 3 on the outcome
(dependent) variable, self-efficacy for PD disease self-management. Therefore, the null
hypothesis could not be rejected.

Table 9
Self-Efficacy: Change Scores From Postintervention (Time 2) and Follow-up at 4
Weeks Postintervention (Time 3)

Time

Group

N

Mean

Standard
Deviation

2

PDIT

16

7.17

.99

PDCC

16

6.97

1.39

PDIT

16

6.51

1.64

PDCC

16

7.39

1.15

3

Total

p value
Group

Time

.34

.70

32
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The Mann-Whitney U test and repeated measures ANOVA were used to conduct
testing of null hypothesis, HU: Time 2 - Time 3 change scores on PDQ-39 Parkinson’s
Disease Quality o f Life Scale will not differ between the two groups. The MannWhitney U test was used to evaluate the effect of the independent variable, elapsed time
(4 weeks), on participants’ scores from immediately postintervention to 4 weeks
postintervention, in PD-HRQOL, as measured by the PDQ-39 Parkinson’s Disease
Quality o f Life Scale. The total number o f participants for whom PDQ-39 Summary
Index scores could be computed was decreased and varied for all time periods due to the
problem of missing data points. Consequently, power was decreased. There was no
statistical significance in change scores o f both groups from Time 2 to Time 3 (4-week
follow-up postintervention) (U = 65.00, p = .77).
Repeated measures ANOVA was conducted to evaluate the effects of elapsed
time on change scores and any between group differences at postintervention (Time 2) to
4-week follow-up postintervention (Time 3) on the outcome (dependent) variable, PDHRQOL (Table 10). As noted previously, the data analysis for Time 3 was conducted
twice due to late responders at Time 3. As seen in Table 10, the results of the ANOVA
repeated measures test indicated that neither group (p = .89) nor time (p = . 12) had a
statistically significant effect on the stability of change scores from Time 2 to Time 3 on
the outcome (dependent) variable, PD-HRQOL. Therefore, the null hypothesis,
could not be rejected.
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Table 10
PDQ-39 Summary Scores and PD-HRQOL at Postintervention (Time 2) and Follow-up
at 4 Weeks Postintervention (Time 3)

Time
PDQ-39 SUM Time 1

PDQ-39 SUM Time 2

N

Mean

PDIT

12

29.9

16.2

PDCC

9

24.6

16.1

PDIT

12

31.9

13.4

PDCC

9

25.7

16.6

Group

PDQ-39 SUM Time 3

p value
Group

Time

.40

.31

.89

.12

21

Total
PDQ-39 SUM Time 2

Standard
Deviation

PDIT

14

31.3

12.5

PDCC

12

30.4

17.5

PDIT

14

28.8

14.6

PDCC

12

28.0

17.3

Total

26

Research Question 4

Is there a difference between change scores from baseline (Time 1) to the 4-week
follow-up (Time 3) on either of the dependent measures {Self-Efficacy fo r Managing
Chronic Disease 6-Item Scale or PDQ-39 Parkinson’s Disease Quality o f Life Scale)
between the PDCC and PDIT groups?
The null hypotheses associated with this question were:
H 0 5 : Time 1 - Time 3 change scores on the Self-Efficacy fo r Managing Chronic
Disease 6-Item Scale will not differ between the two groups.
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Ho6: Time 1 - Time 3 change scores on the PDQ-39 Parkinson’s Disease Quality
o f Life Scale will not differ between the two groups.
A post-hoc secondary analysis was conducted to assess for differences in change
scores across all time points to determine if any meaningful change had occurred among
participants within each group on either dependent measure or its subscales, i.e.,
PDQ-39 subscales. The Wilcoxon matched-pairs signed-rank test was used to evaluate
and rank (based on negative or positive sign) the difference scores on paired data from
participants to evaluate the effect of the independent variable, elapsed time (7 weeks), on
participants’ change scores from baseline (preintervention) to 4 weeks postintervention
in self-efficacy o f PD disease self-management as measured by the Self-Efficacy fo r
Managing Chronic Disease 6-Item Scale (Table 11).
As noted in Table 11, the Wilcoxon matched-pairs signed-rank test revealed no
changes in participants’ difference scores on the Self-Efficacy fo r Managing Chronic
Disease 6-Item Scale that were statistically significant at pretest to 4-week follow-up
postintervention for all participants (p = .86) or between groups, PDIT ( p = .18) and
PDCC ( p - .36). Therefore, the null hypothesis could not be rejected.
The Wilcoxon matched-pairs signed-rank test was used to evaluate and rank (based
on negative or positive sign) the difference scores on paired data from participants within the
two groups to evaluate the effect of the independent variable, elapsed time (7 weeks), on
participants’ change scores from baseline (preintervention) to 4 weeks postintervention,
PD-HRQOL as measured by the PDQ39 Summary Index score (SI) on the PDQ-39
Parkinson’s Disease Quality o f Life Scale (Table 12).
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Table 11
Self-Efficacy: Scores From Baseline (Time 1) to Follow-up at 4 Weeks Postintervention
(Time 3) fo r A ll Participants and by Patient Education Group Assignment
(Wilcoxon Matched-Pairs Signed-Rank Test)
Posttest to Follow-up

Pretest to Posttest
N
Scale/Subscale

Average
Pre

P

N

Average

Pretest to Follow-up
P

N

Post Follow-up

Post

Average
Pre

P

Follow-up

Self-Efficacy
6-Item Scale
(All participants)

33

7.1

7.1

.96

32

7.1

6.9

.94

34

7.0

6.9

.86

Self-Efficacy
6-Item Scale
(PDIT Group)

16

7.1

7.2

.84

16

7.2

6.5

.30

17

7.0

6.5

.18

Self-Efficacy
6-Item Scale
(PDCC Group)

17

7.1

7.0

.76

16

7.0

7.4

.28

17

7.0

7.4

.36

As noted in Table 12, the Wilcoxon matched-pairs signed-rank test revealed no
statistically significant changes in participants’ difference scores on the PDQ-39
Parkinson’s Disease Quality o f Life Scale at pretest to 4-week follow-up
postintervention for all participants (p = .66) within both groups, PDIT (p = .73) and
PDCC (p = .81). Therefore, the null hypothesis was not rejected. Computation of PDQ39SI scores and matched comparisons across time for participants in both groups was
problematic because of missing data points, which accounts for the different numbers
and slightly different means in different analyses at the same time point.
The Wilcoxon matched-pairs signed-rank test did detect that four o f the PDQ-39
subscales revealed statistical levels of significance with respect to change scores at varying
time points. The four subscales (see Appendix L) were: Communication at Time 1 - Time 2
(p = .03) and Time 2 - Time 3 ip = .03) for all participants; Emotional Well-Being
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Table 12
PD-HRQOL: Change Scores on the PDQ-39 QOL Questionnaire From Baseline
(Time 1) to Postintervention (Time 2) to 4-Week Follow-up (Time 3) fo r All
Participants and by Group
Pretest to Posttest
N
Scale/Subscale

Average

Posttest to Follow-up
P

N

Average

Pretest to Follow-up
P

N

Post Follow-up

Average

P

Pre

Post

PDQ-39SI
21
Sum Score
(All participants)

27.7

29.2

.34

26

30.9

28.5

.07

28

26.6

26.3

.66

PDQ-39SI
Sum Score
(PDIT Group)

12

29.9

31.9

.48

14

31.3

28.9

.38

15

28.8

28.2

.73

PDQ-39 SI
Sum Score
(PDCC Group)

9

24.6

25.7

.37

12

30.4

28.0

.14

13

24.2

24.2 '

.81

Pre

Follow-up

(PDIT group) at Time 1 - Time 3 (p = .03); Mobility (PDCC group) at Time 2 - Time 3
(p = .04) and Stigma (PDCC group) at Time 2 - Time 3 (p = .02). These results might
be considered interesting trends, but would not be considered significant after statistical
corrections for multiple testing were applied.
Results o f Participants’ Evaluation of Intervention Sessions

As noted in Chapter III, participants in both groups were asked to complete
evaluation forms (see Appendix J) at the end of each session to assess the content
delivered by the interdisciplinary health care professionals and the effectiveness of each
presenter’s teaching methods. Each evaluation form consisted of 5 to 7 direct questions
with scaled responses (scale range was 1 = not at all, 2 = low, 3 = medium, and 4 - high)
and two open-ended questions. The two open-ended questions asked participants to
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provide comments or suggestions regarding (a) improving the educational content that
was offered at each session, and (b) topics that they wanted to have presented at future
educational sessions.
The Mann-Whitney U test was used to analyze the evaluation responses from the
two independent groups for each of the three sessions. No statistically significant
findings were noted with the Mann-Whitney U test except for speech therapy content
which almost reached a statistical level of significance (p = .052), indicating that the
members o f the PDCC group rated this session higher than members of the PDIT group
at a level approaching significance. All presenters across all sessions received scores
within the 3 to 4 range.
Sparse responses were given to open-ended questions, but distinct differences
were noted between the two groups in that three participants in the PDIT suggested
more “patient involvement” and “interactive” activities, but no one in the PDCC made
such comments. Suggestions for future educational topics are noted in Table 13.

Summary

Results obtained from the 35 participants in this pilot study revealed no
statistically significant differences between the two teaching methods in enhancing
participants self-efficacy for self-managing their PD and other comorbidities. Further,
there were no statistically significant differences noted between the two teaching
methods in terms of enhancing the PD-HRQOL of participants. The scoring
methodology for the PDQ-39 Quality o f Life Questionnaire was problematic with
respect to dealing with missing data points. Missing data points on the PDQ-39 resulted
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Table 13
Participant Suggestions fo r Future PD Education Presentations
Future Education Topics Suggested
by Parkinson’s Study Participants
Insurance coverage

PD research updates

Care strategies to deal
with aches and pains

Resources for obtaining
financial assistance

New medications

Vision changes in PD

Community resources

Alternative and
integrative therapies

Dealing with dementia in
PD

Exercise demonstrations

Sexual problems

in the inability to compute global PDQ-39SI QOL scores for some participants over
time. Consequently, this led to further reduction in power of the study. Lastly, the role of
peer mentors was not evaluated separately on the evaluation forms for the PDCC group.
Analysis o f the null hypotheses for questions 1 through 4 resulted in lack of
evidence to justify rejection of the null hypotheses for questions 1, 2, and 3. Based on
the results of the Wilcoxon matched-pair signed-rank tests, it was shown that difference
scores from Time 1 (baseline) to Time 3 (4 weeks follow-up postintervention) of
participants within the two groups did differ, but were not statistically significant.
Therefore, the null hypotheses for question 4 also could not be rejected.
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CHAPTER V
DISCUSSION
Chapter Overview
This chapter begins with a summary of results, followed by .a discussion of how
the results o f the descriptive and inferential statistical analyses conducted on the outcome
(dependent) measures of this study relate to outcomes of previous studies. Conclusions
and clinical implications related to study findings also are presented. Study limitations
and their impact on the results are summarized. Lastly, recommendations for future PD
research studies are presented and briefly discussed.
Summary of Design and Results
The goals of this single-blind, randomly controlled intervention study were to
collect evidence to determine the effectiveness of two paradigms of patient education
and health care delivery models on influencing (a) perceived self-efficacy in disease self
management of PD, and (b) PD-HRQOL among middle-stage PD patients. A specialty
clinic, the Hauenstein Parkinson Center, which offered a range of interdisciplinary health
care services to Parkinson’s patients, was the single site selected to participate in the
study. All participants in both groups attended three 2-hour patient education sessions
taught by an interdisciplinary team of health care professionals who had expertise in
specific content areas related to management of PD symptoms (Table 3). The PDIT
105

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

106

group (n = 20) received the traditional paradigm and model of patient education. The
PDCC group (n = 21) received the emerging patient-health professional collaborative
care paradigm (Bodenheimer et al., 2002), an experimental model of patient education.
The duration of the intervention was 3 weeks. The 4-week period of no intervention that
followed led to the total study duration of 7 weeks.
The Self-Efficacy fo r Managing Chronic Disease 6-Item Scale (Lorig et al.,
1996) and PDQ-39 Parkinson’s Disease Quality o f Life Scale (Jenkinson et al., 1998)
measurement tools were used to assess participants’ outcomes on the dependent
variables, self-efficacy and health-related quality of life (HRQOL). Measurements were
taken at three points in time: (a) baseline, (b) after completion of the 3-week education
sessions, and (c) at 4 weeks later.
Data collected from all participants were used to answer the following questions,
which are shown here with their results:
1. Is there a difference between pre- and post-test scores (Time 1 - Time 2) on
the Self-Efficacy fo r Managing Chronic Disease 6-Item Scale between
Parkinson’s disease patients who participate in the PDCC or PDIT
intervention?
Null Hypothesis I - Not rejected
Hoi: Pre-post scores on the Self-Efficacy fo r Managing Chronic Disease
6-Item Scale (Stanford University) did not differ between the two groups.
2. Is there a difference between pre- and post test scores (Time 1 - Time 2) on
the PDQ-39 Parkinson’s Disease Quality o f Life Scale between Parkinson’s
disease patients who participate in the PDCC or PDIT intervention?
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Null Hypothesis 2 - Not rejected
Ho2: Pre-post scores on the PDQ-39 Parkinson’s Disease Quality o f Life
Scale did not differ between the two groups.
3. Is there a difference between change scores from post-test (Time 2) to the
4-week follow-up (Time 3) on either of the dependent measures (SelfEfficacy fo r Managing Chronic Disease 6-Item Scale ox PDQ-39
Parkinson's Disease Quality o f Life Scale) between the PDCC and PDIT
groups?
Null Hypothesis 3 - Not rejected
H o3: Time 2 - Time 3 change scores on the Self-Efficacy fo r Managing
Chronic Disease 6-Item Scale did not differ between the two groups.
Null Hypothesis 4 - Not rejected
H o4: Time 2 - Time 3 change scores on PDQ-39 Parkinson’s Disease
Quality o f Life Scale did not differ between the two groups.
4. Is there a difference between change scores from baseline (Time 1) to the
4-week follow-up (Time 3) on either of the dependent measures (SelfEfficacy fo r Managing Chronic Disease 6-Item Scale or PDQ-39
Parkinson’s Disease Quality o f Life Scale) between the PDCC and PDIT
groups?
Null Hypothesis 5 - Not rejected
Hos: Time 1 - Time 3 change scores on the Self-Efficacy fo r Managing
Chronic Disease 6-Item Scale did not differ between the two groups.
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Null Hypothesis 6 - Not rejected
Ho«: Time 1 - Time 3 change scores on the PDQ-39 Parkinson’s Disease
Quality o f Life Scale did not differ between the two groups.
Discussion o f Results
Descriptive Data fo r the Sample
Bertram and Tanzi (2005) have noted that males have a slightly greater
preponderance for developing PD than do females. This parallels the gender distribution
seen in the nonnormally distributed sample in the current study, in that males (n = 24)
comprised the majority o f participants, whereas there were only 17 female participants.
Mean age of participants was 67.6 years of age. The majority (n = 37) were Caucasian.
All participants had at least a high school education and some had 23 years or more of
education. The mean score of the participants on the Mini-Mental State Examination
(MMSE) was 28.85 (range 26 to 30 points) with a standard deviation (a) of 1.28.
The majority o f the community-dwelling PD participants (« = 35) were married
or cohabitated with a significant other, whereas 6 participants lived alone. The majority
(n = 35) of the participants were retired, but 6 were engaged in either full-time or parttime employment. All participants had some type of health insurance coverage.
Mean number o f years living with PD for the participants was 7.0 years (range 0
to 18 years). Despite living and coping with PD for several years, the majority of the
participants and their spouses or partners were interested in obtaining more information
about PD and anticipatory guidance concerning potential PD and related health
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concerns. During the recruitment phase, spouses often expressed concern regarding
participants’ PD symptom management, current health status, and uncertainty for
management of participants’ future health care needs and caregiving demands.
The majority of participants were taking at least one (range 1 to 5) prescribed PD
medication(s) and 70.7% were taking levodopa (Sinemet). All of the participants had at
least one or more (range 1 to 13) comorbid illnesses in addition to PD. Cardiovascular
related diseases, arthritis, and impaired vision were the most common comorbid illnesses
reported by participants. Several participants reported having nonmotor symptoms
associated with PD. Common nonmotor PD symptoms experienced by participants
included: (a) mood disorders reported as anxiety and depression, (b) motor fluctuations
reported as dyskinesias or freeze attacks (the “off” phenomenon due to wearing off of
anti-PD medications), (c) cognitive changes reported as problems with executive
functioning, (d) visual disturbances, (e) hallucinations, and (f) altered sense of smell
and/or taste.
In summary, it could be said that these middle stage patients with PD were fairly
representative of this segment of individuals with the disease. The sample included both
males and females; showed a small degree of racial/ethnic diversity; varied in marital,
living, and employment conditions; and exhibited a range of PD symptomatology and
comorbid conditions. They shared an interest in learning more about their conditions,
and, in some cases, wanting their spouses to learn more as well as evidenced by the
number of spouses or partners that also attended the educational sessions.
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Patient Education, Self-Efficacy, and Disease Self-Management
Although this was not a normally distributed sample, the demographic
characteristics exhibited and PD symptoms reported by the participants were not unlike
those commonly seen in the general population with respect to PD symptomatology and
prior educational experiences (Bertram & Tanzi, 2005; Lang & Lozano, 1998; Nutt &
Wooten, 2005; VanDenEeden et al., 2003). The majority of the participants reported
that they had exerted some effort to educate themselves about PD by accessing
information available from a variety of resources. As previously noted in the present
study, the 41 participants reported that they had attempted to learn more about PD by
accessing Internet resources (n = 12; 29.3%); attending a PD support group {n = 17;
41.5%); attending PD education offerings (n = 21; 51.2%); obtaining PD education
materials from their physicians (n = 27; 65.9%); or from other sources such as
newspaper articles, magazines, or friends (n = 5; 12.2%).
As a chronic, progressive neurodegenerative disease with no known cure, PD
treatments are focused on secondary prevention strategies targeted to slow disease
progression, manage symptoms, prevent complications, lessen the impact on patients’
functional limitations, and thereby improve quality of life. Marks et al. (2005a, 2005b)
have noted that secondary prevention strategies in chronic disease management require
better disease self-management, and that can be promoted through collaborative patient
education programs. Patient education programs that have used self-efficacy, a construct
o f social cognitive theory, as the underpinning of disease self-management education
programs have had positive results in improving patient outcomes and system outcomes
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(Bandura, 1977, 1986, & 2004; Bodenheimer et al., 2002; Lorig, Sobel, et al., 2001;
Lorig, Ritter, et al., 2002). Bodenheimer et al. (2002) noted that the goal o f self
management education is to increase the patient’s perceived self-efficacy (selfconfidence), thereby improving patients’ clinical outcomes and quality of life.
Lorig et al. (1996) developed the Chronic Disease Self-Management Program at
Stanford University based on the philosophy of targeting prevention strategies to help
patients learn to live better with their chronic diseases by delaying disability, minimizing
suffering, and improving quality of life. Lorig et al. noted that their experience of
conducting community-based arthritis patient education classes for over 12 years led to
the conceptual development o f the CDSMP. Patients’ participation in these earlier
community-based arthritis patient education programs were assessed based on patients’
self-reported health behaviors, health status, and health care utilization (Lorig et al.,
1996). Results o f these patient assessments indicated that participants in the arthritis self
management patient education program had reported sustained outcomes of decreased
pain and use o f health care providers, which persisted up to 4 years (Lorig et al., 1996).
These earlier patient assessments do not appear to have been based on any type of
randomly controlled intervention studies.
To expand the chronic disability model of self-management of disease symptoms
to other groups beyond patients with arthritis, Lorig et al. (1996) conducted a
community-based needs assessment by holding a series of 11 focus group sessions with
people who had multiple chronic health problems. Based on results of data collected
from these focus groups, the framework, specific content, and structure (2.5-hour
sessions conducted over 7 weeks) of the CDSMP emerged (Lorig et al., 1996). Over the
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course of the 7-week self-management program, participants were taught self
management health care strategies that could be used to deal with a broad range of
chronic diseases and related health issues. Self-care management strategies that were
taught during the 7-week sessions included: (a) disease information, (b) technical skills
relevant to management o f specific diseases,, (c) problem-solving skills, and (d)
collaboration with health care professionals. The concept of promoting self-efficacy was
and remains the underpinning of the CDSMP. The CDSMP also incorporates the use of
patient peer mentors and development of patient-written action plans based on problems,
goals, and objectives identified by the patient.
Lorig et al. (1996) reported that they had observed positive outcomes based on
their research with N = 1,130 male and female participants with a mean age of 64.4 years
(range 39.2 to 90.5 years) who had participated in Stanford University’s, Chronic
Disease Self-Management Program or were enrolled in a comparison-control group over
the course of 12 years. These participants had been diagnosed and treated for a variety of
chronic health problems including, but not limited to, heart disease, arthritis, asthma,
diabetes, and osteoporosis.
Comparison o f the PDCC Model to the Original CDSMP Model

The four key components (disease information, relevant technical skills, problem
solving skills, and collaboration with health care professionals) recommended by Lorig et
al. (1996) were all incorporated into the PDCC education model that was viewed as the
experimental model in the current research. The comparison model (PDIT) incorporated
the first two elements and interaction with health care professionals, but did not include
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teaching of problem-solving skills or patient peer mentors. The PDCC model emphasized
problem-solving skills using peer mentors as well as further interaction with the health
care professionals in the small group planning time.
Several differences can also be noted between how the model was implemented
in the original research by the group at Stanford and in this small randomized control
trial. A key difference is the nature of the population. The participants in the current
research all had PD in the middle stages, compared with the earlier studies, which
focused on patients with arthritis, heart disease, asthma, and diabetes. Another important
difference was the 3-week duration of the education sessions in the current study,
compared with the 7-week duration recommended by Lorig and her colleagues (1996).
Relating the Findings o f This Study to Prior Research on Self-Efficacy
The lack of a clear effect of the PDCC treatment in this study can be interpreted
with respect to prior research on collaborative care models with a variety of other
populations with chronic disease conditions. The results of the current study provided no
clear evidence o f a positive effect of a peer-mediated collaborative educational model.
On the other hand, the upward trend in mean self-efficacy scores from the baseline
measurement o f self-efficacy till 4 weeks posttreatment (especially when compared with
the downward trend in scores for the participants in the traditional information transfer
educational group) invites further interpretation and comparison with prior investigations
in this area with similar, but not identical, populations and conditions. To review, PDCC
participants’ mean self-efficacy scores for the three time periods were: (a) 6.9 (baseline;
n = 19); (b) 7.0 (postintervention; n - 17), and (c) 7.4 (4-week follow-up; n = 17). PDIT
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participants’ mean self-efficacy scores for the three time periods were: (a) 7.10 (baseline;
n = 19); (b) 7.2 (postintervention; n - 16), and (c) 6.5 (4-week follow-up; n = 17). Thus,
the trajectory for the mean self-efficacy scores for the two groups appeared to be
heading in the expected direction, but did not reach a level of statistical significance.
These findings can be compared with findings from similar studies with a variety of other
populations.
Lorig et al. (1996) used some of the specialized assessment tools developed at
Stanford to measure outcomes for participants in the arthritis self-management program,
who reported a 20% reduction in pain, improved control over stress and fatigue, and
increased ability to perform ADLS (Marks et al., 2005a, 2005b). Lorig et al. (1996)
noted that the arthritis CDSMP participants reported that these outcomes had been
sustained for at least 4 years. The symptoms, as well as the disease progression course,
differ for patients with arthritis, however, compared to those for patients with PD, who
participated in the current study. The 7-week duration of the current study also was
much shorter than the 4-year duration reported by Lorig and her colleagues, making
comparison difficult. Differences in the disease processes would be likely to affect such
long-term outcomes for patients with PD as well. Similar large-scale longitudinal
investigations of patients with PD are needed to learn more about how the disease
progression, and self-efficacy for dealing with its symptoms, might be affected.
Bodenheimer et al. (2002) (the Stanford research group, of which Lorig is a
member) reviewed 10 studies reporting on the results of arthritis self-management
patient education programs. The studies used a variety of outcome measures, but
positive findings were reported as fewer physician visits, fewer hospitalizations, and less
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health care costs than nonparticipant controls. Bodenheimer et al. compared these results
with results reported by researchers studying diabetes and asthma disease self
management patient education programs, which did not have similar sustained results, to
those reported to be sustained for 4 years by patients with arthritis. Those results suggest
caution in expecting similar levels of effect for patients with all types of chronic
conditions.
Summary o f Findings o f This Study Related to Prior Research on Self-Efficacy
In summary, inferential statistical analyses of PDCC and PDIT groups’ selfefficacy scores for PD disease self-management indicated that none of the null
hypotheses about changes in self-efficacy could be rejected for any of the time periods
studied: (a) 3-week pre- to posttest period; (b) 4-week posttest to 4-week follow-up; or
7-week pretest to 4-week follow-up. The most defensible conclusion is that the choice of
educational method made no difference and that no significant changes occurred in either
of the dependent variables for either group.
On the other hand, the study was short, and PD is different from some o f the
other chronic conditions studied by prior researchers. Some trends in the direction of
change in self-efficacy scores for the two groups suggest that extending the weeks of the
intervention from 3 to 7, as recommended by Lorig and her colleagues (1996), would
yield measurable results. A longer period of follow-up also might make it possible to
detect differences based on educational method in the key construct of self-efficacy.
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Patient Education and Health-Related Quality of Life
As introduced in Chapter II, the GPDSSC (2002) reviewed extant research
regarding the role of self-efficacy and patient education for disease self-management
specifically for patients with PD. They found limited existing research and initiated a
study in six countries to determine which factors PD patients identified as being
important to their HRQOL. The study enrolled 1,020 PD patients and 203
interdisciplinary clinicians who provided care to PD patients. A notable finding of the
GPDSSC (2002) study was that development and implementation of conceptual models
for health care delivery and clinical guidelines for care of PD patients has been hindered
by lack of knowledge regarding the roles of self-efficacy and PD patient education for
disease self-management.
Based on the findings of the GPDSSC, Findley (2002), chairperson of the
GPDSSC, noted a lack o f congruence between what PD patients and doctors value in
terms o f PD patients’ perceived HR-QOL. Further, Findley (2002) advocated for a
restructuring of the patient-physician encounter that is aligned with the patientprofessional collaborative health care delivery paradigm.
Measuring Parkinson’s Health-Related Quality o f Life
Peto, Jenkinson, and Fitzpatrick (1998) conducted focus group sessions with PD
patients to determine patient-identified factors that were considered to be indicators of
PD-HRQOL. This gave rise to the development of the 65-item prototype of the PDQ-39
Quality o f Life Scale which either can be self-administered or interviewer-administered.
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Subsequently, they surveyed 359 PD patients from eight branches of the PD Society in
the United Kingdom and subjected responses to a factor analysis. Ultimately, the
redundant items in the original 65-item questionnaire were eliminated and the scale was
reduced to a total of 39 items that queried eight factors that PD patients identified as
denoting PD-HRQOL. The eight factors, each measured by a subscale that comprises the
PDQ-39, are: mobility, activities of daily living, emotional well-being, stigma, social
support, cognition, communication, and bodily discomfort (Peto et al., 1998).
The PDQ-39 QOL measures both motor and nonmotor symptoms of PD. Repeat
testing has shown that the PDQ-39 is sensitive to change (p < 0.01) and able to detect
minimally important differences on serial measures, as well as having good reliability,
validity, and reproducibility (Jenkinson et al., 1995; Peto et al., 1998, 2001). However,
missing data points on the PDQ-39 can make it difficult to assess global QOL for
respondents on serial measures because a summary QOL measure cannot be imputed
using the Expectation Maximization (EM) mathematical methodology, unless the sample
size is at least >A^= 200 (Jenkinson, Heffernan, Doll, & Fitzpatrick, 2006).
It was disappointing to be unable to use some of the data from some of the
participants in the current small study because some participants did not respond at
certain time points to particular items on the PDQ-39 (Jenkinson, Fitzpatrick, & Peto,
1998). Personal communication with one of the tool’s authors (Jenkinson, March 23,
2007), however, confirmed that missing data points could only be interpolated on the
Social Support Scale (which might differ depending on marital status), and not on any of
the other subscales. Because missing data points on other scales in the serial measures of
the PDQ-39 could not be imputed, it was not possible to compute PDQ-39SI global
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QOL across all three time points for some of the participants in this study. This meant a
reduction in the power to find any statistically significant differences.
Although self-administration methods were used in this study, other research
studies have used self-administration methods for gathering data with the PDQ-39 and
have not reported similar difficulties. For example, using the self-administered PDQ-39,
EQ-5D, and SF-36, Schrag, Jahanshahi, and Quinn (2000) assessed 124 probable PD
patients from 15 general practices in the United Kingdom to identify the indicators of
QOL in this population. These test measures were mailed to 124 PD patients; 78%
completed and returned the questionnaires. Research findings revealed that depression
was the strongest indicator o f QOL of in PD patients. Schrag et al.’s (2000) findings
mirrored the results reported by the GPDSSC (2002). The GPDSSC reported that 1,020
PD patients who participated in the study reported that 60% of the variability in their
HRQOL was attributable to depressive symptomatology.
Mental and motor status, both of which are addressed by the scales, can also
influence how individuals respond to questionnaires. Despite attaining a high MMSE
score, a few patients in the current study reported having impaired executive functioning
that required treatment with Aricept and Namenda. Impaired executive functioning
precipitated the early retirement of one of the young-onset PD patients who functioned
in an executive role. Although motor symptoms are recognized as the hallmark of PD,
nonmotor symptoms are finally being recognized as having a significant impact on QOL
in PD patients. Both motor and nonmotor symptoms have implications for the design of
future educational studies and data gathering methods.
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Relating the Findings o f This Study to Prior Research on PD-HRQOL
As Jarman, Hurwitz, Cook, Bajekal, and Lee (2002) noted, a community-based,
patient-professional collaborative care model was successfully implemented in the United
Kingdom by specialist nurses who cared for PD patients (A=l,859). Although PD
patients reported a preserved sense of well-being, they did not report any significant
change in health outcomes (Jarman et al., 2002). These findings suggested that the
construct o f HR-QOL may be difficult to affect with patient education for patients with
PD. They are consistent with findings of the current study.
Shimbo et al. (2004) conducted a cross-sectional study in Japan to assess
whether providing patient education to PD patients (N= 762) was related to improved
PD-HRQOL as measured by the SF-36 survey, components of the UPDRS, and five
questions about PD patient education related to disease process and treatments. The
Japanese government had recently adopted a national health policy that provided
reimbursement for patient education, especially for lifestyle-related chronic diseases and
intractable diseases such as PD (Shimbo et al., 2004). The patient education satisfaction
score was rated on a Likert scale of 1 to 5 (1 = not satisfied at all, to 5 = very satisfied).
The mean PD patient education score was 2.96 (SD = 0.88) which indicated that the
patients were neither dissatisfied nor particularly satisfied with the PD education that
they had received. Shimbo et al. (2004) further noted a positive association between PD
patients’ level o f satisfaction with PD patient education and their HRQOL scores. PD
patients who reported greater satisfaction with PD patient education had higher HRQOL
scores on each o f the subscales of the SF-36, except for physical functioning and bodily
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pain (Shimbo et al., 2004). These findings suggest that individuals may respond
differently to receiving the same educational experiences based on other intrinsic
differences.
Although individual differences were not a controlled variable in the current
study, there were some indications that personal preference may have played a role.
Support for this interpretation was indicated by the one patient who left the study after
learning he had been randomized to the condition in which participants would talk with
others about their condition. He withdrew from the study after attending the first session.
Several members of the traditional group, on the other hand, indicated that they would
have benefited from more opportunities to interact with others. Personal preference
should be studied directly in future research.
Some QOL indicators are unique to the population of patients with PD. Nutt and
Wooten (2005) noted that about 75% of PD patients initially experience bradykinesia
which interferes with their ability to perform fine motor tasks. In the current study, the
most common motor symptoms of PD reported by the majority of participants were
tremor and bradykinesia. A few patients did report having difficulty with dressing-related
activities such as buttoning clothing items. Maijama-Lyons and Shomon (2003) noted
that bradykinesia can be exhibited as difficulty with fine motor tasks and initiating
movement; change in gait; freeze attacks; masked facies; and speech and communication
disturbances reported as dysphagia, hypophonia, and micrographia. Change in gait
patterns, mobility, motor fluctuations noted primarily as dyskinesias, also were reported
by most participants in the present study.
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The majority of participants in this sample reported having speech and
communication problems due to their PD. In the current study, only a few patients
reported having swallowing problems. Miller, Noble, Jones, and Burn (2006) noted that
80-90% of PD patients experience hypophonia or other voice changes and 45-50% have
articulation changes. Communication issues are easier to address than speech production
issues, and future educational programs might be designed to focus on these differences.
The majority of participants in the current study also reported experiencing
another cardinal symptom ofPD —rigidity. As a result of the rigidity, several participants
had complained that their sense of balance had been affected and, thus, they had
experienced problems with falling. Two participants reported having sustained fractures
due to their rigidity and balance problems. One male had sustained a hip fracture and had
undergone total hip joint replacement surgery to treat the fracture. One female had
sustained a humeral fracture and experienced delayed healing of the fracture due to the
effect of PD-related tremorous activity on bone healing. These are challenging conditions
to address, and anticipating such issues may influence how participants perceive their
HRQOL.
Summary o f Findings o f This Study Related to Prior Research on PD-HRQOL

In summary, statistical analyses of PDCC and PDIT groups’ mean PDQ-39SI
(summary index) QOL scores showed that the null hypotheses could not be rejected for
any of the time periods measured. In interpreting these results and looking for any
trends, it is important to bear in mind that higher scores on this instrument signal lower
perceptions o f PD-related QOL. PDCC participants’ mean PDQ-39SI summary QOL
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scores across the three time periods were: (a) 24.0 (baseline; n = 14); (b) 30.4
(postintervention; n = 12), and (c) 28.0 (4-week follow-up; n = 17). PDIT participants’
mean PDQ-39SI QOL scores across the three time periods were: (a) 27.4 (baseline; n =
17); (b) 31.3 (postintervention; n - 14), and (c) 28.3 (4-week follow-up; n = 17).
According to these findings, the trend for both groups was for perceived QOL to
get somewhat worse immediately following the educational sessions (although not
significantly worse). One possibility is that information about problems expected with PD
might have been perceived with new clarity, and, as a result, patients felt less optimistic
about their HR-QOL issues. Four weeks later, these perceptions again moved in the
more positive direction (as reflected in the lower mean scores), although again, not
significantly so.
As discussed in this section, there may be several reasons for the lack of
significance in this study that could be investigated in future research. Measuring
perceived QOL after educational sessions also brings with it a number of special
challenges. One concern in the current study was the loss of data from several
participants who did not complete certain items. It would be helpful in future studies to
institute a process to ensure that all items are completed at the time o f the data gathering
activity.
Conclusions and Clinical Implications

The results o f this study did not support a conclusion that one educational
method was preferable to the other in terms of effects either on perceived self-efficacy or
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HRQOL. The results of the course evaluations, however, did suggest that participants of
both groups evaluated the sessions as being generally helpful to them.
This study offered some indications that clinicians should consider individual
preference when designing patient education activities. As noted, 1 participant did
withdraw from the experimental group (PDCC) because he preferred not to share his
personal information during the small group, peer mentoring component of the
collaborative care group. On the other hand, 3 participants in the traditional group
commented on their session evaluations that they would have preferred a more
interactive group process. This suggests that individual preference is an important
variable, which may have been obscured by the current experimental design with random
assignment to groups and choice of dependent measures.
Given the chronic, progressively degenerative nature of PD, it was not surprising
that participants’ self-efficacy and QOL scores did not change over the 7-week duration
of the intervention to reach a statistical level of significance. However, Peto et al. (2001)
noted that minimally important changes detected on the PDQ-39 QOL questionnaire,
based on patients’ responses, may represent clinically significant changes in QOL to the
patient even though they might not reach a statistical level of significance. The results of
this study should not be taken as indicating that patient education programs are of no
value.
Session evaluations submitted by each participant indicated that they valued both
the content presented in each of the sessions as well as the effectiveness of each of the
presenters. A few participants indicated that each 2-hour session should have been
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assigned to only one presenter so more content could have been provided to participants
and more time allocated for questioning.
Study Limitations
This study had some significant limitations. First, the small sample size (AT—41)
o f this pilot study was impacted further by attrition of 6 participants, thereby reducing
the power to detect any significant results. Second, it focused on a fixed population, i.e.,
only middle-stage PD patients, recruited from a single PD specialty clinic who
volunteered to participate in the study. Third, the intervention was of short duration,
lasting only 3 weeks, compared to the model recommended by Lorig et al. (1996), which
ran 7 weeks. The total time since pretest to the follow-up measure in the current study
was only 7 weeks, limiting the ability to detect any longer term effects. Fourth, the study
could have benefited from a third no-treatment comparison group, which would allow
observation of any effects due to the natural progression of the disease. Fifth, a major
issue that significantly impacted the ability to assess and compare QOL across all time
points for both groups was the scoring methodology of the PDQ-39SI and the problem
of dealing with missing data. Finally, limited funding resources were available to conduct
the study on a larger scale over a longer period of time.
Recommendations for Future Research
The research agenda for PD should focus on both bench and translational
research studies. Longitudinal studies, involving all stages of PD patients, which focus
on patient and caregiver education, need to be conducted to assess factors that promote

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

125

patients’ QOL and self-efficacy for disease self-management. A no-treatment comparison
group should also be included. As dictated by research ethics, a no-treatment comparison
group should not receive less than standard of care treatment during interventional
studies. If the experimental intervention is shown to be more efficacious than standard of
care treatment, then the no-treatment comparison group should be offered the
opportunity to receive the experimental intervention upon completion of the study.
Further research needs to address the role and needs of caregivers of PD patients,
including factors that prognosticate caregiver burnout and likelihood of long-term care
placement of PD patients. Future studies should involve multiple centers including
community-based private neurology, internal medicine, family practice clinics, and PD
specialty clinics to compare quality and effectiveness of care based on patients’ and
systems outcomes.
As noted in Chapter IV, post-hoc analysis conducted with the Wilcoxon
matched-pairs signed-rank test (see Appendix L) did reveal that four of the PDQ-39
subscales (i.e., communication, emotional well-being, mobility, and stigma) reached
statistical levels o f significance with respect to change in difference scores in predicted
directions at varying time points and based on group assignment. Although no statistical
test was used to correct for multiple comparisons, results noted on these subscales may
warrant further research. For example, interventions could be implemented to address
PD patient issues encompassed by each of these subscales, such as rehabilitation needs
involving physical and occupational therapies or speech therapy.
The role o f telemedicine in increasing PD patients’ and caregivers’ access to
health care services, such as rehabilitation professionals, that can help patients maintain
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and restore their functional abilities, promote independence and mobility, and limit
disability, needs to be pursued and funded. Application of telemedicine to monitor
changes in PD patients’ health status and adherence or nonadherence to prescribed
treatment regimens such as use of PD medications, also should provide ample fodder for
future research since extant research on these topics is limited. Telemedicine technology
also can be used to deliver patient and caregiver education that can be tailored to meet
the specific health care information needs of PD patients and their caregivers. Patient and
caregiver education may encompass information relevant to management of comorbid
chronic diseases as well as PD information. Telemedicine technology can be used to
provide specialized training and continuing education to health care professionals living
in rural areas who provide care to PD patients. Although the initial financial investment
in telemedicine technology may be expensive, over time it may be shown to be a more
cost-effective strategy for delivering health care services and monitoring health status in
some patient populations such as rural PD patients with limited access to transportation
services.
Health services research and policy analyses studies need to be conducted to
develop public policies designed to better meet the current and future health and social
issues with which PD patients and families have to contend. This will become an even
greater need given the expected increase in PD prevalence and other chronic diseases
over the next few decades coupled with the demographic aging trend in the U.S. These
factors will likely exert a costly and burdensome impact on the nation’s health system
and its other social infrastructures. Some study participants expressed concern over the
impact that their PD symptoms had on their ability to continue working. Some stated
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that they had been compelled to seek early retirement, and two had had their jobs
terminated due to their PD symptoms. Given the protections provided by the American
Disabilities Act (http://www.usdoj.gov/crt/ada/adahoml.htm), 2 participants reported
that they had retained legal counsel in an attempt to regain their jobs, but to no avail.
Thus, it may be worthwhile to reexamine the American Disabilities Act to ascertain if the
rights of people with disabilities are being adequately protected or if it needs to be
amended given changing U.S. demographics.
Lastly, policies need to be developed and implemented that support research
studies to investigate genetic and environmental factors that trigger the development of
PD and fund essential bench research that may result in development of targeted
therapies to treat, prevent, or cure PD. Specifically, federal legislation that supports the
advancement o f stem cell research needs to be enacted and adequately funded. Such
legislation also needs to encompass all types of stem cell research, including the use of
human embryonic stem cells, for development of targeted therapies to be used in
treatment and prevention of human diseases. Prior federal legislation that impedes
scientific progress such as stem cell research would need to be either amended or
rescinded. The Dickey Amendment that was passed in 1996 by the U.S. House of
Representatives is an example of such legislation. The Dickey Amendment prohibited the
Department of Health and Human Services and the National Institutes of Health from
appropriating federal funds for use in research that involves the creation, endangerment,
or destruction o f human embryos. It was attached as a rider, Section 128 of Public Law
104-199, to the Consolidated Appropriations Act for the Departments of Health and
Human Services, Education, and Labor in 1996 (Congressional Research Service, 2002,
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2004, 2005). Further, it has been incorporated into the Department of Health and Human
Services section of the Consolidated Appropriations Acts for Fiscal Years 1997 through
2007 (section 509, division F, Public Law 108-447).
In the meantime, public policies must continue to be developed and implemented
that fund intervention research targeted to address better methods for living well both
with, and in spite of, Parkinson’s disease. Despite its limitations, participants assessed the
informational content and disease-management strategies offered by both educational
models in this interventional research study as having positive value for them. Further,
the report o f the GPDSSC (2002) substantiates the need for more research into factors
which contribute to PD-HRQOL and promote development of health care delivery
models and clinical guidelines to improve the care management of PD patients.
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MODEL 1
Conceptual Model o f Patient Self-Efficacy and Parkinson’s Disease Self-Management
Education and Their Impact on Parkinson’s Disease Quality of Life - (L. Pearl-Kraus)

Parkinson’s Disease
Self-Management
Education

Patient Self-Efficacy for
Parkinson’s Disease
Self-Management

Development of Action Plans Based on
Patient-Identified Problems and Mutually Established
Short-term Goals and Objectives

PD Patient’s
Implementation or
Nonimplementation of Action Plans

Impact on Parkinson’s Disease
Quality of Life
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MODEL 2
Conceptual Model for Collaborative Care and Patient Education for
Self-Management of Parkinson’s Disease (L. Pearl-Kraus)
Patient - Professional Partnership
(Collaborative Care)

/
Parkinson Disease
Interdisciplinary Health Care Professional Team
Members
• Physicians
•
NPs/CNSs/PAs
•
Nurses
•
Pharmacists
•
Nutritionists
o
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o
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o
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o
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o
Occupational Therapist
v
o
Speech/Language Pathologist
o
Social Worker

Parkinson’s
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Patient

Personal
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Lived
Experience
and Life
Situation

Patient’s
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Teaching
Problem
Solving
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Patient
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MODEL 3
Conceptual Model for Traditional Care and Patient Education
in Parkinson’s Disease - (L. Pearl-Kraus)

Parkinson s Disease
Interdisciplinary Health
Care Team Members (Prof)
Rehab. Professionals
Physicians
NPs/CNSs/PA
P.T
O.T
Nurses
Neuropsych
Pharmacists
Physiatrist
Nutritionists
S.W.
SLP
Patient Common
Chronic Diseases and
Health-Related Problems

Identify Parkinson s
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for Disease
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Related to
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Issues Related to
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Interventions to
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for Nonadherence
Implemented by
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Abbreviations
NP - Nurse Practitioner - CNS - Clinical Nurse Specialist - P.A. - Physician Assistant
P.T. - Physical Therapist O.T. - Occupational Therapist; Neuropsychologist & Physiatrist;
SW - Social Worker - SLP - Speech-Language Pathologist
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Patient

Patient Education
Disease
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Information on
Technical Skills
(e.g.: handout on
exercise)

Patient NonAdherence to
Prescribed
Treatment Plan

Patient
Adherence to
Prescribed
Treatment Plan

Impact on
Parkinson’s Disease
Qualify of Life
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W e s t ern M ic h ig a n U n iv e r s it y
Human Subjects Institutional Review Board

Date: February 8, 2007
To:

Nickola Nelson, Principal Investigator
Lorraine Pearl-Kraus, Student Investigator for dissertation

From: Amy Naugle, Ph.D.,
Re:

HSIRB Project Number: 06-07-03

This letter will serve as confirmation that the changes to your research project “Parkinson’s
Disease Education, Disease Self-Management, and Self-Reported Quality o f Life Outcomes”
requested in your memo dated 2/8/2007 (2 questions added to follow-up) have been approved by
the Human Subjects Institutional Review Board.
The conditions and the duration of this approval are specified in the Policies of Western
Michigan University.
Please note that you may only conduct this research exactly in the form it was approved. You
must seek specific board approval for any changes in this project. You must also seek reapproval
if the project extends beyond the termination date noted below. In addition if there are any
unanticipated adverse reactions or unanticipated events associated with the conduct of this
research, you should immediately suspend the project and contact the Chair of the HSIRB for
consultation.
The Board wishes you success in the pursuit of your research goals.

Approval Termination:

July 19, 2007

Walwood Hall, Kalamazoo, Ml 49008-5456
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Date: August 14, 2006
To:

Nickola Nelson, Principal Investigator
Lorraine Pearl-Kraus, Student Investigator for dissertation

From: Mary Lagerwey, Ph.D., Chair
Re:

HSIRB Project Number: 06-07-03

This letter will serve as confirmation that your research project entitled “Parkinson’s
Disease Education, Disease Self-Management, and Self-Reported Quality o f Life
Outcomes” has been approved under the full category of review by the Human Subjects
Institutional Review Board. The conditions and duration of this approval are specified in
the Policies of Western Michigan University. You may now begin to implement the
research as described in the application.
Please note that you may only conduct this research exactly in the form it was approved.
You must seek specific board approval for any changes in this project. You must also
seek reapproval if the project extends beyond the termination date noted below. In
addition if there are any unanticipated adverse reactions or unanticipated events
associated with the conduct of this research, you should immediately suspend the project
and contact the Chair of the HSIRB for consultation.
The Board wishes you success in the pursuit of your research goals.

Approval Termination:

July 19, 2007
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M i c h i g a n U n i v e r s it y
Human Subjects Institutional Review Board

Date: July 19, 2006
To:

Nickola Nelson, Principal Investigator
Lorraine Pearl-Kraus, Student Investigator for dissertation

From: Mary Lagerwey, Ph.D., Chair
Re:

{Y \

HSIRB Project Number: 06-07-03

This letter will confirm that your research project entitled “Parkinson’s Disease Education,
Disease Self-Management, and Self-Reported Quality o f Life Outcomes” was reviewed under the
full category o f review on July 19,2007 by the Human Subjects Institutional Review Board.
Before final approval can be given please address each of the following concerns. We expect
that you will find the revisions requests to be productive and that you will revise your protocol
according to our suggestions or in similar ways. If you think a particular revision is not in the
best interest o f the human subjects in your study, or you think an entirely different approach to
the issue is best, please provide a written explanation and/or call us for consultation.
The board has no major concerns.
The following required revisions are listed in the order they appear in the protocol:
1. Informed Consent Process section o f the protocol outline: Please clarify the role o f the
witness and why having a witness is necessary.
2. Research Procedure section o f the protocol outline:
• Please assure that all investigators are appropriately trained regarding their roles for
this project.
• Please provide an explanation for why you will consult the participants’ medical
charts.
• How are peer mentors compensated for their involvement in the study?
3. Benefits o f Research section o f the protocol.outline: If the intervention is helpful, will it
be offered to the control group?
4. Confidentiality o f Data section o f the protocol outline:
• Please omit any references to anonymity, as participation will not be anonymous.
Instead, assure that participant’s identities will be kept confidential.
• You are asking some questions that provide contact information, not data Please
provide a rationale for requesting this information. Also, in order to protect
participants’ confidentiality, please do not inquire about the name o f the person’s
physician or o f their insurance provider.
Walwood Hall, Kalamazoo, Ml 49008-5456
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6. Consent Document:
• Please use second person language (e.g., ‘you’) consistently throughout the document.
•• Please ask for permission to access the participants’ medical records.
• Please provide references for alternative sources o f education for participants who do
not want to participate in this study.
• Please do not refer to the study as a clinical trial.
• In the section entitled “What about Confidentiality?’ please delete any references to
anonymity. Instead, please assure confidentiality.
Individual board members brought up the following suggestions. HSIRB approval is not
contingent upon your response to these suggestions.
1. Research Procedure section o f the protocol:
• There may be a potential bias if the researcher is both providing and evaluating the
training.
• Consider requesting that the data be added to the patient files.
• The 20-30 minutes socialization time may confound the control group intervention.
2. Consent Document: You may want to shorten the consent form.
3. HIPAA Consent Document: hi order to reduce potential confusion, you may want to
consistently refer to Nickola Nelson using the same name.
In a cover letter to the HSIRB, indicate whether you have made the requested change; addressed
the issue in a different way than the one the reviewers suggested; are directing the reviewers to
the pages in your protocol that address the issue; or are providing a justification for not making
the requested change.
Please submit your cover letter and one copy of the revised protocol with the changes highlighted
within the document to the HSIRB, 251W Walwood Hall (East Campus). Once granted, your
approval will expire on July 19,2007 so submitting revisions in a timely manner will mean you
have more time for data collecting. Remember to include the HSIRB project number (above).
Conducting this research without final approval from the HSIRB is a violation of
university policy as well as state and federal regulations.
I f there is anything you don’t understand about these comments, you are welcome to call
the research compliance coordinator (387-8293) for consultation.
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To:

Lorraine J. Pearl-Kraus, RN, PhD-c, CS, FNP-C
0-11002 12th Avenue NW
Grand Rapids, MI 49534-6743

Re:

Amendment/Revision for: “Parkinson’s Disease Education, Disease
Self-Management and Self-Reported Quality of Life Outcomes”
JRB File #06-0828-05

Date:

February 13, 2007

This is to inform you that Saint Mary’s Health Care Institutional Review Board has
received and reviewed your revised letter to study participants of the above captioned
study containing two additional follow up questions.
It has been determined that this change is minor and does not increase the risk to the
participants in the study. Furthermore, the additional questions do not demand revisions
in the approved consent document, study protocol or investigational brochure.
Therefore, by means o f an expedited process, this letter is approved for use in your
study, effective February 19, 2007.
Thank you for keeping the IRB informed of these changes. The renewal date for this
study will remain August 28, 2007 with a progress report due July 1, 2007.

Sheryl Veurink-Balicki, RN, MSN, CEN
IRB Chairperson
Copy: File
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H E A L T H CARE

8/28/2006
Lorraine J. Pearl-Kraus, RN, PhD-c, CS, FNP-C
0-11002 12"’Avenue NW
Grand Rapids, MI 49534-6743
RE: New Study Protocol: “Parkinson’s Disease Education, Disease Self-Management and
Self-Reported Quality o f Life Outcomes”
-

Dear Dr. Fearl-Kraiis:

"

.... ...............~

—

...—

--

On August 28,2006 Saint Mary’s Health Care IRB met and reviewed the aforementioned study,
the associated consent document, the HIPAA disclosure document, questionnaires and
communication documents. During our conversation you indicated a change you wish to make in
the consent document. The IRB noted the need to change Saint Mary’s Health Care’s name on
page 4 o f 6. The statement on page 5 of 6 regarding the approval o f the consent document by
Western Michigan University IRB remains acceptable as stated for Saint Mary’s IRB purposes.
With the changes noted above in the consent document, Saint Mary’s IRB approves this
study and associated documents effective August 28,2006 until August 28,2007. We will
need to receive the updated consent document before foil implementation of the study can begin.
IRB monitoring procedures demand that you complete a progress report no later than July 1,
2007. Should the study be completed before that time, a progress report covering the appropriate
time frame and written notification that the study is closed is due at that time.
Any additional changes in the study protocol and or associated documents must receive our IRB
approval before they are implemented.
Any safety incidences occurring as a result of the study must be submitted in writing to Saint
Mary’s IRB within ten days of your knowledge of them.
Sincerely,

Sister Myra Bergman
IRB Chair
cc: Nickola W. Nelson, PhD, CCC-SLP
Leslie Neuman, MD

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

155

fi
SAINT MARY'S
IT
HEALTH CARE

200 Jefferson A venue SE
G rand Rapids, M ichigan 49503
P 616.752.6090
w w w .sm heaithcare.org

August 22, 2006

Laurie Pearl-Kraus, RN, PhD-c, CS, FNP-C
0-11002 12th Avenue
Grand Rapids, Ml 49534-6743
Dear Ms. Pearl-Kraus:
This is to inform you that the Saint Mary’s Health Care Research Committee has
completed its review of your protocol entitled, ‘Parkinson’s Disease Education,
Disease Self-Management & Self-Reported Quality of Life Outcomes.”
Your protocol has received full approval and will be forwarded on to the Saint
Mary’s Health Care Institutional Review Board. You will be advised of time and
place for the protocol presentation to this committee. For questions regarding
IRB presentation, please phone Cindy Johnston at (616) 752-6198.
Should you have any questions or concerns, please feel free to contact me at
752-6413.
Sincerely,

Da\
.. „ . .
Chairman, Saint Mary’s Health Care Research Committee

c:

Nickola W. Nelson, PhD, CCC-SLP
Leslie Neuman, MD
Sr. Myra Bergman/Cindy Johnston
File
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Hauenstein Center Letterhead
Letter to Prospective Research Participant
Dear
I am writing to inform you of a research study that we will be offering to interested
Parkinson’s patients who receive care at the Hauenstein Parkinson’s Center. The study will be
conducted at the facilities of the Hauenstein Parkinson’s Center by researchers from the College
of Health and Human Services at Western Michigan University. They will be investigating the
effectiveness of two health care-patient education methods for teaching disease management and
how they impact the quality of life for Parkinson’s patients. Patients who accept the invitation to
participate will be asked to commit to attend three two-hour, patient education sessions that will
be taught by various health care professionals who are members of our interdisciplinary health
care team at the Hauenstein Parkinson’s Center. Patients also will be asked to complete two brief
questionnaires at three points during the study that are designed to assess their Parkinson’s
disease quality of life and sense of how well they can manage their Parkinson’s disease and
related symptoms.
Here’s what you will learn about:
♦ Information to help you manage your Parkinson’s disease
♦ Medicines used to treat Parkinson’s disease, their importance, and how to manage them
♦ Exercises to help increase your mobility, strength, balance, and flexibility
♦ Ways to prevent injuries by make your home safer and more user friendly
♦ Ways to improve speech and communication skills that may have been impacted by
Parkinson’s
♦ Available community resources and services and how to access them
♦ How to manage other chronic diseases that you may
If you are interested in finding out more about this study and possibly participating in it, a
researcher, Lori Pearl-Kraus, RN, PhD-c, CS, FNP-C, from Western Michigan University will
contact you to explain the study further and to answer any questions. A study brochure is
enclosed which describes the study and eligibility requirements for participating in it. If you are
willing to permit us to share your name, address, and phone number with these researchers solely
for the purpose of allowing them to contact you to explain the study to you, please fill out and
return the enclosed, postage-paid response form directly to Lori Pearl-Kraus. Shortly after receipt
of your returned response form, Lori will contact you to set up a time to meet with you and
explain the study to you. If you have any questions regarding this request, please feel free to
contact either myself or Julie Sager, RN, BSN, nurse manager, at the Hauenstein Parkinson’s
Center at 616-752-5400.
Sincerely,
Dr. Leslie Neuman,
Medical Director - Hauenstein Parkinson’s Center
ljpk:050606
Enclosures
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PD Patient Response Form
If you are interested in learning more about this study and possibly participating
in it, please mail this prepaid form b y _________ _____ (date) to Lori Pearl-Kraus,
RN, PhD-c, CS, FNP-C, who will contact you about next steps.
If you are willing to have Lori Pearl-Kraus contact you to explain this study further to
you, please provide your name, address, phone number, and preferred times below:
Name:
Phone number(s):
Address:
Please circle the best day and time to call you:
Monday Tuesday Wednesday Thursday Friday
Morning
Afternoon

Saturday Sunday
Evening

What is your year of birth?_____________
(year)
Do you have access to reliable transportation? Yes _____

N o ______
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Hauenstein Parkinson’s Center
Western Michigan University

(Insert HPC Logo)

Parkinson’s Patient Education and Disease Management Study
What is the Parkinson’s Patient Education and Disease Management Study ?
The Parkinson’s Patient Education and Disease Management Study is an important
research project intended to study two educational methods for teaching patients with
Parkinson’s disease (PD) to manage their treatments and symptoms. It will also study
the impact o f these two educational methods on the quality of life for patients with PD.
Who is sponsoring the Parkinson’s Patient Education and Disease
Management Study?
This research project is sponsored by Western Michigan University in Kalamazoo,
Michigan and the Hauenstein Parkinson’s Center at St. Mary’s Medical Center in Grand
Rapids, Michigan. The study is coordinated by a group of researchers from Western
Michigan University. We will be recruiting a total of 48 men and women to participate
in the Parkinson’s Patient Education and Disease Management Study.
Why study Parkinson’s Patient Education and Disease Management?
Studying new approaches to teaching Parkinson patients about their disease and how to
manage it may help them to improve their mobility and balance, speech and
communication skills, improve their use of medications, promote safer living
environments, maintain their independence, and improve their quality of life. This may
also help to reduce injuries in PD patients. All of these things can help to reduce the cost
of health care while improving the quality of care and the lives of PD patients.
Who can participate in the Parkinson’s Patient Education and Disease
Management Study ?
You may be able to participate in this study if:
• You are a man or woman between the ages of 30 and 80 years old.
• Your Parkinson’s symptoms affect both sides of your body (in the middle stages of
Parkinson’s disease).
• You have not been diagnosed with dementia..
• You are able to hear good enough to participate in large and small group
interactions.
• You are able to speak, read, write, and understand English.
• You have an educational level of 9th grade or higher.
• You have a telephone (land line or cellular) in your home.
• You have access to reliable transportation to and from the Hauenstein Parkinson’s
Center.
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•

You will be available on the planned dates for the educational sessions (one 2-hour
session held one day per week for 3 consecutive weeks this Fall).
What will happen if I participate in the Parkinson’s Patient Education and
Disease Management Study?

If you decide to participate in our study, you will read and sign consent forms that
explains the Parkinson's Patient Education and Disease Management Study and
protection o f your health information in more detail.
You will then be assigned by chance to participate in one of the two patient educational
and disease management groups offered in this study. You will also be asked to complete
a patient general information form. Two brief screening tests will be given to you to
assess your stage of Parkinson’s disease and mental status.
If you choose to participate in this study, you will be asked to commit to attending three
two-hour, patient education sessions that will be taught be various health care
professionals that will teach you about ways to deal with your PD symptoms. You will
be asked to complete two brief questionnaires at three points during the study (at the
beginning o f the study, upon completion of the 3-week intervention, and one month after
completing the study). You will also be asked to complete a patient general information
form and a brief evaluation form at the end of each session.
The study will be completed in seven weeks. It is important for you to plan to stick with
the study until it ends. However, if you change your mind, you may leave the study at
any time for any reason.
Why might I want to participate in the Parkinson’s Patient Education and
Disease Management Study!
As a participant in the Parkinson’s Patient Education and Disease Management Study,
you will be a partner in medical research and may benefit from having the chance to gain
knowledge and skills related to management of your Parkinson’s disease. You may also
benefit from having the opportunity to discuss your health concerns with professionals
and other patients. The results of this study may also benefit other PD patients and their
families by helping us to understand how educational programs help patients learn to
manage their disease. Please discuss this brochure with your doctor, family, and friends.
How can I j oin the Parkinson’s Patient Education and Disease Management
Study?
If you are interested in participating, or want to find out more about the study, please
contact Dr. Leslie Neuman, medical director, or Julie Sager, RN, BSN, nurse manager,
at the Hauenstein Parkinson’s Center at 616-752-5400.
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Hauenstein Parkinson’s Center at
St. Mary’s Medical Center
Grand Rapids, Michigan

(Insert Logo)

Western Michigan University
College of Health and Human Services
Interdisciplinary Health Studies Program
CONSENT FOR RESEARCH
PARKINSON’S PATIENT EDUCATION, DISEASE MANAGEMENT,
AND QUALITY OF LIFE OUTCOMES STUDY
Study Number: WMU HSIRB Project Number: 06-07-03
SMHC HSIRB Project Number: 06-0828-05
Sponsors: St. Mary’s Medical Center and Hauenstein Parkinson’s Center and
Western Michigan University, College of Health and Human Services.
Principal Investigator: Nickola Nelson, PhD, CCC-SLP
Co-Principal/Student Investigator: Lorraine J. Pearl-Kraus, RN, PhD-c, CS, FNP-C

We are inviting you to participate in a research study entitled, “Parkinson’s Patient
Education, Disease Management, Quality o f Life Outcomes Study. ” This study includes
only patients who chose to take part in it.
WHY IS THIS STUDY BEING DONE?
This research is intended to study two educational methods for teaching patients with
Parkinson’s disease (PD) to manage their treatments and symptoms. It will also study the
impact o f educational methods on the quality of life for patients with PD. This study is
being conducted as partial fulfillment of the requirements for the degree of Doctor of
Philosophy for Lorraine J. Pearl-Kraus, RN, PhD-c, CS, FNP-C.
WHO IS CONDUCTING THIS STUDY?
If you decide to take part in this study, you will be taking part in a clinical trial conducted
by the Hauenstein Parkinson’s Center at St. Mary’s Medical Center in Grand Rapids,
Michigan and Western Michigan University’s College of Health and Human Services in
Kalamazoo, Michigan.
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HOW MANY PEO PLE WILL TAKE PART IN THIS STUDY?
This study will enroll 48 patients who are 30 years of age and not more than 80 years old
and who have Parkinson’s symptoms that affect both sides of their body (middle stage
PD).
WHAT IS INVOLVED IN THIS STUDY?
If you agree to participate, we will ask you to attend one two-hour, patient education
session per week for three consecutive weeks. The sessions will include information
about:
• Medications
• Exercise
• Communication Skills
• Social Support
Before you start participating in the study, you will be asked to fill out two brief
questionnaires. One will assess how your Parkinson’s disease is affecting your quality of
life; the other will assess how you feel about your ability to manage your disease. You will
be asked to complete these questionnaires at three points during the study: (a) at baseline
(entry into study), (b) after completion of the two-hour sessions offered over three
consecutive weeks, and (c) one month after completion of the educational sessions. You
will also be asked to fill out an evaluation form after each session.
HOW LONG W ILL I BE IN THIS STUDY?
As a participant, you will be enrolled in this study for a total period of 7 weeks (consisting
of 3 weeks o f two-hour educational sessions with a foliowup mailing of two study
questionnaires to be filled out by you at one month after completion of the educational
sessions).
W HAT ARE TH E RISKS OF THE STUDY?
Although we believe that the educational session may provide some benefits to you, there
may be unforeseen risks as well, as in all research. We foresee the following possible risks
with this study: (1) inconveniences, such as, time spent doing the interviews, reviewing the
materials, completing questionnaires; (2) fatigue; (3) emotional distress due to confronting
health concerns; (4) participating in a group process; (5) concerns regarding
confidentiality o f personal data; and (6) difficulty in arranging transportation to and from
the educational sessions.
Attempts to minimize inconveniences to the participants will include scheduling interviews
and other meetings at times and safe locations that are convenient for the participant. To
minimize participants’ potential fatigue and emotional distress, scheduled periods (breaks)
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for relaxation and social support which may be derived from having the opportunity to
interact with others, have been incorporated into each of the three educational sessions.
To minimize potential risks that participants may incur due to participating in a group
process, ground rules that protect and respect the rights of each individual will be
established for participating in the group process and agreed upon by consensus of each
group.
WHAT ABOUT CONFIDENTIALITY?
Anonymity is a risk that exists with any research project, especially during interviews and
group interactions. Attempts will be made to minimize risks associated with loss of
confidentiality and anonymity by using a pseudonym in lieu of participant’s legal name on
respondent’s questionnaires. Given the very nature of the study’s intervention, however, it
is not possible to assure absolute anonymity to study participants. The only persons that
will have access to participant’s study-related materials will be Lorraine J. Pearl-Kraus,
RN, PhD-c, CS, FNP-C, doctoral advisor (Principal Investigator) Dr. Nickola Nelson at
Western Michigan University, Dr. Leslie Neuman, medical director of the Hauenstein
Parkinson Center, and biostatistician consultant. Others who will interact with the
participants during the training sessions, and thus be aware of who is participating in the
study, will include several health care professionals. However, none of these helpers will
be able to associate your survey responses with you as an individual. All of the information
collected from you will be held in strictest confidence and you will not be identified in any
reports o f the research results. That means that your name or any other personal identifiers
will not appear on any papers on which this information is recorded. The forms will all be
coded, and the investigators will keep a separate master list with the names of participants
and the corresponding codes in locked cabinets. Once the data have been collected and
analyzed, the master list will be destroyed. All other forms will be retained for at least
three years in a locked file in the principal investigator’s office at Western Michigan
University.
ARE THERE BENEFITS TO TAKING PART IN THIS STUDY?
One way in which you may benefit from this activity is by having the chance to gain
knowledge and skills related to management of your Parkinson’s disease and a chance to
discuss your health concerns with professionals and other patients. The results of this
research may benefit other patients with Parkinson’s disease and their families in their
understanding of how educational programs help patients learn to manage their disease.
WHAT ARE THE COSTS?
There will be no charge for any o f these sessions, and we will not be able to pay you to
participate in the study. Neither you nor your insurer will bear the costs of this
intervention. You will be responsible for providing your own transportation to and from
the educational sessions that will held at the Hauenstein Parkinson’s Center. Free parking
is available in the St. Mary’s Medical Center visitor parking lots.
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If an accidental injury occurs, appropriate emergency measures will be taken; however, no
compensation or additional treatment will be made available to you except as otherwise
stated in this consent form. In the unlikely event of any injury from this research, you will
not receive reimbursement, compensation, or free medical treatment. Your hospital and/or
medical care will continue under the care of your personal physicians and incurred
expenses will be billed to your insurer in the usual manner.
WHAT ARE MY RIGHTS AS A PARTICIPANT?
Taking part in this study is voluntary. You may decide not to accept our invitation to
participate in this activity without any penalty or loss of access to services you would
otherwise receive. You may also decide to quit at any time during the study without
prejudice or penalty or reduction in your usual care. You will have access to the results of
this research study when they become available. You may contact the researchers to
request that a copy of the study results be mailed to you.
WHO DO I CALL IF I HAVE QUESTIONS OR PROBLEMS?
If you have any questions or concern about this study, you may contact either doctoral
research student, Lorraine Pearl-Kraus, RN, MSN, CS, FNP-C, at 616-391-6292 or
faculty advisor, Nickola W. Nelson, Ph.D., CCC-SLP, at 269-387-7990. You may also
contact the Chair, Human Subjects Institutional Review Board (269-387-8293) or the
Vice President for Research at Western Michigan University (269-387-8298) if questions
or problems arise during the course of the study. If you have any questions about your
rights as a research study participant, you may also contact the Human Subjects
Institutional Review Board representative, Sister Myra Bergman, at St. Mary’s Medical
Center at 616-752-6090.
This consent document has been approved for use for one year by the Human Subjects
Institutional Review Board at Western Michigan University and St. Mary’s Medical
Center in Grand Rapids, as indicated by the stamped date and signature of the board chair
in the upper right corner. Do not participate in this study if the stamped date is more than
one year old.
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SIGNATURE
Your signature below indicates that you have and/or had explained to you the purpose and
requirements of the study and that you agree to participate.

Signature (Participant)

Date

Consent obtain by__________________
Researcher’s Initials

____
Date

Signature o f Witness (optional)

Date
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Authorization to Use or Disclose (Release)
Personal Health Information for Research
PARKINSON’S PATIENT EDUCATION, DISEASE MANAGEMENT,
AND QUALITY OF LIFE OUTCOMES STUDY
Study Number:
1. What is the purpose of this form?
According to the Health Insurance Portability and Accountability Act (HIP AA) of
1996, patients must provide written authorization for the release of their Personal
Health Information (PHI). Western Michigan University and the Hauenstein
Parkinson’s Center at St. Mary’s Medical Center are organizations that do research to
learn about ways to treat and to improve the care of patients with Parkinson’s disease.
Researchers would like to use your personal health information for research. This
information may include data that identifies you. Please carefully review the
information below. If you agree that researchers can use your personal health
information, you must sign and date this form to given them your permission.
2. What personal health information do the researchers want to use?
Researchers want to extract and use the portions of your medical record that they will
need for the research study in which you may agree to participate. If you agree to
participate in a Western Michigan University research study, information that will be
used and/or released may include your complete medical record, and in particular, the
following:
■ the history arid diagnosis of your disease
■ specific information about treatments that you may have received
■ information about other medical conditions that may affect your treatment
■ medical data, including laboratory test results, CT scans, MRIs, X-rays,
and pathology results
■ information on side effects (adverse events) you may experience, and how
these were treated
■ long-term information about your general health status and the status of
your disease
■ tissue and/or blood samples, associated data related to the analysis of the
samples
■ numbers or codes that will identify you, including but not limited to your
social security number, medical record number, birthdate, telephone
number, address, and/or email address
3. Why do the researchers want my personal health information?
Western Michigan University will collect your personal health information and share it
with the Hauenstein Parkinson’s Center at St. Mary’s Medical Center if you choose to
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participate in this research study, or to evaluate your eligibility for this study. Western
Michigan University researchers will use your information for the follow Parkinson’s
disease research study W M U HSIRB Project Number: 06-07-03; SMHC HSIRB
Project Number: 06-0828-05.
4. W ho will be able to use my personal health information?
Western Michigan University and the Hauenstein Parkinson’s Center at St. Mary’s
Medical Center will use your personal health information for research purposes only.
As part o f this research, they may provide your information to the following groups.
As required by law, the following groups also have the right to review your original
records.
■ Western Michigan University researchers and their staff
■ The Human Subjects Institutional Review Board at Western Michigan
University
■ The Human Subjects Institutional Review Board at St. Mary’s Medical
Center
■ The Food and Drug Administration (FDA)
■ Public health agencies and other government agencies as authorized or
required by law
■ Other people or organizations assisting with Western Michigan
University’s research efforts
■ Central laboratories, central review centers, and central reviewers. The
central laboratories and review agencies may also give your personal health
information to those groups listed above.
5. How will information about me be kept private?
Western Michigan University and the Hauenstein Parkinson’s Center at St. Mary’s
Medical Center will keep all personal health information confidential to the fullest
extent possible. Western Michigan University and the Hauenstein Parkinson’s Center
will not release personal health information about you to others, except as authorized
by this form, or required by law. If your personal health information must be shared
with other organizations, the privacy laws that govern those organizations would
apply.
6. W hat if I do not authorize you to collect and release my personal health
information?
If you decide not to authorize release of your personal health information as part of
this study, your decision will in no way affect your medical care or cause you to lose
any benefits to which you are entitled. You cannot, however, be in this research study
if you do not agree to release your personal health information, or information relating
to medical benefits for this research study.
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7. If I sign this form, will I automatically be entered into the research study?
No, you cannot be entered into any research study without further discussion and
separate consent. After discussion, you may decide to take part in the research study.
At that time, you will be asked to sign a separate research consent form.
8. What happens if I want to withdraw my authorization?
You can change your mind at any time and withdraw this authorization. This request
for withdrawal must be made in writing. Beginning on the date you withdraw your
authorization, no new personal health information will be used for research. However,
researchers may continue to use the personal health information that was provided
before you withdrew your permission.
If you sign this form and enter the research study, but later change your mind and
withdraw your authorization, you will be removed from the research study at that
time.
To withdraw you authorization, please contact the person below. He/She will make
sure your written request to withdraw your authorization is processed correctly.
Principal Investigator: Nickola W. Nelson, Ph.D., CCC-SLP
Charles Van Riper Professor of Speech Pathology and Audiology (2005-2008)
Director, Ph.D. in Interdisciplinary Health Studies
College of Health and Human Services
Western Michigan University
1903 W. Michigan
Kalamazoo, MI 49008-5355
office: 269-387-7990
fax: 269-387-8912 e-mail: nickola.nelson@wmich.edu
9. How long will this authorization last?
If you agree by signing this form that researchers can use your personal health
information, this authorization has no expiration date. However, as stated above, you
can change your mind and withdraw your permission at any time, but you must do so
in writing.
10. What are my rights regarding my personal health information?
You have the right to refuse to sign this authorization form. You have the right to
review and/or copy records of your personal health information as pertains to this
study that are kept by Western Michigan University and the Hauenstein Parkinson’s
Center. You do not have the right to review and/or copy records kept by Western
Michigan University or other researchers associated with this research study.
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SIGNATURES
I agree that my personal health information may be used and disclosed for research
purposes described in this form. I will receive a signed copy of this form.
Signature o f Patient:_____________________________

D ate:______________

Printed Name of Patient:_____________________ _____
Signature o f Person Obtaining Authorization:______________________________
Printed Name of Person Obtaining Authorization:___________________________
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M easurement Scales
Modified Hoehn & Yahr Scale
(for Staging Severity of Parkinson’s disease)
1.
2.
3.
4.
5.
6.

Stage 0 = No signs o f disease.
Stage 1 = Unilateral disease.
Stage 1.5 = Unilateral disease plus axial involvement.
Stage 2 = Bilateral disease, without impairment of balance.
Stage 2.5 = Mild bilateral disease, with recovery on pull test.
Stage 3 = Mild to moderate bilateral disease; some postural instability; physically
independent.
7.
Stage 4 = Severe disability; still able to walkor stand unassisted.
8.Stage 5 = Wheelchair bound or bedridden unless aided.

Retrieved from: MD Virtual University’s website for Parkinson’s Disease Rating Scales.
The Modified Hoehn & Yahr Scale is incorporated within the Unified Parkinson’s Disease
Rating Scale which is available on the WorldWideWeb at:
http://www.mdvu.org/pdf/updrs.pdf
Fahn S, Elton R, Members o f the UPDRS Development Committee.
In: Fahn S, Marsden CD, Caine DB, Goldstein M, eds. Recent Developments in
Parkinson's Disease, Vol 2. Florham Park, NJ. Macmillan Health Care Information 1987,
pp 15 3-163, 293-304
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Mini-Mental State Examination (MMSE)
Screening Tool: The Mini-Mental State Examination (MMSE)
P atien t_____________________________
D ate__________

Examiner_____________________

Maximum Score = 30 Points
Orientation
5 • What is the (year) (season) (date) (day) (month)?
5 • Where are we (state) (country) (town) (hospital) (floor)?
Registration
3 • Name 3 objects (Ball, Flag, Tree): 1 second to say each. Then ask the patient all 3
after you have said them. Give 1 point for each correct answer.
Then repeat until he/she learns all 3. Count trials and record.
Trials________________
Attention and Calculation
5 • Serial 7’s. 1 point for each correct answer. Stop after 5 answers.
(Alternatively spell “world” backward.
Recall
3 • Ask for the 3 objects repeated above. (Give 1 point for each correct answer.)
Language
2 • Name a pencil and watch.
1 • Repeat the following “No ifs, ands or buts.”
3 • Follow a 3-stage command:
“Take a paper in your hand, fold it in half and put it on the floor.”
1 • Read and obey the following CLOSE YOUR EYES.
1 • Write a sentence.
1 • Copy the design shown.
____________Total Score
ASSESS level of consciousness along a continuum _________________________
Alert
Drowsy
Stupor
Coma
“Mini-Mental State.” A Practical Method for Grading the Cognitive State of Patients
for the Clinician. Journal o f Psychiatric Research, 12(3): 189-198, 1975.
Used with permission.
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How to obtain permission to use the Mini-Mental State Examination:
The Mini-Mental State Examination is copyright protected. Materials can be purchased
through www.minimental.com. (Note: Permission to use the MMSE needs to be obtained
and materials purchased from the American Psychological Association which now holds
the copyright for this test.)
The M ini M ental State Examination (M M SE)
By: Lenore Kurlowicz, PhD, RN, CS, and Meredith Wallace, PhD, RN, MSN
WHY: Cognitive impairment is no longer considered a normal and inevitable change of aging.
Although older adults are at higher risk than the rest of the population, changes in cognitive
function often call for prompt and aggressive action. In older patients, cognitive functioning is
especially likely to decline during illness or injury. The nurses’ assessment of an older adult’s
cognitive status is instrumental in identifying early changes in physiological status, ability to
learn, and evaluating responses to treatment.
BEST TOOL: The MMSE is a tool that can be used to systematically and thoroughly assess
mental status. It is an 11-question measure that tests five areas of cognitive function:
orientation, registration, attention and calculation, recall and language. The maximum score is
30. A score of 23 or lower is indicative of cognitive impairment. The MMSE takes only 5-10
minutes to administer and is therefore practical to use repeatedly and routinely. TARGET
POPULATION: The MMSE is effective as a screening tool for cognitive impairment with
older, community dwelling, hospitalized and institutionalized adults. Assessment of an older
adult’s cognitive function is best achieved when it is done routinely, systematically and
thoroughly. VALIDITY/RELIABILITY: Since its creation in 1975, the MMSE has been
validated and extensively used in both clinical practice and research. STRENGTHS AND
LIMITATIONS: The MMSE is effective as a screening instrument to separate patients with
cognitive impairment from those without it. In addition, when used repeatedly the instrument is
able to measure changes in cognitive status that may benefit from intervention. However, the
tool is not able to diagnose the case for changes in cognitive function and should not replace a
complete clinical assessment of mental status. In addition, the instrument relies heavily on
verbal response and reading and writing. Therefore, patients that are hearing and visually
impaired, intubated, have low English literacy, or those with other communication
disorders may perform poorly even when cognitively intact.
MORE ON THE TOPIC:
Folstein, M., Folstein, S.E., McHugh, P.R. (1975). “Mini-Mental State” a Practical Method for
Grading the Cognitive State of Patients for the Clinician. Journal o f Psychiatric Research,
12(3); 189-198.
Foreman, M.D., Grabowski, R. (1992). Diagnostic Dilemma: Cognitive Impairment in the
Elderly. Journal o f Gerontological Nursing, 18; 5-12.
Foreman, M.D., Fletcher, K., Mion, L.C., & Simon, L. (1996). Assessing Cognitive Function.
Geriatric Nursing, 17; 228-233
Permission is hereby granted to reproduce this material for non-for-profit educational purposes only, provided The Hartford Institute for
Geriatric Nursing, Division of Nursing, New York University is cited as the source. Available on the intranet at www.hartfordign.org. Email notification of usage to: Hartford.ign@nyu.edu
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Parkinson’s Disease Questionnaire (PDO-39) and Quality of Life
DUE TO HAVING PARKINSON’S DISEASE, how often have you experienced the
following, DURING THE LAST MONTH?
Due to having Parkinson’s disease, how
often during the last month have you...
1.

2.
3.

Had problems walking a half mile?

5.

Had problems walking 100 yards?

6.

Had problems getting around the
house as easily as you would like?
Had difficulty getting around in
public?
Needed someone else to accompany
you when you went out?

8.
9.
10.
11.
12.
13.

Ocasionally

Sometimes

Had difficulty doing the leisure
activities which you like to do?
Had difficulty looking after your
lome, housework, cooking?
Had difficulty carrying bags of
shopping?

4.

7.

Never

Felt frightened or worried about
falling over in public?
Been confined to the house more
than you would like?
Had difficulty washing yourself?
Had difficulty dressing yourself?

14.

Had problems doing up buttons or
shoe laces?
Had problems writing clearly?

15.

Had difficulty cutting your food?

16.

Had difficulty holding a drink
without spilling it?

17.

Felt depressed?

18.

Felt isolated and lonely?

19.

Felt weepy or tearful?

20.

Felt angry or bitter?

21.

Felt anxious?
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Due to having Parkinson’s disease, how
often during the last month have you...
Felt worried about your future?
22.
23.
24.
25.
26.
27.
28.
29.

30.

Ocasionally

Sometimes

Felt you had to conceal your
Parkinson’s from people?
Avoided situations which involve
eating or drinking in public?
Felt embarrassed in public due to
having Parkinson’s disease?
Felt worried by other people’s
reaction to you?
Had problems with your personal
relationships?
Not had support in the ways you
need from your spouse or partner?
Not had support in the ways you
need from your family or close
friends?
Unexpectedly fallen asleep during
the day?

31.

Had problems with your
concentration, for example, when
reading or watching TV?

32.

Felt your memory was bad?

33.

Had distressing dreams or
hallucinations?

34.
35.

Had difficulty with your speech?

36.

Felt ignored by people?

37.

Had painful muscle cramps or
spasms?

38.

Had aches and pains in your joints
or body?
Felt unpleasantly hot or cold?

39.

Never

Felt unable to communicate with
people properly?
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The instructions for scoring the PDQ-39 are as follows:
Sum of scores for each question in dimension divided by 4 x number of questions
in dimension and then x 100 to get a percent.
Total Score (PDQ-39SI): Sum of scores for questions 1-39 divided by 4 x 39 and
then x 100.
Subscales of Test
Mobility: Sum of scores for questions 1-10 divided by 4 x 10 and then x 100.
Activities of Daily Living (ADL): Sum o f scores for questions 11-16 divided by 4 x 6 and
t h e n x 100.
Emotional Well-being: Sum of scores for questions 17-22 divided by 4 x 6 and then x 100.
Stigma: Sum of scores for questions 23-26 divided by 4 x 4 and then x 100.
Social Support: Sum of scores for questions 27-29 divided by 4 x 3 and then x 100. If
respondents indicate they they do not have a spouse or partner (question 28), then social
support can be calculated as follows:
Social support = (scores of questions 27 + 29)/ (4 x 2) x 100
Cognition: Sum o f scores for questions 30-33 divided by 4 x 4 and then x 100.
Communication: Sum of scores for questions 34-36 divided by 4 x 3 and then x 100.
Bodily Discomfort: Sum of scores for questions 37-39 divided by 4 x 3 and then x 100.
F or the scoring:
Never = 0
Occasionally = 1
Sometimes = 2
Often = 3
Always or cannot do = 4

Reference
Jenkinson, C., Fitzpatrick, R., & Peto, V. (1998). The Parkinson’s Disease Questionnaire: User
manual for the PDQ-39, PDQ-8, and PDQ Summary Index. Oxford University: Health Services
Research Unit - Department of Public Health.
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Self-Efficacy for M anaging Chronic D isease 6-Item Scale
We would like to know how confident you are in doing certain activities. For each of the following
questions, please choose the number that corresponds to your confidence that you can do the tasks
regularly at the present time.
1. How confident are you that you can keep the fatigue caused
not at all | 1 | 1 | | | | | | totally
confident 1 2 3 4 5 6 7 8 9 10 confident

do?

_________
2. How confident are you that you can keep the physical
discomfort or pain of your disease from interfering with the not
not at all
all |1 1 1 II 1 1 1 1 1 totally
confident 1 2 3 4 5 6 7 8 9 10confident
things you want to do?
3. How confident are you that you can keep the emotional
distress caused by your disease from interfering with the
things you want to do?

not at all 1 i 1 1 1 1 1 1 II totally
confident 1 2 3 4 5 6 7 8 9 10confident

4. How confident are you that you can keep any other
symptoms or health problems you have from interfering
with the things you want to do?

not at all 1 1 1 1 1 1 1 11 1 totally
confident 1 2 3 4 5 6 7 8 9 10 confident

5. How confident are you that you can do the different tasks
and activities needed to manage your health condition so as
not at all 1 1 1 1 1 1 II 1 1 totally
to reduce you need to see a doctor?
confident 1 2 3 4 5 6 7 8 9 10 confident
6. How confident are you that you can do things other than just
taking medication to reduce how much you illness affects not at all 1 1 1 1 1 1 1 1 1 1 totally
your everyday life?
confident 1 2 3 4 5 6 7 8 9 10 confident

Scoring
The score for each item is the number circled. If two consecutive numbers are circled, code the
lower number (less self-efficacy). If the numbers are not consecutive, do not score the item. The
score for the scale is the mean of the six items. If more than two items are missing, do not score the
scale. Higher number indicates higher self-efficacy.

Characteristics
Tested on 605 subjects with chronic disease
No. of
items

Observed
Range

Mean

Standard
Deviation

Internal Consistency
Reliability

Test-Retest
Reliability

6

1-10

5.17

2.22

.91

NA
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Source o f Psychometric Data
Stanford/Garfield Kaiser Chronic Disease Dissemination Study. Psychometrics reported in: Lorig
KR, Sobel, DS, Ritter PL, Laurent, D, Hobbs, M. Effect of a self-management program for
patients with chronic disease. Effective Clinical Practice, 4, 2001,pp. 256-262.

Comments
This 6-item scale contains items taken from several SE scales developed for the Chronic Disease
Self-Management study. We use this scale now, as it is much less burdensome for subjects. It
covers several domains that are common across many chronic diseases, symptom control, role
function, emotional functioning and communicating with physicians. For internet studies, we add
radio buttons below each number. There are 2 ways to format these items. We use the format on
this document, the other is shown on die web page. A 4-item version of this scale available in
Spanish.

References
Lorig KR, Sobel, DS, Ritter PL, Laurent, D, Hobbs, M. Effect of a self-management program for
patients with chronic disease. Effective Clinical Practice, 4, 2001,pp. 256-262.
This Scale Is Free To Use Without Permission
Stanford Patient Education Research Center
1000 Welch Road, Suite 204
Palo Alto CA 94304
(650) 723-7935
(650) 725-9422 Fax
self-management@stanford.edu
http://patienteducation.stanford.edu
Funded by the National Institute of Nursing Research (NINR)
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Participant Information Sheet
1. Name: ____________________________ _____________ 2. Study ID#:
(First)

(Middle)

(Last)

3. Home Address:__________________________________________
(Street)
(Apt. #)
(City)

(State)

(9 digit zip code)

Alternate/Winter address:_______________________________
(Street)
(Apt. #)
(City)

(State)

(9 digit zip code)

1. Home Phone Number: ___- ____ - _____
Cell phone #
Alternate/Winter Phone # : ____ - ____ 5. E-mail address (if available)_____________ _______ ______
6. Date of Birth:

-_____

.
(Month/Day/Year)

7. Year diagnosed with Parkinson’s Disease:_____________
(Month/Day/Year)

8. Hoehn & Yahr PD Stage: (circle one) 0 1 1.5 2 2.5
9. What is your marital status? (circle one)
(a) Single, never married (b) Married (c) Divorced
(e) Separated
10.

3 4 5

(d) Widowed

(f) Live with partner, but not married

Race (circle only one)
(a) White or Caucasian

(b) Black or African American

(c) Native Hawaiian or Pacific Islander

(d) Asian

(e) American Indian or Native Alaskan

(f) Unknown

11. Ethnicity (Spanish/Hispanic Origin): (circle all that apply)
(a) Not Spanish
(b) Spanish/Hispanic Origin:
Mexican

Central America

Puerto Rican

South America

Cuban

O ther______________________

(c) NOS (Not otherwise specified)

(d) Unknown
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12. Do you have any insurance coverage? (check one) Y es
N o ____
I f yes, who is the insurer? (check all th at apply)
(a) Government _____
(b) Private insurer_______
Medicare _____
Medicaid _____
Both Medicare & Medicaid______
Military or Veteran’s Administration______
13. Do you ever make choices based on your ability to pay for: (m ark an X on
appropriate response)
(a) medications? Y es
N o ___
(b) seeing health care providers? Y es
N o ____
(c) taking part in health care programs that charge a fee? Y es
N o __
14. I f employed, please provide employer and occupational information?
P ositio n :____________________________
(Job title)

Employer:

___________________________
(Name of company)

Address: ________________________________ _______
(Street)
(City)

(State)

(9 digit zip code)

Phone Number: _____- _____ - _______
15. Years of education completed? (circle the highest year of school that you
have completed)
1 23 45 6
(primary)

7 8 9 10 11 12

13 14 15 16

(high school)

(college/university)

17 18 19 20 21 22

23+

(graduate school)

16. Do you ever use hearing aids? (check the appropriate response)
Yes
No
17. Has anyone ever suggested that you might need hearing aids? (check the
appropriate response)
Yes
No
18. Would it help you to have an assistive listening device when you come to the
learning activities? (check the appropriate response)
Yes
No
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19. When listening in a large group activity, which statement best describes
you? (check only one appropriate response)
I almost never have trouble hearing and understanding what the speaker
says if the speaker uses a microphone.
I sometimes have trouble hearing and understanding what the speaker
says if the speaker uses a microphone.
I almost always have trouble hearing and understanding what the
speaker says even if the speaker uses a microphone.
20. When talking in a small group? (check only one appropriate response)
I almost never have trouble hearing and understanding, even if other
people are talking somewhere else in the room.
I sometimes have trouble hearing and understanding, particularly if other
people are talking somewhere else in the room.
I almost always have trouble hearing and understanding even when the
room is really quiet.
21. Please provide the names, addresses, and phone numbers of two people
(other than spouse or partner) who can be reached in case of an
emergency.
Relationship:___________
A. Nam e:_________________
Address:___________________
'_________________
(Street)

(City)

(State)

(9 digit zip code)

Home Phone Number:____ -_____ -_______
Mobile/Cell Phone Number:
B. Nam e:____
Relationship:
Address:
(Street)

(City)

(State)

(9 digit zip code)

Home Phone Number:
Mobile/Cell Phone Number:
22. Personal physician information (in case of emergency):
Name:
Address:
(Street)
(City)

Office Phone Number:

(State)

(9 digit zip code)

-_____ -_______

23. Who is the neurologist that monitors your Parkinson’s disease?
Name:
Address:
(Street)
(City)

(State)

(9 digit zip code)

Office Phone Number:
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24. What have you done to learn more about Parkinson’s disease? (check all
that apply)
Internet resources
Attended PD support group
Attended PD education offerings
PD education materials provided by physician’s office
25. What is your preferred method of learning? (check all that apply)
Auditory (being told how to do something)
Visual (being shown how to do something)
___ Both audio and visual learning
By demonstration
26.

Please check YES or NO to show us what types of chronic conditions you
have, (please mark an X for the appropriate response)
Diabetes
YES___ N O _____
Heart Failure

YES___ N O _____

History of Heart Attack

YES___ N O _____

High Blood Pressure

YES__ NO

History of Stroke

YES__ NO

Abnormal heart rhythm

YES__ NO

Disease affecting blood vessels
& circulation (indicate type: _____________ )

YES___NO

Kidney disease

YES__ NO

Asthma

YES__ NO

Emphysema or COPD (Chronic
Obstructive Pulmonary Disease)

YES

Other lung disease
(Indicate type:
Arthritis or other joint disease

)

NO

YES___ NO
YES___ NO

Cancer (either in remission or cured)______________YES___ NO
Vision problems
(Indicate type:________________ )_____________ YES___ NO
Problems with sense o f smell
Other chronic condition
(Indicate type:__________

YES___ NO
)___________ YES___ NO
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27. Please check YES or NO to show us what types of medications that you
take every day. (please mark an X for the appropriate response)
Prescription pain medicine

Y E S _____N O ____

Over-the-counter pain medicine

Y E S _____N O ____

Medicine to strengthen the heart

Y E S _____ N O ___

Medicine to treat heart rhythm

Y E S _____ N O ____

Water pill (diuretic)

Y E S _____N O ____

Medicine to treat high blood pressure (other
than a diuretic or in combination with a
diuretic, for example, zestoretic)
Y E S _____ N O ____
Medicine to treat low blood count (anemia)

Y E S ____ NO

Eye drops to treat glaucoma

YES ____NO

Eye drops to treat dry eye

Y E S ____ NO

Inhaler for breathing problems

Y E S ____ NO

Pills for breathing problems

Y E S ____ NO

Pill to control blood sugar

Y E S ____ NO

Insulin to control blood sugar

Y E S ____ NO

Medicine to control depression

Y E S ____ NO

Medicine to feel calm (control anxiety)

YES

NO _

Sleeping pill____________________________ Y E S ____ NO
Medicine to control seizures

Y E S ____ NO

28. In general, do you think that your health is: (check one)
Excellent

_____

Very Good _____
Good

____

Fair _____
Poor
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SCRIPT TO CONTACT
PARTICIPANTS FOR CONSENT FORM
RESEARCHER: We would like to invite you to participate in some interesting research
on “Parkinson’s Patient Education, Disease Management, and Quality o f Life
Outcomes. ” This research project intends to study two educational methods for teaching
patients with Parkinson’s disease (PD) how to manage their treatments and symptoms. It
will also study the impact o f educational methods on the quality o f life for patients with
PD. This is a voluntary research project in which you may choose to either participate in
or not. You have the right to refuse to participate in this study at any time.
If you agree to participate in this research, you will be involved in a study that may help
health care providers determine effective ways of teaching Parkinson’s patients to better
manage their disease and improve their quality o f life. If you agree to participate, we will
ask you to attend one two-hour, patient education session per week for three consecutive
weeks. The sessions will include important information for Parkinson’s patients about
medications, exercises, communication skills, and social support. Before you start
participating in the study, you will be asked to fill out two brief questionnaires to assess
how Parkinson’s disease is affecting your quality of life and how you feel about your
ability to manage your disease. You will be asked to complete these questionnaires at
three points during the study: (a) at baseline (entry into study), (b) after completion o f the
two-hour sessions offered over three consecutive weeks, and (c) one month after
completion of the educational sessions. You will also be asked to fill out an evaluation
form after each educational session.
Thank you for your interest in the “Parkinson's Patient Education, Disease Management,
and Quality o f Life Outcomes Study. ” If you wish, I will be glad to schedule an
informational meeting with you to discuss this study and participation requirements in
further detail. During this meeting, I would plan to review the consent forms for this
study. If you were interested in enrolling in the study, I would also review with you the
eligibility requirements for participating in it and screen you for your eligibility to enroll. If
you are determined to be eligible for enrolling in this research, then next steps for
participating in the study will also be discussed at this time.
Time:
Place:
If you have any questions or concerns about this study prior to this meeting, please
contact me (Lori Pearl-Kraus) at 616.453.3923 or 616.391.6292 .
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Letter to Potential Patient Peer Leader
Dear ______ ;__________,
I am writing to inform you of a research study that we will be offering to
Parkinson’s patients who receive care at the Hauenstein Parkinson’s Center. The study
will be conducted at the facilities of the Hauenstein Parkinson’s Center by researchers
from the College of Health and Human Services at Western Michigan University. They
will be investigating the effectiveness of two patient education and disease management
methods and how they impact the quality of life for Parkinson’s patients. Patients will be
asked to attend three two-hour, patient education sessions that will be taught by various
health care professionals who are members of the interdisciplinary health care team at the
Hauenstein Parkinson’s Center. Patients will also be asked to complete two brief
questionnaires at three points in time that will assess their Parkinson’s disease quality of
life and disease self-management ability.
An important aspect of this research study, will be the mentoring o f study
participants by their fellow patient peers who have been diagnosed with Parkinson’s
disease and have been living with it for some time. Patient peers who have had to deal
with the diagnosis of Parkinson’s and its impact on their physical health, social
interactions, and overall well-being, can be very helpful in teaching other Parkinson’s
patients about their disease and ways to effectively manage it, which may enhance the
quality o f life for these patients. I would like to invite you to consider sharing your
expertise and lived experience as a Parkinson’s patient, by participating in this research
study as a Patient Peer Leader. Prior to the start of the research study, you would receive
training as a Patient Peer Leader. You would also need to be able to attend all three of the
two-hour educational sessions for the study’s participants. If you have been diagnosed as
having Parkinson’s disease for at least six (6) months or longer and would like to find out
more about this research study and the opportunity to become a Patient Peer Leader, one
o f the researchers from Western Michigan University will be glad to contact you.
If you are willing to permit us to share your name, address, and phone number
with the researchers solely for the purpose of allowing them to contact you to explain the
study and the Patient Peer Leader role to you, please fill out and return the enclosed,
postage-paid postcard to the Hauenstein Parkinson Center. Shortly after receipt of your
returned postcard, the researchers will contact you to set up a time to meet with you and
explain the study to you. If you have any questions regarding this study, please feel free
to contact either myself or Julie Sager, RN, BSN, nurse manager, at the Hauenstein
Parkinson’s Center at 616-752-5400.
Sincerely,
Dr. Leslie Neuman,
Medical Director - Hauenstein Parkinson’s Center
Ljpk:52606
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Potential PD Patient Peer Leader Return Postcard
If you are interested in learning more about this study and possibly participating in
it as a patient-peer leader, please return this post-card b y _______________ (date) to
the Nurse Manager of the Hauenstein Parkinson’s Center (HPC), and Lori PearlKraus, RN, MSN, CS, FNP-D, will contact you about next steps.
Will you give your permission to the HPC to give your contact information (name,
address, and phone number) to the research investigators so they can contact you?
If so, provide the preferred times, address, and phone number below:
Name:
Phone number(s):
Address:
Please circle the best day and time to call you:
Monday Tuesday Wednesday Thursday Friday
Morning
Afternoon

Saturday Sunday
Evening

What is your year o f birth?_____________
(year)
In what year were you diagnosed as having Parkinson’s disease? _______
Do you have access to reliable transportation? Y es

No

'
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Letter to Study Participant
Dear (name of study participant):
Thank you for your participation in the patient educational sessions for the, “Parkinson’s
Disease Self-Management and Self-Reported Quality o f Life, ” research study that was
recently conducted at the Hauenstein Parkinson’s Center. We hope that this educational
intervention has helped you to gain additional insight into the management of your
Parkinson’s disease.
In order for us to know if this educational intervention was helpful to you and may be
helpful in improving the quality of life for other Parkinson’s patients, we would appreciate
it if you would complete the enclosed questionnaires, the PDQ-39 Parkinson’s Disease
Quality o f Life Questionnaire and the Self-Efficacy Measure, within this next week. To
determine how effective this program has been for PD patients and its potential benefit to
others, it is important for you to give your honest responses to these questions, as well as
other suggestions that you may have for improving the program. After you have
completed them, please use the enclosed self-addressed, postage-paid envelope and return
them to the researchers listed below.
Once again, thank you for participating in this study and your time and effort spent in
completing these study forms. If you have any questions about the study or these forms,
please feel free to contact the principal investigator of the study, Lorraine J. Pearl-Kraus,
RN, PhD-c, CS, FNP-C, at 616-391-6292 or 616-453-3923.
Sincerely,

Lorraine J. Pearl-Kraus, RN, PhD-c, CS, FNP-C
Doctoral Student and Principal Investigator

Nickola W. Nelson, Ph.D., CCC-SLP
Co-Principal Investigator and
Director, Ph.D. in Interdisciplinary Health Studies
College o f Health and Human Services
Western Michigan University

Ljpk: 52606
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Letter to Study Participant (revised)
Dear (name of study participant!:
Thank you for your participation in the patient educational sessions for the “Parkinson’s Disease
Self-Management and Self-Reported Quality o f Life ” research study that was recently conducted
at the Hauenstein Parkinson’s Center. We hope that this educational intervention has helped you to
gain additional insight into the management of your Parkinson’s disease.
In order for us to know if this educational intervention was helpful to you and may be helpful in
improving the quality of life for other Parkinson’s patients, we would appreciate it if you would
complete the enclosed questionnaires, the PDQ-39 Parkinson’s Disease Quality o f Life
Questionnaire and the Self-Efficacy Measure, within this next week. To determine how effective
this program has been for PD patients and its potential benefit to others, it is important for you to
give your honest responses to these questions, as well as other suggestions that you may have for
improving the program. We would appreciate it if you would also please answer the additional
questions below. After you have completed all items, please use the enclosed self-addressed,
postage-paid envelope and return them to the researchers listed below. Please mail these
questionnaires back to us b y ____________ , 2007.
Once again, thank you for participating in this study and your time and effort spent in completing
these study forms. If you have any questions about the study or these forms, please feel free to
contact the principal investigator of the study, Lorraine J. Pearl-Kraus, PhD-c, RN, CS, FNP-C, at
616-391-6292 or 616-453-3923.
Sincerely,
Lorraine J. Pearl-Kraus, PhD-c, RN, CS, FNP-C
Doctoral Student and Principal Investigator

Nickola W. Nelson, Ph.D., CCC-SLP
Co-Principal Investigator and Director, Ph.D.
in Interdisciplinary Health Studies
College of Health and Human Services
Western Michigan University

PLEASE ANSWER THESE ADDITIONAL QUESTIONS*:
1. Has there been any change(s) in your Parkinson’s medications since you enrolled in this
study? Yes
No____ (if yes, please write down the changes.)

2. If you have had any medication changes, do you think that these changes have affected
your quality of life? Yes
No
(If yes, please describe those
changes.)_____________________________________ ____________________
*As before, all aspects of this research project are voluntary and you may decide to decline to
answer any question without penalty.
ljpk:020107
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TITLE: Evaluation Form for Parkinson’s Disease Patient Education Session #1
DATE: _______________________________ at Hauenstein P arkinson’s Center
To assist us in evaluating the effectiveness of this educational session and to make
recommendations for its future offerings, please complete this evaluation form by circling
the appropriate rating.
SESSION EVALUATION
KEY:

1 = NOT AT ALL

2 = LOW

3 = MEDIUM

4 = HIGH

1. I found this information on Parkinson’s disease was helpful to me.

1 2

2. I thought this information about medications used to treat
Parkinson’s disease was helpful to me.

1 2

3

4

3. Were the meeting facilities satisfactory?

1 2

3

4

4. How would you rate (insert nurse’s name! teaching effectiveness?

1 2

3

4

3

4

5. How would you rate (insert pharmacist’s name) teaching effectiveness? 1 2

3

4

6. How do you think that the educational content o f this session could be improved?

7. What topics/subject areas would you like presented at future educational sessions?
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TITLE: Evaluation Form for Parkinson’s disease Patient Education Session #2
DATE: _______________________________ at Hauenstein Parkinson’s C enter
To assist us in evaluating the effectiveness of this educational session and to make
recommendations for its future offerings, please complete this evaluation form by circling
the appropriate rating.
SESSION EVALUATION
KEY:

1 = NOT AT ALL

2 = LOW

3=M EDIUM

4 = fflGH

1. I found the information on exercise and improving mobility in
Parkinson’s disease was helpful to me.

1 2

3

4

2. I thought the information about making home environment changes
to make it safer and more functional was helpful to me.
1 2

3

4

3. Were the meeting facilities satisfactory?

3

4

3

4

5. How would you rate (insert occupational therapist’s name! teaching effectiveness?
1 2
3

4

1 2

4. How would you rate (insert physical therapist’s name) teaching effectiveness?
1 2

8. How do you think that the educational content of this session could be improved?

9. What topics/subject areas would you like presented at future educational sessions?
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TITLE: Evaluation Form for Parkinson’s Disease Patient Education Session #3
DATE:

_______

at Hauenstein Parkinson’s Center

To assist us in evaluating the effectiveness of this educational session and to make
recommendations for its future offerings, please complete this evaluation form by circling
the appropriate rating.
SESSION EVALUATION
KEY:

1 = NOT AT ALL

2 = LOW

3 = MEDIUM

4 = HIGH

1 .1 found the information on accessing community agencies and
services was helpful to me.

1 2

3

4

2. I thought the information about ways to improve my speaking voice
was helpful to me.
1 2

3

4

3. I thought the information about ways to improve my other communication
skills was helpful to me.
1
2

3

4

4. I thought the information about ways to conserve my energy
was helpful to me.

1 2

3

4

5. Were the meeting facilities satisfactory?

1 2

3

4

6. How would you rate (insert social worker’s name! teaching effectiveness?
1 2

3

4

7. How would you rate (insert speech therapist’s name! teaching effectiveness?
1 2

3

4

8. How do you think that the educational content of this session could be improved?

9. What topics/subject areas would you like presented at future educational sessions?
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Reminder Letter to Study Participant
Dear (name of study participant):
Thank you for your participation in the patient educational sessions for the, “Parkinson’s
Disease Management and Self-Reported Quality o f Life, ” research study that was
recently conducted at the Hauenstein Parkinson’s Center. We hope that this educational
intervention has helped you to gain additional insight into the management of your
Parkinson’s disease.
In order for us to know if this educational intervention was helpful to you and may be
helpful in improving the quality of life for other Parkinson’s patients, we would appreciate
it if you would complete the questionnaires that were recently mailed to you, the PDQ-39
Parkinson’s Disease Quality o f Life Questionnaire and the Self-Efficacy Measure, within
this next week. To determine how effective this program has been for PD patients and its
potential benefit to others, it is important for you to give your honest responses to these
questions, as well as other suggestions that you may have for improving the program. In
case you misplaced the questionnaires, we are enclosing new copies o f these
questionnaires for your convenience. After you have completed them, please use the
enclosed self-addressed, postage-paid envelope and return them to the researchers listed
below. If you have already completed and just recently mailed these forms, please accept
our appreciation for taking the time to do so and discard these extra copies.
Once again, thank you for participating in this study and your time and effort spent in
completing these study forms. If you have any questions about the study or these forms,
please feel free to contact the principal investigator of the study, Lorraine J. Pearl-Kraus,
RN, PhD-c, CS, FNP-C, at 616-391-6292 or 616-453-3923.
Sincerely,

Lorraine J. Pearl-Kraus, RN, PhD-c, CS, FNP-C
Doctoral Student and Principal Investigator

Nickola W. Nelson, Ph.D., CCC-SLP
Co-Principal Investigator and
Director, Ph.D. in Interdisciplinary Health Studies
College o f Health and Human Services
Western Michigan University

Ljpk: 52606
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Table LI
PD-HRQOL: Stability o f Change Scores on the PDQ-39 QOL Questionnaire
from Baseline (Time 1) to Postintervention (Time 2) to 4-Week Follow-up
(Time 3) fo r A ll Participants
Pretest to Posttest

Scale/Subscale
N

Average
Pre

Post

Posttest to Follow-up
P

N

Average
Post

Follow
up

Pretest to Follow-up
P

N

Average
Pre

Follow
up

P

PDQ-39
Sum Score

21

27.7

29.2

.34

26

30.9

28.5

.07

28

26.6

26.3

.66

Mobility

28

35.2

35.6

.88

29

37.2

33.4

.07

32

35.5

33.5

.18

Activities of
Daily Living

30

28.5

29.4

.67

30

31.0

30.4

.81

33

28.9

30.9

.29

Emotional WellBeing

31

26.7

28.5

.19

32

27.3

26.3

.61

32

25.0

26.7

.20

Stigma

31

17.7

17.9

.91

32

16.2

12.5

.16

32

15.8

12.3

.12

Social Support

30

14.7

18.0

.13

31

15.3

13.2

.37

32

13.5

13.5

.91

Cognition

30

31.5

28.3

.21

32

27.5

30.1

.30

32

31.6

30.9

.64

Communication

30

26.4

32.5

.03

32

34.1

27.6

.03

31

26.9

27.7

.78

Bodily
Discomfort

31

41.1

46.5

.10

32

41.9

43.4

.14

32

40.4

40.6

.98
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Table L2
PD-HRQOL: Stability o f Change Scores on the PDQ-39 QOL Questionnaire from Baseline
(Time 1) to Postintervention (Time 2) to 4-Week Follow-up (Time 3) fo r PDIT
(Information Training) Group Participants
Scale/Subscale

Posttest to Follow-up

Pretest to Posttest
N

Average

P

Pre-

Post

N

Average

Pretest to Follow-up
P

Post

Follow
up

N

Average
Pre

Follow
up

P

PDQ-39
Sum Score

12

29.9

31.9

.48

14

31.3

28.9

.38

15

28.8

28.2

.73

Mobility

15

39.8

38.0

.51

15

38.0

35.8

.53

17

40.3

36.5

.12

Activities of
Daily Living

15

30.6

30.0

.83

15

30.0

30.6

.91

17

30.8

31.1

.84

Emotional WellBeing

14

25.3

29.8

.06

16

27.1

27.1

.98

15

24.4

29.2

.03

Stigma

14

15.2

11.6

.28

16

10.5

10.9

.78

15

14.2

11.2

.30

Social Support

14

11.3

15.5

.18

16

13.5

12.0

.67

15

12.2

13.9

.49

Cognition

14

27.2

26.8

.79

16

25.4

26,2

.82

15

29.6

28.8

.87

Communication

14

20.8

26.8

.08

16

29.7

25.0

.20

15

21.7

24.4

.47

Bodily
Discomfort

14

42.9

51.2

.16

16

51.0

42.2

.07

15

41.7

37.8

.37

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

203
Table L3
PD-HRQOL: Stability o f Change Scores on the PDQ-39 QOL Questionnaire from
Baseline (Time 1) to Postintervention (Time 2) to 4-Week Follow-up (Time 3) fo r
PDCC (Collaborative Care) Group Participants
Scale/Subscale

Pretest to Posttest
N

Average

Posttest to Follow-up
P

Pre

Post

24.6

25.7

.37

N

Average

Pretest to Follow-up
P

Post

Follow
up

12

30.4

28.0

.14

N

Average

P

Pre

Follow
up

13

24.2

24.2

.81

PDQ-39
Sum Score
9
Mobility

13

29.8

32.9

.36

14

36.6

30.9

.04

15

30.2

30.2

.98

Activities of
Daily Living

15

26.4

28.9

.38

15

31.9

30.3

.65

16

26.9

30.8

.24

Emotional
Well-Being

17

27.9

27.5

.90

16

27.6

25.5

.45

17

25.5

24.5

.91

Stigma

17

19.9

23.2

.40

16

21.9

14.1

.02

17

17.3

13.2

.23

Social Support

16

17.7

20.3

.44

14

17.2

14.4

.37

17

14.7

13.2

.43

Cognition

16

31.2

29.7

.11

16

29.7

34.0

.24

17

33.5

32.7

.65

Communication

16

31.2

37.5

.17

16

38.5

30.2

.08

16

31.8

30.8

.81

Bodily
Discomfort

17

39.7

42.6

.34

16

44.8

44.8

.92

17

39.2

43.1

.26
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Research Planning Tool: Variables Related to Research Questions
Dependent and Independent Variables
Research Questions
Ouestion 1:
Is there a difference in
pre-post test scores
(Time 1 - Time 2) on
the Self-Efficacyfo r
Managing Chronic
Disease 6-Item Scale
between Parkinson’s
disease patients who
participate in the PDCC
or PDTT intervention?

Dependent
Variable
Self-reported
Perceived
Self-Efficacy
(in
Disease SelfManagement
Skills)

Independent
Confounding
Variable(s)
Variables
Patient
■ Demographic
Education
variables (age,
Method
gender, race,
(2 levels:
ethnicity, marital
Experimental &
status, education,
Control)
financial)
■ Duration of Illness
* Stage/Severity of
Illness
■ # of prescribed
medications
■ Change in
medication
regimen
■ Comorbidities
■ Health beliefs/
Values
* Health perceptions
■ Social Support

Statistical Test(s)
Descrintive statistics:
Frequencies, percentages, means,
and standard deviations were used
to describe characteristics of sample
population and to conduct tests of
skewness and kurtosis.
Inferential statistics:
Independent t-test,
Chi-square, Fisher’s Exact, and
Maim-Whitney U test measures
were used to analyze between group
differences at pre-test time (Time 1
- baseline) to verify equivalent
groups were achieved by
randomization process.
Repeated measures ANOVA were
used to analyze between group
differences on the dependent
measure, Self-Efficacy, from
baseline to post-intervention
(Time 1 —Time 2) and from post
intervention to 4-week follow-up
post-intervention (Time 2 - Time
3).
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Research Questions
Question 2:
Is there a difference in
pre-post test scores
(Time 1 - Time 2) on
the PDQ-39
Parkinson's Disease
Quality o f Life Scale
between Parkinson’s
disease patients who
participate in the PDCC
or PDIT intervention?

Ouestion 3:
If the groups differ at
Time 1, is there a
difference between
change scores from
baseline (Time 1) to
post-test (Time 2)
versus the change
scores from post-test
(Time 2) and the fourweek follow-up (Time
3) on either of the
dependent measures
(Self-Efficacyfor
Managing Chronic
Disease 6-Item Scale or
PDQ-39 Parkinson's
Disease Quality o f Life
Scale) between the
PDCC and PDIT
groups?

Dependent
Variable
Self-reported
Perceived
PD-Healthrelated QOL

Maintenance
of change
(from pre
post tests)
scores on
perceived
self-efficacy
in disease
selfmanagement
of PD and
PD-HRQOL
one month
after
completing
intervention

Independent
Confounding
Variable(s)
Variables
■ Health beliefs/
Patient
Values
Education
■ Health perceptions
Method
■ § of prescribed
(2 levels:
medications
Experimental &
■ Change in
Control)
medication
regimen
■ Comorbidities
■ Caregiver Support
■ Social Support
Systems
■ Duration of Illness
■ Stage/Severity of
Illness
■ Demographic
variables (age,
gender, race,
ethnicity, marital
status, education,
financial)

Elapsed Time
(4-weeks)

■ Health beliefs/
Values
■ Health perceptions
■ # of prescribed
medications
■ Duration of Illness
■ Stage/Severity of
Illness
■ # of prescribed
medications
■ Change in
medication
regimen
■ Comorbidities
■ Caregiver Support
■ Social Support
Systems
■ Demographic
variables (age,
gender, race,
ethnicity, marital
status, education,
financial)

Statistical Test(s)
Descrintive statistics:
Frequencies, percentages, means,
and standard deviations were used
to describe characteristics of sample
population and to conduct tests of
skewness and kurtosis.
Inferential statistics:
Independent t-test,
Chi-square, Fisher’s Exact, and
Mann-Whitney U test measures
were used to analyze between group
differences at pre-test time (Time 1
- baseline) to verify equivalent
groups were achieved by
randomization process.
Repeated measures ANOVA were
used to analyze between group
differences on the dependent
measure, PD-HRQOL, from
baseline to post-intervention
(Time 1 - Time 2) and from postintervention to 4-week follow-up
post-intervention (Time 2 - Time
3).
Inferential statistics:
Repeated measures ANOVA were
used to analyze between group
differences of change scores on both
dependent measures, Self-Efficacy
and PD-HRQOL from baseline to
post-intervention
(Time 1 - Time 2) and from post
intervention to 4-week follow-up
post-intervention (Time 2 - Time
3).
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Research Questions
Ouestion 4:
Is there a difference
between change scores
from baseline (Time 1)
to the four-week
follow-up (Time 3) on
either of the dependent
measures (SelfEfficacyfo r Managing
Chronic Disease 6Item Scale or PDQ-39
Parkinson’s Disease
Quality o f Life Scale)
between the PDCC
and PDIT groups?

Dependent
Variable
Differences in
change (from
pre-post-4
week follow
up tests)
scores on
perceived
self-efficacy
in disease
self
management
of PD and
PD-HRQOL
one month
after
completing
intervention

Independent
Variable(s)
Elapsed Time
(7 weeks

Confounding
Variables
■ Health beliefs/
Values
■ Health perceptions
■ # of prescribed
medications
* Duration of Illness
* Stage/Severity of
Illness
■ # of prescribed
medications
■ Change in
medication
regimen
■ Comorbidities
■ Caregiver Support
■ Social Support
Systems
■ Demographic
variables (age,
gender, race,
ethnicity, marital
status, education,
financial

Statistical Test(s)
Inferential statistics:
Repeated measures ANOVA were
used to analyze between group
differences of change scores on both
dependent measures, Self-Efficacy
and PD-HRQOL from baseline to
4-week follow-up post-intervention
(Time 1 - Time 3).
Nonparametric Wilcoxon MatchedPairs Signed-Ranks test also was
used to analyze difference of change
scores on both dependent measures,
Self-Efficacy and PD-HRQOL
from baseline to 4-week follow-up
post-intervention (Time 1 - Time
3).
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